trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	actualenddate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12615001328561	DESNET2	Phase 2	NOT_RECRUITING		Help: Date registered 2015-12-04			Octreotide; Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Novartis Protocol Number: CSOM230FAU04T	Phase II study evaluating the efficacy of Pasireotide LAR (SOM230) dose escalation in patients with refractory non-functional GEP NETs	Gastro-entero-pancreatic neuroendocrine tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001328561
ACTRN12616001187437	MatchMel	Phase 2	NOT_RECRUITING	NSW	Help: Date registered 2016-08-29			Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	RET_inhibitor; ALK_inhibitor,first_generation; KIT_inhibitor,ATP-competitive; YES1_inhibitor; mTORC1_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; EGFR_inhibitor,first_generation; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; HDAC_inhibitor; FLT3_inhibitor; VEGFR2_inhibitor; KIT_inhibitor,first_generation; CRAF_inhibitor; ALK/ROS1/IGF1R_inhibitor; PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; CDK4/6_inhibitor; ROS1_inhibitor; KIT_inhibitor; VEGFR_inhibitor; MET_inhibitor,type_2; ERBB2_inhibitor,first_generation; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; proteasome_inhibitor; EGFR_inhibitor,type_II; MEK_inhibitor; MET_inhibitor,type_1; anti-VEGFR2_monoclonal_antibody; PDGFRA_inhibitor; PARP_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation	Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	ALK/ROS1/IGF1R_inhibitor; ALK_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation; FLT3_inhibitor; HDAC_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT_inhibitor; KIT_inhibitor,ATP-competitive; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_2; PARP_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; mTORC1_inhibitor; proteasome_inhibitor	Protocol Number MIA2015/174	Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing.	Metastatic Melanoma	2050 - Camperdown; 2065 - Wollstonecraft; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001187437
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	Help: Date registered 2017-08-15			Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	thymidine_phosphorylase_inhibitor; Trifluridine; topoisomerase_inhibitor; Tipiracil Hydrochloride; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite	Irinotecan + Panitumumab; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5000 - Adelaide; 5042 - Bedford Park; 5011 - Woodville	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12618000382279	CS1003-101	Phase 1	NOT_RECRUITING	NSW, SA, VIC	Help: Date registered 2018-03-14			CS1003	anti-PD-1_monoclonal_antibody	CS1003	anti-PD-1_monoclonal_antibody	None	A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors	Participants with Advanced Solid Tumors	5000 - Adelaide; 2010 - Darlinghurst; 2109 - Macquarie Park; 3168 - Clayton; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000382279
ACTRN12618000977279	HLX20-001	Phase 1	NOT_RECRUITING	NSW, QLD, SA, VIC	Help: Date registered 2018-06-12			HLX20	anti-PD-1_monoclonal_antibody	HLX20	anti-PD-1_monoclonal_antibody	HLX20-001	A Phase 1 Study on the safety and maximum tolerated dose of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein, in Patients with Advanced Solid Tumors	Metastatic Solid Tumour for patients who have failed/not tolerated/not available standard treatment	4575 - Birtinya; 5000 - Adelaide; 4215 - Southport; 2010 - Darlinghurst; 2109 - Macquarie Park; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000977279
ACTRN12618001573246	CRIO	Phase 2	NOT_RECRUITING	QLD	Help: Date registered 2018-09-20			Carboplatin; Carboplatin + Durvalumab + Radiotherapy; Durvalumab; Radiotherapy	platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-L1_monoclonal_antibody; radiotherapy	Carboplatin + Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Nil known	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	skin cancer; squamous cell carcinoma	4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001573246
ACTRN12619000566134	OXTOX	Phase 2	RECRUITING	NSW, VIC	Help: Date registered 2019-04-10	2021-01-28		Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	platinum-based_antineoplastic_agent; PDE4_inhibitor; PDE4_inhibitor + platinum-based_antineoplastic_agent	Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	3128 - Box Hill; 2800 - Orange; 2444 - Port Macquarie; 2640 - Albury; 2139 - Concord; 2500 - Wollongong; 2250 - Gosford; 2065 - St Leonards; 2109 - Macquarie Park; 2747 - Kingswood	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619001298101	ASN-002-IL	Phase 2	NOT_YET_RECRUITING	QLD	Help: Date registered 2019-09-20			Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	Fluorouracil; SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine	Fluorouracil + Gusacitinib; Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine; Fluorouracil	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Carcinoma; Basal Cell Nevus Syndrome (BCNS)	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	RECRUITING	VIC	Help: Date registered 2020-05-20	2021-09-02		EO1001	ERBB2_inhibitor,second_generation; EGFR_inhibitor,second_generation	EO1001	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ErbB-1(EGFR) positive cancer; ERbB-4 (HER4) positive cancer; ErbB-2(HER2) positive cancer	3004 - Melbourne; 3144 - Malvern; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620001198910	MODERN-LUNG	Phase 2	RECRUITING	NSW	Help: Date registered 2020-11-10	2021-04-15		Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane; radiotherapy	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2170 - Liverpool; 2148 - Blacktown; 2560 - Campbelltown; 2145 - Westmead; 2298 - Waratah; 2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12620001261909	ASC-02001V	Phase 1	NOT_RECRUITING	SA	Help: Date registered 2020-11-24	2021-01-08		Lanreotide	somatostatin_analog	Lanreotide	somatostatin_analog	ASC-02001V	A Phase I Study to evaluate the Pharmacokinetics and the Safety of a Controlled Release Formulation of Lanreotide acetate in Healthy Male Volunteers	Neuroendocrine Tumours; Acromegaly	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001261909
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	RECRUITING	NSW	Help: Date registered 2021-02-15	2021-08-30		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	ACE_inhibitor; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Perindopril	ACE_inhibitor; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Unresectable; Melanoma - Metastatic	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000273886	ADELE	Phase 2	RECRUITING	NSW, NZ, QLD, SA, VIC, WA	Help: Date registered 2021-03-11	2022-06-03		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	2298 - Waratah; 2250 - Gosford; 2065 - St Leonards; Northland; 3121 - Richmond; 3000 - Melbourne; 3168 - Clayton; 2050 - Camperdown; 4029 - Herston; 2031 - Randwick; Auckland; 5042 - Bedford Park; 6009 - Nedlands; 4814 - Douglas; 2145 - Westmead; Wellington; 5000 - Adelaide; 3052 - Parkville; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000312842	MoST-Addendum-14	Phase 2	NOT_RECRUITING	NSW, NT, QLD, SA, TAS, VIC, WA	Help: Date registered 2021-03-22	2021-09-03	2024-12-19	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	CTC 0141 – addendum 14	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	ALK gene alterations; Cancer; Non-small cell lung cancer	5000 - Adelaide; 2145 - Westmead; 6009 - Nedlands; 4102 - Woolloongabba; 2217 - Kogarah; 0810 - Tiwi; 2065 - St Leonards; 7000 - Hobart; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000611820	PICAASO	Phase 2	RECRUITING	NSW, VIC	Help: Date registered 2021-05-21	2021-11-02		Dasatinib	SRC_inhibitor; YES1_inhibitor; BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor; KIT_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	2010 - Darlinghurst; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	Help: Date registered 2021-05-28	2022-08-04		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	aromatase_inhibitor; PI3K_alpha_inhibitor; CDK4/6_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Platinum resistant high-grade epithelial cancers of primary peritoneum; Low grade epithelial cancers of ovary; Endometrial stromal sarcomas; Leiomyosarcomas; Granulosa cell tumours; Platinum resistant high-grade epithelial cancers of ovary; Platinum resistant high-grade epithelial cancers of fallopian tube; Other gynaecological cancers (excluding endometrial cancers); Endometrial cancer	4029 - Herston; 2031 - Randwick; 2050 - Camperdown; 3168 - Clayton; Auckland; 4101 - South Brisbane; 5042 - Bedford Park; 2065 - St Leonards; 2305 - New Lambton Heights; 3000 - Melbourne; 7000 - Hobart; 2500 - Wollongong; 2640 - Albury; 2485 - Tweed Heads; 6009 - Nedlands; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000747820	TaxAdapt	Phase 1 / Phase 2	NOT_RECRUITING	NSW	Help: Date registered 2021-06-11			Docetaxel	taxane	Docetaxel	taxane	Nil known	TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer	Castration-resistant prostate cancer	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000747820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	RECRUITING	QLD	Help: Date registered 2021-06-18	2021-07-21		Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	autologous_CAR-T-cell_therapy,CD19-targeting; antimetabolite; alkylating_agent; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Royal Brisbane Hospital; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	RECRUITING	NSW	Help: Date registered 2021-06-25			177Lu-edotreotide; Temozolomide	177Lu-DOTA-radioconjugate; alkylating_agent	Temozolomide; 177Lu-edotreotide	alkylating_agent; 177Lu-DOTA-radioconjugate	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000848808	EQ143-101	Phase 1	RECRUITING	NZ	Help: Date registered 2021-07-01	2021-06-21		Almonertinib	EGFR_inhibitor,third_generation	Almonertinib	EGFR_inhibitor,third_generation	EQ143-101	A Single Dose Phase 1 Study in Healthy Participants to Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populations	Non Small Cell Lung Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000848808
ACTRN12621000991819	PDCCiHNC	Not Applicable	STATUS_UNKNOWN	NSW	Help: Date registered 2021-07-28			Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; YES1_inhibitor; JAK1/JAK2_inhibitor; gemcitabine; EGFR_inhibitor,first_generation; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; ATR_inhibitor; FLT3_inhibitor; PI3K/mTOR_inhibitor; CRAF_inhibitor; Fluorouracil; topoisomerase_inhibitor; PDGFR_inhibitor; CDK4/6_inhibitor; ROS1_inhibitor; antimetabolite; KIT_inhibitor; vinca_alkaloid; VEGFR_inhibitor; mTORC1/mTORC2_inhibitor; taxane; antifolate; platinum-based_antineoplastic_agent; doxorubicin; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; SMO_inhibitor; anthracycline; fluoropyrimidine	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SMO_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; fluoropyrimidine; mTORC1/mTORC2_inhibitor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid; Fluorouracil; doxorubicin; gemcitabine	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001347853	SPEAR	Phase 2	NOT_RECRUITING	ACT, NSW, QLD, SA, TAS, VIC, WA	Help: Date registered 2021-10-07	2023-06-19		Sulfasalazine	SLC7A11_inhibitor	Sulfasalazine	SLC7A11_inhibitor	None	A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma	Pancreatic cancer	3076 - Epping; 2076 - Wahroonga; 3121 - Richmond; 7000 - Hobart; 4215 - Southport; 2298 - Waratah; 2148 - Blacktown; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001347853
ACTRN12621001419853	OP-1250-002	Phase 1	RECRUITING	NSW, QLD, VIC, WA	Help: Date registered 2021-10-21	2022-02-03		Fulvestrant; Fulvestrant + Palbociclib; Palazestrant; Palazestrant + Palbociclib; Palbociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	Fulvestrant + Palbociclib; Palazestrant; Palazestrant + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	OP-1250-002	A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	6000 - Perth; 3168 - Clayton; 4101 - South Brisbane; 3220 - Geelong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001419853
ACTRN12621001444875	The-SOCRATES-HCC-Study	Phase 2	RECRUITING	ACT, NSW, NT, QLD, SA, VIC, WA	Help: Date registered 2021-10-25	2022-11-29		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	TROG 21.07	A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)	Early Hepatocellular Carcinoma	2747 - Kingswood; 3050 - Parkville; 2217 - Kogarah; 0810 - Tiwi; 2050 - Camperdown; 3168 - Clayton; 4029 - Herston; 4102 - Woolloongabba; 5042 - Bedford Park; 4215 - Southport; 3004 - Melbourne; 6150 - Murdoch; 2170 - Liverpool; 5000 - Adelaide; 4575 - Birtinya; 6009 - Nedlands; 3084 - Heidelberg; 3128 - Box Hill; 2145 - Westmead; 2305 - New Lambton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001444875
ACTRN12621001458820	CHARMM	Phase 1	NOT_YET_RECRUITING	NSW	Help: Date registered 2021-10-26			Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Dexamethasone; Hydroxychloroquine	proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid; anti-malarial_agent	Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Hydroxychloroquine	anti-malarial_agent; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; proteasome_inhibitor	none	Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib	Myeloma; Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001458820
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	RECRUITING	NSW	Help: Date registered 2021-11-10	2021-10-25		Idronoxil; Idronoxil + Nivolumab; Nivolumab	idronoxil_suppository; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository	Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2228 - Miranda; 2076 - Wahroonga; 2217 - Kogarah; 2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12622000016730	HER2Pro-1B	Phase 1	RECRUITING	NSW, QLD	Help: Date registered 2022-01-11	2023-06-20		Dexamethasone; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab; Prochlorperazine; Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; glucocorticoid; taxane; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Prochlorperazine	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; antihistamine	None	Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study	Metastatic HER2-positive breast cancer	2010 - Darlinghurst; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000016730
ACTRN12622000083796	20)	Phase 3	RECRUITING	QLD	Help: Date registered 2022-01-21	2022-12-14		Placebo; delta-9-tetrahydrocannabinol	placebo; tetrahydrocannabinol	delta-9-tetrahydrocannabinol; Placebo	tetrahydrocannabinol; placebo	Nil Known	Medicinal Cannabis (MedCan 3) – a randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer	Cancer	4163 - Cleveland; 4101 - South Brisbane; 4300 - Springfield Central; 4169 - Kangaroo Point	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000083796
ACTRN12622000973718	SHERLOCK	Phase 2	NOT_RECRUITING	NSW, QLD, SA, TAS, VIC	Help: Date registered 2022-07-11	2022-09-23	2025-06-10	Bevacizumab; Carboplatin; Pemetrexed; Sotorasib	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor; antimetabolite	Carboplatin; Pemetrexed; Sotorasib; Bevacizumab	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor; antimetabolite; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody	TOGA 21/011  CTC 0377	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	3000 - Melbourne; 7000 - Hobart; 2065 - St Leonards; 4032 - Chermside; 3168 - Clayton; 2747 - Kingswood; 4814 - Douglas; 5011 - Woodville South; 3084 - Heidelberg; 2444 - Port Macquarie; 2170 - Liverpool; 2086 - Frenchs Forest; 4575 - Birtinya	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000973718
ACTRN12622000993796	ACTRN12622000993796	Phase 1	RECRUITING	NSW, VIC, WA	Help: Date registered 2022-07-14	2022-11-15		AXA-042; Cemiplimab	anti-PD-1_monoclonal_antibody; TLR2/TLR6_agonist	AXA-042; Cemiplimab	TLR2/TLR6_agonist; anti-PD-1_monoclonal_antibody	None	A Phase 1a/1b, first-in-human, open-label, non-randomised, multicenter, dose-escalation and dose -expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours: phase 1a	Advanced solid tumors	3000 - Melbourne; 2298 - Waratah; 3175 - Dandenong; 2050 - Camperdown; 2031 - Randwick; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000993796
ACTRN12622001003763	X22-0072	Phase 2	RECRUITING	NSW	Help: Date registered 2022-07-18	2023-03-08		Evolocumab	anti-PCSK9_monoclonal_antibody	Evolocumab	anti-PCSK9_monoclonal_antibody	Protocol Number: X22-0072	A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer	Metastatic Castrate Resistant Prostate Cancer	2050 - Camperdown; 2010 - Darlinghurst; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001003763
ACTRN12622001201763	TRAS-GB	Phase 2	RECRUITING	NZ	Help: Date registered 2022-09-07	2024-07-08		Metformin; Propranolol	beta-adrenergic_blocker; biguanide_antihyperglycaemic_agent	Metformin; Propranolol	beta-adrenergic_blocker; biguanide_antihyperglycaemic_agent	none	Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial	Glioblastoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001201763
ACTRN12622001339741	HH3806-A101	Phase 1	_NOT_RECRUITING	QLD, VIC	Help: Date registered 2022-10-18	2023-03-13		HH3806	BET_inhibitor	HH3806	BET_inhibitor	HH3806-A101	A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies	Solid Tumors; relapsed/refractory Non-Hodgkin’s lymphomas (NHL)	3199 - Frankston; 3168 - Clayton; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001339741
ACTRN12622001378718	TheraPb-phase-I-II	Phase 1 / Phase 2	RECRUITING	QLD	Help: Date registered 2022-10-26	2023-11-01		212Pb-ADVC001	radioligand,PSMA-targeting	212Pb-ADVC001	radioligand,PSMA-targeting	none	Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II)	Metastatic Prostate Cancer	4029 - Royal Brisbane Hospital; 4102 - Woolloongabba; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001378718
ACTRN12622001514796	KARPOS	Not Applicable	RECRUITING	SA	Help: Date registered 2022-12-06	2023-05-17		Bevacizumab; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; GD2-iCAR-PBT; Ifosfamide	anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; anti-VEGF_monoclonal_antibody; alkylating_agent + antimetabolite; autologous_CAR-T-cell_therapy,GD2-targeting; antimetabolite; alkylating_agent	Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; GD2-iCAR-PBT; Ifosfamide	alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting	Nil Known	KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme	Glioblastoma Multiforme	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001514796
ACTRN12623000073606	SLAP-trial	Phase 0	NOT_YET_RECRUITING	NSW	Help: Date registered 2023-01-23			Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	None	A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer	Prostate cancer	2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000073606
ACTRN12623000096651	LUMOS2	Phase 2	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	Help: Date registered 2023-01-27	2023-09-11		Cadonilimab; Cadonilimab + Niraparib; Niraparib; Paxalisib; Selinexor	bispecific_PD-1/CTLA4_antibody; PARP_inhibitor; dual_PI3K/mTOR_inhibitor; XPO1_inhibitor; PARP_inhibitor + bispecific_PD-1/CTLA4_antibody	Cadonilimab; Cadonilimab + Niraparib; Paxalisib; Selinexor	PARP_inhibitor + bispecific_PD-1/CTLA4_antibody; XPO1_inhibitor; bispecific_PD-1/CTLA4_antibody; dual_PI3K/mTOR_inhibitor	CTC0378  COGNO2201	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	Grade 2 Glioma; Grade 3 Glioma	7000 - Hobart; 3000 - Melbourne; 3065 - Fitzroy; 2298 - Waratah; 2010 - Darlinghurst; 2065 - St Leonards; 3168 - Clayton; 4029 - Herston; 5042 - Bedford Park; 4102 - Woolloongabba; 3084 - Heidelberg; 6009 - Nedlands; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000096651
ACTRN12623000185662	SSO110-01	Phase 1	ACTIVE_NOT_RECRUITING	NSW, QLD, SA, VIC, WA	Help: Date registered 2023-02-22	2023-06-30	2025-07-01	Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	SSO110-01	A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with immune checkpoint inhibition (The LuSato1 Study).	Extensive Stage Small Cell Lung Cancer	3165 - East Bentleigh; 6150 - Murdoch; 5000 - Adelaide; 2010 - Darlinghurst; 4102 - Woolloongabba; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000185662
ACTRN12623000216617	RESCUE	Phase 1	NOT_YET_RECRUITING	NZ	Help: Date registered 2023-02-28			177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioligand,PSMA-targeting; radioconjugate,PSMA-targeting; radiotherapy	177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioconjugate,PSMA-targeting; radioligand,PSMA-targeting; radiotherapy	Nil Known	A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands	Metastatic Prostate Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000216617
ACTRN12623000223639	iLSTA	Phase 1	RECRUITING	WA	Help: Date registered 2023-03-02	2023-04-03		Certepetide; Certepetide + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab; Gemcitabine; Nab-paclitaxel	tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody; gemcitabine; antimetabolite; taxane	Certepetide + Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine	Nil known	A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)	Cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000223639
ACTRN12623000307606	NP-105	Phase 1	RECRUITING	NSW, VIC	Help: Date registered 2023-03-21	2023-06-15		RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	NP-105	A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2747 - Kingswood; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000307606
ACTRN12623000652673	ELVN-002-002	Phase 1	WITHDRAWN	WA	Help: Date registered 2023-06-16			ELVN-002; ELVN-002 + Itraconazole; Itraconazole	ERBB2_inhibitor,exon_20_selective + SMO_inhibitor; SMO_inhibitor; ERBB2_inhibitor,exon_20_selective	ELVN-002; ELVN-002 + Itraconazole; Itraconazole	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + SMO_inhibitor; SMO_inhibitor	ELVN-002-002	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers: Part C Open-label Drug-Drug Interaction	Non-small Cell lung cancer	6009 - Nedlands; 6027 - Joondalup	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000652673
ACTRN12623000874617	Biomarcer-2	Phase 2	RECRUITING	ACT, NSW, QLD, TAS, VIC, WA	Help: Date registered 2023-08-15	2024-10-08		Cetuximab; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Fluorouracil; Irinotecan; Leucovorin	Fluorouracil; topoisomerase_inhibitor; folinic_acid; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil	None	Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression	Advanced RAS Wild type right sided Colorectal cancer	3144 - Malvern; 3280 - Warrnambool; 3076 - Epping; 3844 - Traralgon; 3000 - Melbourne; 2298 - Waratah; 2305 - New Lambton Heights; 3011 - Footscray; 2340 - Tamworth; 2605 - Garran; 6150 - Murdoch; 3084 - Heidelberg	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000874617
ACTRN12623000956606	Australia	Phase 1	RECRUITING	NSW, QLD, SA, VIC	Help: Date registered 2023-09-04	2023-11-15		AT-0174	dual_IDO/TDO_inhibitor	AT-0174	dual_IDO/TDO_inhibitor	Antido Therapeutics (Australia) Protocol No. AT-0174-001	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	Locally Advanced Solid Tumours	5000 - Adelaide; 4575 - Birtinya; 3065 - Fitzroy; 3350 - Ballarat Central; 2228 - Miranda	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000956606
ACTRN12623001072606	LuCape	Phase 1	RECRUITING	WA	2023-10-06	2023-10-13		Capecitabine; Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting; fluoropyrimidine	Capecitabine; Lu-177 vipivotide tetraxetan	fluoropyrimidine; radioconjugate,PSMA-targeting	Nil known	A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)	metastatic castration-resistant prostate cancer	6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001072606
ACTRN12623001077651	EMITT-1	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC	Help: Date registered 2023-10-10	2024-04-18		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01 Module 2	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2.	Advanced solid malignancies	3084 - Heidelberg; 2148 - Blacktown; 3004 - Melbourne; 2010 - Darlinghurst; 2500 - Wollongong; 5042 - Bedford Park; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001077651
ACTRN12623001126606	TCaP	Phase 1 / Phase 2	RECRUITING	QLD, VIC	2023-11-01	2024-05-14		Cytarabine; Cytarabine + Pembrolizumab; Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody; antimetabolite; alkylating_agent	Cytarabine + Pembrolizumab; Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; alkylating_agent	Nil known	Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme	Glioblastoma multiforme/astrocytoma grade 4	4102 - Woolloongabba; 4006 - Bowen Hills; 3084 - Heidelberg; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001126606
ACTRN12623001164684	ACTRN12623001164684	Not Applicable	RECRUITING	QLD	2023-11-09			Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	melatonin; HMG-CoA_reductase_inhibitor; biguanide_antihyperglycaemic_agent; anti-malarial_agent	Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Nil	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for adult cancer by Circulating Tumour Cell (CTC) analysis: A case-series	Cancer	4209 - Willow Vale	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001164684
ACTRN12623001217695	ACTRN12623001217695	Phase 1	NOT_YET_RECRUITING	NSW	2023-11-27			IMD-101	IL2_conjugate	IMD-101	IL2_conjugate	AFB-105	An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours.	Advanced malignant solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001217695
ACTRN12623001333606	CCaLM	Phase 2	NOT_YET_RECRUITING	NSW	2023-12-19			Labetuzumab	anti-CEACAM5_monoclonal_antibody	Labetuzumab	anti-CEACAM5_monoclonal_antibody	Nil known	The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)	Colon cancer	2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001333606
ACTRN12624000110583	SOCRATES-PILOT	Not Applicable	RECRUITING	NSW	2024-02-08	2024-08-19		Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; taxane; aromatase_inhibitor; CYP17A1_inhibitor; alkylating_agent; PARP_inhibitor; HMG-CoA_reductase_inhibitor	Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; HMG-CoA_reductase_inhibitor; PARP_inhibitor; alkylating_agent; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; taxane	CTC 0393	SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies	Cardio Vascular Disease; Cancer	2050 - Camperdown; 2031 - Randwick; 2050 - Missenden Road; 2139 - Concord	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000110583
ACTRN12624000268549	LEPO	Phase 1	NOT_YET_RECRUITING	NSW	2024-03-15							ADRI002	LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma	Mesothelioma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000268549
ACTRN12624000288527	REZOLV3R	Phase 3	RECRUITING	NSW, QLD, VIC	2024-03-20			Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	CTC 0398	Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (REZOLV3R)	Recurrent malignant ascites; Chemotherapy resistant solid tumours	2060 - North Sydney; 2139 - Concord	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000288527
ACTRN12624000532505	INTER-EWING-1	Phase 3	RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	2024-04-29	2024-02-23		Cyclophosphamide; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Doxorubicin; Etoposide; Ifosfamide; Radiotherapy; Regorafenib; Vincristine; Vinorelbine	topoisomerase_inhibitor; radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; doxorubicin; alkylating_agent + vinca_alkaloid; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent; vinca_alkaloid	Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Radiotherapy	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; radiotherapy; doxorubicin	ISRCTN17938906  RG_21-151	International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)	Ewing Sarcoma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000532505
ACTRN12624000588594	PORCUPINE2-Australian-Extension	Phase 2	NOT_YET_RECRUITING	NSW	Help: Date registered 2024-05-08			Denosumab; Denosumab + Zamaporvint; Zamaporvint	PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	Denosumab + Zamaporvint; Zamaporvint	PORCN_inhibitor; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody	None	A Phase 2, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care	Pancreatic Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000588594
ACTRN12624000644561	ACTRN12624000644561	Not Applicable	NOT_YET_RECRUITING	NSW	2024-05-20							None	A randomised controlled trial comparing animation-based with written patient information for educating patients about robotic-assisted radical prostatectomy	prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000644561
ACTRN12624000911594	CICAFU	Phase 3	NOT_YET_RECRUITING	QLD	2024-07-26			Fluorouracil	Fluorouracil; fluoropyrimidine	Fluorouracil	fluoropyrimidine; Fluorouracil	Nil known	CICAFU Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)	Skin Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000911594
ACTRN12624000917538	CetPro	Phase 2	NOT_YET_RECRUITING	QLD	2024-07-29			Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; anti-EGFR_monoclonal_antibody; antihistamine	Cetuximab; Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antihistamine	none	Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma: CetPro study	solid organ transplant recipients; skin cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000917538
ACTRN12624000962538	RATIONAL-PT	Phase 2 / Phase 3	NOT_YET_RECRUITING	ACT, NSW, SA, VIC	2024-08-08							TRU-RPT-22	A randomised platform trial evaluating the role of interventions to prevent infection in patients with acquired hypogammaglobulinemia secondary to haematological malignancies - RATIONAL-PT (Dose-Ig Domain)	haematological malignancy; hypogammaglobulinemia		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000962538
ACTRN12624001067561	ACTRN12624001067561	Not Applicable	NOT_YET_RECRUITING	SA	2024-09-03							Nil known	Evaluate the effectiveness of implementing a supportive care navigation tool for people diagnosed with pancreatic cancer.	unmet needs; pancreatic cancer; survival	5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001067561
ACTRN12624001101572	EXHIBIT	Not Applicable	NOT_YET_RECRUITING	VIC	2024-09-12							None.	The safety and feasibility of exercise in patients with melanoma undergoing adjuvant immunotherapy with immune checkpoint inhibitor therapy – the EXHIBIT Study	Cutaneous melanoma	3144 - Malvern; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001101572
ACTRN12624001119583	ACTRN12624001119583	Not Applicable	NOT_YET_RECRUITING	VIC	2024-09-17							Nil	Transperineal prostate biopsy under local anaesthetic in adults with suspected or confirmed prostate cancer: an analysis of cost, efficacy and patient tolerability in Australia	Prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001119583
ACTRN12624001120561	PECAN	Not Applicable	NOT_YET_RECRUITING	WA	2024-09-17							None	Patient Initiated Follow Up (PIFU) in Endometrial Cancer (PECAN) – a Randomised Pilot Feasibility Study	Endometrial cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001120561
ACTRN12624001123538	ITM-2221-01CT	Phase 1	NOT_YET_RECRUITING	NSW, QLD	2024-09-18							ITM-2221-01CT	A Multicentre, Open-label, Interventional, Repeated Dose Escalation/De-escalation Phase I Trial to Determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer	Progressive metastatic castration resistant prostate cancer (mCRPC)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001123538
ACTRN12624001188527	G-DISCO	Phase 1	RECRUITING	WA	2024-09-30	2025-01-10		Docetaxel; Docetaxel + Gemcitabine; Gemcitabine	antimetabolite + taxane; gemcitabine; antimetabolite; taxane	Docetaxel + Gemcitabine	antimetabolite + taxane; gemcitabine	ANZUP 2403	G-DISCO: A Phase 1 study of feasibility, safety and tolerability of synchronous intravesical administration of gemcitabine and docetaxel - ANZUP 2403.	High risk non muscle invasive bladder cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001188527
ACTRN12624001330538	The-Ginger-MAP-Study	Not Applicable	NOT_YET_RECRUITING	QLD	2024-11-01							Nil	The effect of low dose versus high dose ginger supplementation compared to standard care (no ginger) on gastric motility (measured by body surface gastric mapping) in patients receiving chemotherapy classified as at moderate to high risk of emesis.	chemotherapy-induced nausea and vomiting; cancer	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001330538
ACTRN12624001340527	PaxPlus-ABC	Phase 1	NOT_YET_RECRUITING	QLD	2024-11-05			Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paxalisib + Pembrolizumab; Gemcitabine; Nab-paclitaxel; Olaparib; Olaparib + Paxalisib; Paxalisib; Paxalisib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + dual_PI3K/mTOR_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + dual_PI3K/mTOR_inhibitor + platinum-based_antineoplastic_agent + taxane; gemcitabine; dual_PI3K/mTOR_inhibitor; taxane; platinum-based_antineoplastic_agent; PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + dual_PI3K/mTOR_inhibitor	Carboplatin + Gemcitabine + Nab-paclitaxel + Paxalisib + Pembrolizumab; Olaparib + Paxalisib; Paxalisib + Pembrolizumab	PARP_inhibitor + dual_PI3K/mTOR_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + dual_PI3K/mTOR_inhibitor + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + dual_PI3K/mTOR_inhibitor; gemcitabine	KZA-0084-ABC001	A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer	Breast cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001340527
ACTRN12624001342505	ACTRN12624001342505	Not Applicable	NOT_YET_RECRUITING	QLD	2024-11-05			Cytarabine	antimetabolite	Cytarabine	antimetabolite	Nil known	A Prospective, Open-Label, Randomized, Controlled Post-Market Clinical Trial Investigating the Safety and Effectiveness of Human Amnion Membrane (AM) in a Cohort of Patients with Loss of Full Thickness Skin Graft Following Reconstruction of a Cutaneous Nasal Defect Secondary to Skin Cancer Resection.	Failed full thickness skin graft following resection of a cutaneous nasal defect; skin cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001342505
ACTRN12624001458527	DARO-LIPID	Phase 2	NOT_YET_RECRUITING	NSW, QLD, VIC, WA	2024-12-16			Darolutamide; Darolutamide + Opaganib; Opaganib	sphingosine_kinase-2_inhibitor; antiandrogen,nonsteroidal,second_generation + sphingosine_kinase-2_inhibitor; antiandrogen,nonsteroidal,second_generation	Darolutamide + Opaganib	antiandrogen,nonsteroidal,second_generation + sphingosine_kinase-2_inhibitor	ANZUP Cancer Trials Group Ltd: ANZUP2205	Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205)	Prostate Cancer	2830 - Dubbo; 2145 - Westmead; 6009 - Nedlands; 2065 - St Leonards; 2010 - Darlinghurst; 2298 - Waratah; 4102 - Woolloongabba; 3630 - Shepparton; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001458527
ACTRN12624001484538	GBMI12	Phase 2	NOT_YET_RECRUITING	NSW, QLD	2024-12-19			Ifosfamide; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	alkylating_agent + radiotherapy; alkylating_agent; radiotherapy	Radiotherapy + Temozolomide; Ifosfamide	alkylating_agent + radiotherapy	Nil known	Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM).	Glioblastoma multiforme	4120 - Greenslopes; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624001484538
ACTRN12625000197437	NIL-Known	Phase 2	NOT_YET_RECRUITING	QLD	2025-02-20			Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	NIL Known	A single arm, phase II trial of Cemiplimab in Head and Neck Cutaneous Squamous Cell Carcinoma with Large Nerve Perineural Spread	Cutaneous Squamous Cell Carcinoma; Skin Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000197437
ACTRN12625000203459	ENG19	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2025-02-20	2025-04-22		PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	EGFR EDV-D682/GC Trial	An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial)	Colorectal cancer; Bladder/Kidney cancer; EGFR expressing solid tumors; Pancreatic ductal adenocarcinoma (PDAC); Triple negative breast cancer (TNBC); Lung cancer (NSCLC and Mesothelioma)	2060 - North Sydney; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000203459
ACTRN12625000334404	EIK-1005-001	Phase 1	NOT_YET_RECRUITING	VIC	2025-04-17			EIK1005	WRN_inhibitor	EIK1005	WRN_inhibitor	EIK 1005-001	Healthy Participant Study to Assess Safety, Tolerability and Pharmacokinetic Profile of EIK1005, a Werner helicase inhibitor.	MSI-H Solid Tumors	3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000334404
ACTRN12625000361404	ACTRN12625000361404	Phase 1	NOT_YET_RECRUITING	QLD, SA, VIC, WA	2025-04-24							None	A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.	Advanced solid tumours	6150 - Murdoch; 3084 - Heidelberg; 4509 - North Lakes; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000361404
ACTRN12625000697482	DULCE	Phase 2	NOT_YET_RECRUITING	NSW, NT	Help: Date registered 2025-07-01			Placebo	placebo	Placebo	placebo	Nil known	A parallel-group, 2-arm, Phase 2, multisite, stratified, double-blind, randomised, study to investigate the safety and effectiveness of doxycycline or placebo in conjunction with standard of care in adults with metastatic adenocarcinoma of the lung undergoing targeted anti-cancer therapy.	Lung cancer	2145 - Westmead; 0870 - Alice Springs; 2010 - Darlinghurst; 2500 - Wollongong; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000697482
ACTRN12625000779471	ENG20	Phase 1 / Phase 2	NOT_YET_RECRUITING	NSW, SA, VIC	Help: Date registered 2025-07-24			Doxorubicin	doxorubicin; anthracycline	Doxorubicin	anthracycline; doxorubicin	EDV-GBM Trial	A Phase I/IIa Study of EGFR-targeted EDVs Carrying Doxorubicin (E-EDV-Dox) Combined with EDVs Carrying a-Galactosyl Ceramide (EDV-GC) in People with Recurrent Glioblastoma.	Recurrent Glioblastoma	3199 - Frankston; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000779471
ACTRN12625000863437	ACTRN12625000863437	Phase 1	RECRUITING	NSW, VIC, WA	Help: Date registered 2025-08-08	2025-01-23		AXA-042; AXA-042 + Cemiplimab; Cemiplimab	TLR2/TLR6_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; TLR2/TLR6_agonist	AXA-042 + Cemiplimab	TLR2/TLR6_agonist + anti-PD-1_monoclonal_antibody	None	A Phase 1a/1b, first-in-human, open-label, non-randomised, multicenter, dose-escalation and dose -expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours: Phase 1b	Advanced solid tumours	6009 - Nedlands; 2298 - Waratah; 3000 - Melbourne; 3175 - Dandenong; 2050 - Camperdown; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000863437
ACTRN12625000906459	ACTRN12625000906459	Not Applicable	ACTIVE_NOT_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	Help: Date registered 2025-08-20	2024-12-27	2025-06-10					Nil known	Testing the feasibility, acceptability and impact of an online delivered stress management program for Australian with breast and colorectal cancer: a pilot study	colorectal cancer; breast cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000906459
ACTRN12625000964415	EVOLVE-II--HOVON-177--2024-512733-32-00	Phase 3	NOT_YET_RECRUITING	NSW, QLD, SA, VIC, WA	Help: Date registered 2025-09-03			Azacitidine; Azacitidine + Revumenib + Venetoclax; Azacitidine + Venetoclax; Revumenib; Venetoclax	Bcl2_inhibitor + antimetabolite + menin-MLL1_inhibitor; DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; menin-MLL1_inhibitor; Bcl2_inhibitor; antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + menin-MLL1_inhibitor	Azacitidine + Revumenib + Venetoclax; Azacitidine + Venetoclax; Revumenib; Venetoclax	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + menin-MLL1_inhibitor; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + menin-MLL1_inhibitor; menin-MLL1_inhibitor	EVOLVE II  HOVON 177  2024-512733-32-00	ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy	Acute myeloid leukaemia (AML); Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000964415
ACTRN12625000971437	OPTIMAL-PSMA	Phase 2	RECRUITING	NSW	Help: Date registered 2025-09-03	2025-06-16		Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Nil known	Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA Therapy in Patients Diagnosed with Metastatic Castrate Resistant Prostate Cancer : A Randomised Phase II trial: OPTIMAL-PSMA	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000971437
ACTRN12625000989448	MSC-Dental-Implant-Trial	Not Applicable	NOT_YET_RECRUITING	NSW	Help: Date registered 2025-09-08							None	A randomised controlled trial comparing effectiveness of rough and smooth dental implants on jaw function after jaw reconstruction for cancer patients.	Head and Neck Cancer; Dental Implants; Jaw Reconstruction	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000989448
ACTRN12625000995471	2025-522767-15--HOVON-181-AML--AMLSG-37-25	Phase 3	NOT_YET_RECRUITING	NSW, QLD, SA, VIC, WA	2025-09-09			Bleximenib; Cytarabine; Daunorubicin; Daunorubicin + Idarubicin; Idarubicin; Placebo	placebo; anthracycline; KMT2A_inhibitor; antimetabolite	Bleximenib; Cytarabine; Daunorubicin + Idarubicin; Placebo	KMT2A_inhibitor; anthracycline; antimetabolite; placebo	2025-522767-15  HOVON 181 AML  AMLSG 37-25	ALLG AMLM31: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study.	Cancer; Acute myeloid leukaemia (AML)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625000995471
ACTRN12625001015437	none	Not Applicable	NOT_YET_RECRUITING		Help: Date registered 2025-09-12							none	EffIcacy of Intracavitary Manual Lymphatic Drainage as a Treatment for Vaginal Stenosis in Women With Sequelae of Post-Breast Cancer Treatment	breast cancer; vaginal stenosis		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625001015437
ACTRN12625001075471	FIGURE-pall-HNC	Not Applicable	NOT_YET_RECRUITING	QLD	Help: Date registered 2025-10-02			Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	None	Feasibility of functional magnetic resonance Imaging GUided Radiation therapy dose Escalation in Head and Neck Cancer patients (FIGURE-pall HNC)	Head and neck cancer	4575 - Birtinya	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625001075471
ACTRN12625001083482	SP-03-B101	Phase 1 / Phase 2	NOT_YET_RECRUITING	ACT, NSW, NT, QLD, SA, TAS, VIC, WA	Help: Date registered 2025-10-03			Everolimus; Exemestane; Exemestane + Filgrastim + Metformin; Filgrastim; Metformin	aromatase_inhibitor; granulocyte_colony_stimulating_factor; mTORC1_inhibitor; aromatase_inhibitor + biguanide_antihyperglycaemic_agent + granulocyte_colony_stimulating_factor; biguanide_antihyperglycaemic_agent	Everolimus; Exemestane; Exemestane + Filgrastim + Metformin	aromatase_inhibitor; aromatase_inhibitor + biguanide_antihyperglycaemic_agent + granulocyte_colony_stimulating_factor; mTORC1_inhibitor	SP-03-B101	A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Combination with Exemestane in Post-Menopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer After Progression on a Non-Steroidal Aromatase Inhibitor.	Breast Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12625001083482
NCT02582697	P3BEP	Phase 3	RECRUITING	NSW, NZ, QLD, SA, TAS, VIC, WA	2015-10-19	2014-02	2029-12-31	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim + Pegfilgrastim; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; antineoplastic_antibiotic	Bleomycin + Cisplatin + Etoposide + Filgrastim + Pegfilgrastim	antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	ANZUP1302	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	1023 - Grafton - Starship Children's Hospital; 1142 - Grafton - Auckland Hospital; 2031 - Sydney - Prince of Wales Hospital; 2050 - Sydney - Chris O'Brien Lifehouse; 2065 - St Leonards - Royal North Shore Hospital; 2076 - Wahroonga - SAN Clinical Trials Unit; 2109 - Sydney - Macquarie Cancer Clinical Trials; 2139 - Sydney - Concord Repatriation General Hospital; 2145 - Sydney - Westmead Hospital - (WITHDRAWN); 2298 - Newcastle - Calvary Mater Newcastle; 2485 - Tweed Heads - Tweed Hospital; 2751 - Sydney - Nepean Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital - (WITHDRAWN); 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3690 - Wodonga - Border Medical Oncology; 4029 - Brisbane - Royal Brisbane & Women's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 4102 - Woolloongabba - Princess Alexandra; 4442 - Roslyn - Palmerston North Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6847 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital; 8011 - Christchurch - Christchurch Hospital; 9054 - Dunedin - Dunedin Hospital - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02628067	KEYNOTE-158	Phase 2	ACTIVE_NOT_RECRUITING		Help: Date registered 2015-12-11	2015-12-18		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	163196  3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Small Cell Lung Carcinoma; Anal Cancer; Neuroendocrine Tumor; Bile Duct Cancer; Vulvar Carcinoma; Salivary Cancer; Endometrial Carcinoma; Advanced Solid Tumors; Carcinoid Tumor; Thyroid Carcinoma; Colorectal Carcinoma; Biliary Cancer; Cervical Cancer; Cholangiocarcinoma; Thyroid Cancer; Salivary Gland Cancer; Vulvar Cancer; Small Cell Lung Cancer (SCLC); Salivary Gland Carcinoma; Parotid Gland Cancer; Anal Carcinoma; Advanced Cancer; Endometrial Cancer; Cervical Carcinoma; Mesothelioma		https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2	RECRUITING	NSW	2015-12-30	2021-11-22	2028-12	Ceritinib; Ribociclib; Ribociclib + Trametinib; Trametinib	MEK_inhibitor; ALK/ROS1/IGF1R_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	Ribociclib + Trametinib; Trametinib; Ceritinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor; ALK/ROS1/IGF1R_inhibitor	MIA2015/174	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2145 - Westmead - Westmead Hospital; 2260 - Wollstonecraft - Melanoma Institute Australia	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02861573	KEYNOTE-365	Phase 1 / Phase 2	RECRUITING	NSW, NZ	2016-08-05	2016-11-17	2027-10-22	Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Belzutifan; Belzutifan + Pembrolizumab; Carboplatin; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Docetaxel; Enzalutamide; Enzalutamide + Pembrolizumab; Etoposide; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Vibostolimab; Prednisone; Vibostolimab	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; antiandrogen,nonsteroidal,second_generation; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; HIF2a_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; VEGF_inhibitor; glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	Abiraterone + Pembrolizumab + Prednisone; Belzutifan + Pembrolizumab; Carboplatin + Etoposide; Carboplatin + Etoposide + Pembrolizumab; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib + Pembrolizumab; Pembrolizumab + Vibostolimab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland - Merck Sharp & Dohme (New Zealand) Ltd.,; North Ryde - MSD Australia	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02960022	9785-CL-0123	Phase 2	RECRUITING	NSW, NZ, VIC, WA	2016-11-07	2016-12-22	2026-07-31	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Enzalutamide + Leuprolide Acetate; Leuprolide Acetate; Prednisone	antiandrogen,nonsteroidal,second_generation + synthetic_gonadotropin-releasing_hormone; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; GnRH_analogue; CYP17A1_inhibitor; GnRH_analogue + antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Enzalutamide + Leuprolide Acetate	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; GnRH_analogue + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation + synthetic_gonadotropin-releasing_hormone	9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	2076 - Wahroonga - Site AU61012 - (COMPLETED); 2076 - Wahroonga - Site AU61017; 2145 - Westmead - Site AU61004; 2485 - Tweed Heads - Site AU61001 - (COMPLETED); 2640 - Albury - Site AU61014 - (COMPLETED); 3021 - St Albans - Site AU61016; 3165 - East Bentleigh - Site AU61007 - (COMPLETED); 3350 - Ballarat - Site AU61019; 9016 - Dunedin - Site NZ64005; Ashford - Site AU61006; Hamilton - Site NZ64001; Malvern - Site AU61009 - (COMPLETED); Parkville - Site AU61021 - (COMPLETED); South Brisbane - Site AU61008 - (COMPLETED); V2S 3N5 - Auckland - Site NZ64002	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT03093116	TRIDENT-1	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC	2017-03-21	2017-03-07	2028-02-29	Repotrectinib	ALK_inhibitor,third_generation; TRK_inhibitor,second_generation; ROS1_inhibitor	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	CA127-1024	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Locally Advanced Solid Tumors; Metastatic Solid Tumors	2050 - Camperdown - Local Institution - 6102 - (COMPLETED); 3000 - Melbourne - Local Institution - 6101 - (COMPLETED); 3002 - East Melbourne - Local Institution - 3301 - (COMPLETED); 5042 - Adelaide - Local Institution - 6103 - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03175224	SPARTA	Phase 2	RECRUITING	VIC	2017-06-01	2017-09-27	2026-11-30	Vebreltinib	MET_inhibitor,type_1	Vebreltinib	MET_inhibitor,type_1	APL-101-01	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Solid Tumors; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; NSCLC; Lung Cancer; Brain Tumor; Glioblastoma Multiforme; EGFR Gene Mutation; MET Amplification; HGF; Thyroid Cancer; Pancreatic Cancer; Colon Cancer; MET Alteration; MET Fusion; Exon 14 Skipping	Melbourne - St Vincents Hospital Melbourne	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03229200	PCYC-1145-LT	Phase 4	ENROLLING_BY_INVITATION	NSW, NZ, QLD, SA, VIC	2017-07-24	2017-05-22	2027-05-10	Ibrutinib	BTK_inhibitor	Ibrutinib	BTK_inhibitor	PCYC-1145-LT	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.	Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, B-cell; Graft Vs Host Disease; Solid Tumor	0622 - Auckland - North Shore Hospital; 2025 - Papatoetoe - Middlemore Hospital; 2139 - Sydney - Concord Repatriation General Hospital - Haematology Clinical Trials; 2217 - Kogarah - St. George Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Fitzroy - St Vincent Hospital; 3128 - Box Hill - Eastern Health; 3168 - Clayton - Monash Health-Monash Medical Centre; 3350 - Ballarat - Ballarat Health Services; 4102 - Woolloongabba - Princess Alexandra Hospital; 5067 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT03229200
NCT03319628	XMT-1536-1	Phase 1	ACTIVE_NOT_RECRUITING		Help: Date registered 2017-10-24	2017-12-12		Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	XMT-1536-1	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Platinum Resistant Ovarian Cancer; Non Small Cell Lung Cancer Metastatic		https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03363867	BEACON	Phase 2	UNKNOWN	VIC	2017-12-04	2018-07-10	2025-06-30	Atezolizumab; Atezolizumab + Bevacizumab + Cobimetinib; Bevacizumab; Cobimetinib	MEK_inhibitor; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	BEACON	BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03363867
NCT03424005	Morpheus-panBC	Phase 1 / Phase 2	RECRUITING	VIC, WA	2018-02-05	2018-03-30	2028-05-03	Abemaciclib; Abemaciclib + Fulvestrant + Inavolisib; Abemaciclib + Inavolisib + Letrozole; Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Fulvestrant; Fulvestrant + Inavolisib + Ribociclib; Gemcitabine; Inavolisib; Inavolisib + Letrozole + Ribociclib; Inavolisib + Trastuzumab Deruxtecan; Ipatasertib; Ladiratuzumab Vedotin; Letrozole; Nab-paclitaxel; Ribociclib; Sacituzumab Govitecan; Selicrelumab; Tocilizumab; Trastuzumab Deruxtecan	anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor; anti-CD40_agonistic_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; selective_estrogen_receptor_degrader; gemcitabine; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; aromatase_inhibitor; anti-Trop2_antibody-drug_conjugate; anti-LIV1_antibody-drug_conjugate; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-IL-6_monoclonal_antibody; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; pan-AKT_inhibitor; macrocyclic_ketone_analogue; taxane; platinum-based_antineoplastic_agent; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; fluoropyrimidine; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane	Abemaciclib + Fulvestrant + Inavolisib; Abemaciclib + Inavolisib + Letrozole; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine; Fulvestrant + Inavolisib + Ribociclib; Inavolisib + Letrozole + Ribociclib; Inavolisib + Trastuzumab Deruxtecan	CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; fluoropyrimidine; gemcitabine	CO40115	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)	Metastatic Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne; 6150 - Murdoch - Fiona Stanley Hospital - Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03486873	3475-587	Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC, WA, Waikato Region	2018-03-29	2018-08-21	2043-08-04	Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Olaparib; Pembrolizumab	anti-LAG3_monoclonal_antibody; VEGF_inhibitor; PARP_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Olaparib; Pembrolizumab	PARP_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	3475-587	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	Solid Tumors; Hematologic Malignancies	1023 - Auckland - Auckland City Hospital ( Site 1503); 2050 - Camperdown - Chris OBrien Lifehouse ( Site 3003); 2050 - Camperdown - Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016); 2060 - North Sydney - Mater Hospital Sydney ( Site 3007); 2065 - St Leonards - Royal North Shore Hospital-Medical Oncology Clinical Trials ( Site 3025); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 3001); 2109 - Macquarie University - Macquarie University ( Site 3010); 2145 - Westmead - Westmead Hospital ( Site 3000); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 3021); 2298 - Waratah - Calvary Mater Newcastle ( Site 3005); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3020); 2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 3027); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3008); 3021 - St Albans - Western Health-Sunshine & Footscray Hospitals ( Site 3023); 3065 - Melbourne - St Vincent's Hospital-Oncology Clinical Trials ( Site 3018); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3004); 3168 - Clayton - Monash Health ( Site 3015); 3204 - Hamilton - Waikato Hospital ( Site 1502); 3355 - Wendouree - Ballarat Oncology & Haematology Services ( Site 3022); 4029 - Herston - Royal Brisbane and Women's Hospital ( Site 3009); 4101 - Brisbane - Mater Misericordiae Limited-Medical Oncology ( Site 3019) - (COMPLETED); 4102 - Woolloongabba - Princess Alexandra Hospital ( Site 3002); 4120 - Brisbane - Gallipoli Medical Research Ltd ( Site 3011); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 3012); 4814 - Townsville - The Townsville Hospital ( Site 3017); 5000 - Adelaide - Royal Adelaide Hospital ( Site 3014); 5011 - Woodville - The Queen Elizabeth Hospital ( Site 3026); 6008 - Subiaco - St John of God Subiaco Hospital ( Site 3013); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 3006); 6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital ( Site 1501); 8011 - Christchurch - Canterbury Regional Cancer & Blood Service ( Site 1500)	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03522064	HiTeCH	Phase 2	RECRUITING	NSW	2018-05-10	2018-07-30	2025-12-30	Carboplatin; Carboplatin + Testosterone Enanthate; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone; platinum-based_antineoplastic_agent + testosterone	Carboplatin + Testosterone Enanthate	platinum-based_antineoplastic_agent + testosterone	HiTECH	High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Castration-resistant Prostate Cancer; Homologous Recombination Deficiency	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03537482	APG2575-001	Phase 1	RECRUITING	VIC	2018-05-15	2018-08-07	2025-02-15	Lisaftoclax	Bcl2_inhibitor	Lisaftoclax	Bcl2_inhibitor	APG2575-001	A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	3065 - Fitzroy - St. Vincent Hospital; 3121 - Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03557619	M16-185	Phase 1	RECRUITING	VIC	2018-06-14	2019-07-30	2026-03-21	Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	M16-185	A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	3002 - East Melbourne - Peter MacCallum Cancer Centre-East Melbourne /ID# 225247	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03564340	R4018-ONC-1721	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2018-06-08	2018-05-21	2027-01-31	Cemiplimab; Cemiplimab + REGN4018; REGN4018; REGN4018 + Tocilizumab; Tocilizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting; anti-IL-6_monoclonal_antibody; bispecific_T-cell_engager,MUC16-targeting; anti-PD-1_monoclonal_antibody; anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting	Cemiplimab + REGN4018; REGN4018 + Tocilizumab	anti-IL-6_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,MUC16-targeting	R4018-ONC-1721	A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers	Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer; Endometrial Cancer; Low-grade Serous Ovarian Cancer	3000 - Melbourne - Peter MacCallum Cancer Center; NSW 2031 - Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT03564340
NCT03746431	FPX-01-01	Phase 1 / Phase 2	RECRUITING	SA, VIC	2018-11-15	2019-01-17	2026-06	FPI-1175; FPI-1175 + FPI-1547; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175 + FPI-1547; FPI-1547	IGF1R-radionucleotide_conjugate	FPX-01-01	A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours	Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma	3084 - Heidelberg - Austin Hospital; 5000 - Adelaide - Royal Adelaide Hospital - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03787602	KRT-232-103	Phase 1 / Phase 2	UNKNOWN	QLD	2018-12-21	2019-03-19	2025-08	Avelumab; Avelumab + Navtemadlin; Navtemadlin	MDM2_inhibitor; anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab + Navtemadlin; Navtemadlin	MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	Merkel Cell Carcinoma	Woolloongabba - Princess Alexandra Hospital Oncology	https://clinicaltrials.gov/ct2/show/NCT03787602
NCT03816254	U1111-1224-8251--CC-95251-ST-001	Phase 1		VIC	2018-12-21	2019-03-01		CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab; Cetuximab; Rituximab	anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody; anti-EGFR_monoclonal_antibody	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab	anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-SIRPa_monoclonal_antibody	U1111-1224-8251  CC-95251-ST-001	A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers	Neoplasms	3084 - Heidelberg; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03816254
NCT03900442	PTX-100-PD-012017	Phase 1	UNKNOWN_STATUS	VIC	2019-03-30	2019-09-01	2025-08-08	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100-PD-012017	Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer; PTCL	3002 - Melbourne - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03906331	NCT03906331		APPROVED_FOR_MARKETING	NSW, NZ, QLD, VIC, WA	2019-04-04			Selpercatinib	RET-selective_inhibitor	Selpercatinib	RET-selective_inhibitor	17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration	2050 - Camperdown - NSW Health - Sydney Local Health District; 2065 - St Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4032 - Chermside - Queensland Health - Metro North Hospital and Health Service; 6009 - Nedlands - Linear Clinical Research; 91346 - Auckland - University of Auckland	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03947385	IDE196-001	Phase 1 / Phase 2	RECRUITING	NSW	2019-05-09	2019-06-28	2027-03-31	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Crizotinib + Darovasertib + Lomustine; Darovasertib; Lomustine	ALK_inhibitor,first_generation; PKC_inhibitor + ROS1_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor + alkylating_agent; ALK_inhibitor,first_generation + PKC_inhibitor; alkylating_agent; MET_inhibitor,type_1 + PKC_inhibitor + alkylating_agent; MEK_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor + alkylating_agent; MEK_inhibitor + PKC_inhibitor; PKC_inhibitor	Binimetinib + Darovasertib; Crizotinib + Darovasertib; Crizotinib + Darovasertib + Lomustine; Darovasertib	ALK_inhibitor,first_generation + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor + alkylating_agent; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor + alkylating_agent; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; PKC_inhibitor + ROS1_inhibitor + alkylating_agent	IDE196-001	A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors	Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03970447	GBM-AGILE	Phase 2 / Phase 3	RECRUITING	NSW, QLD, SA, VIC	2019-05-30	2019-07-30	2030-06	AZD1390; AZD1390 + Temozolomide; Lomustine; Lomustine + Radiotherapy + Temozolomide; Paxalisib; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + Troriluzole; Radiotherapy + Temozolomide + VAL-083; Regorafenib; Temozolomide; Temozolomide + Troriluzole; Troriluzole; VAL-083	glutamate_modulator; dual_PI3K/mTOR_inhibitor; radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent; arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + glutamate_modulator; ATM_inhibitor + alkylating_agent; alkylating_agent + radiotherapy; alkylating_agent + glutamate_modulator + radiotherapy; ATM_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy	AZD1390 + Temozolomide; Lomustine + Radiotherapy + Temozolomide; Paxalisib + Radiotherapy + Temozolomide; Pegargiminase; Pegargiminase + Temozolomide; Radiotherapy + Regorafenib + Temozolomide; Radiotherapy + Temozolomide; Radiotherapy + Temozolomide + Troriluzole; Radiotherapy + Temozolomide + VAL-083; Temozolomide + Troriluzole; Troriluzole	ATM_inhibitor + alkylating_agent; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + radiotherapy; alkylating_agent + arginine_deiminase-polyethylene_glycol_conjugate; alkylating_agent + dual_PI3K/mTOR_inhibitor + radiotherapy; alkylating_agent + glutamate_modulator; alkylating_agent + glutamate_modulator + radiotherapy; alkylating_agent + radiotherapy; arginine_deiminase-polyethylene_glycol_conjugate; glutamate_modulator	GCAR-7213	GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM	Glioblastoma	2065 - St Leonards - Northern Sydney Cancer Centre/Royal North Shore Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3084 - Heidelberg - Austin Health; 4029 - Herston - Royal Brisbane and Women's Hospital; 5042 - Bedford Park - Flinders Medical Centre; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03970447
NCT04064060	ACE-536-LTFU-001	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2019-08-19	2019-08-12	2028-05-12	Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	ACE-536-LTFU-001	A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis	2050 - Camperdown - Royal Prince Alfred Hospital; 3168 - Clayton - Local Institution - 102 - (COMPLETED); 4101 - South Brisbane - Local Institution - 100 - (COMPLETED); 5000 - Adelaide - Royal Adelaide Hospital	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04077463	Chrysalis-2	Phase 1	NOT_RECRUITING		Help: Date registered 2019-09-04	2019-09-04		Amivantamab; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; antimetabolite	Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Lazertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody	73841937NSC1001  CR108656	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT04077463
NCT04106492	SQ3370-001	Phase 1 / Phase 2	RECRUITING	NSW, SA	2019-09-25	2020-08-01	2026-07-09	SQ3370	anthracycline	SQ3370	anthracycline	SQ3370-001	A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - Sydney - Royal North Shore Hospital; 5000 - Adelaide - Cancer Research Institute	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04164199	BGB-A317-290-LTE1	Phase 3	ENROLLING_BY_INVITATION	NSW, NZ, QLD, SA, VIC	2019-11-14	2019-12-19	2026-12	BGB-15025; BGB-15025 + Tislelizumab; BGB-A445; BGB-A445 + Tislelizumab; Fruquintinib; Fruquintinib + Tislelizumab; LBL-007; LBL-007 + Tislelizumab; Lenvatinib; Lenvatinib + Tislelizumab; Ociperlimab; Ociperlimab + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Sitravatinib; Sitravatinib + Tislelizumab; Temozolomide; Tislelizumab; Tislelizumab + Zanidatamab; Zanidatamab	RET_inhibitor; alkylating_agent; HPK1_inhibitor; PDGFR_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor; VEGFR_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor; anti-OX40_agonistic_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + alkylating_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-LAG3_monoclonal_antibody; VEGF_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; bispecific_ERBB2/ERBB2_antibody; PARP_inhibitor; VEGFR1/2/3_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody	BGB-15025; BGB-15025 + Tislelizumab; BGB-A445 + Tislelizumab; Fruquintinib + Tislelizumab; LBL-007 + Tislelizumab; Lenvatinib + Tislelizumab; Ociperlimab + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab; Tislelizumab + Zanidatamab; Zanidatamab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR1/2/3_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody	BGB-A317-290-LTE1	An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies	Advanced Malignancies	1023 - Auckland - Auckland City Hospital; NSW 2031 - Randwick - Prince of Wales Hospital; NSW 2065 - St Leonards - Northern Cancer Institute; NSW 2298 - Waratah - Calvary Mater Newcastle; QLD 4101 - South Brisbane - Icon Cancer Centre South Brisbane; SA 5011 - Woodville South - The Queen Elizabeth Hospital; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3168 - Clayton - Monash Health	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04170283	BGB-3111-LTE1	Phase 3	ENROLLING_BY_INVITATION	ACT, NSW, NZ, QLD, SA, TAS, VIC, WA	2019-11-19	2020-01-21	2028-12	Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor; anti-PD-1_monoclonal_antibody	Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody	BGB-3111-LTE1	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	0622 - Takapuna - North Shore Hospital; 1023 - Auckland - Auckland City Hospital; 2025 - Auckland - Aotearoa Clinical Trials; 2065 - St Leonards - Royal North Shore Hospital; 2139 - Concord - Concord Repatriation General Hospital; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2298 - Waratah - Calvary Mater Newcastle; 2606 - Canberra - Paratus Clinical Research Woden; 2640 - East Albury - Border Medical Oncology; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3084 - Heidelberg - Austin Health; 3112 - Tauranga - Tauranga Hospital; 3128 - Box Hill - Box Hill Hospital; 3144 - Malvern - Cabrini Hospital Malvern; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula Private Hospital; 3204 - Hamilton Waikato - Waikato Hospital; 3220 - Geelong - Barwon Health the Geelong Hospital; 4066 - Auchenflower - Icon Cancer Centre Wesley; 4102 - Brisbane - Princess Alexandra Hospital; 4120 - Greenslopes - Brisbane Clinic For Lymphoma; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park; 5042 - Bedford PK - Flinders Medical Centre; 6000 - Perth - Royal Perth Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6021 - Wellington - Wellington Regional Hospital (Ccdhb); 7000 - Hobart - Royal Hobart Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04185883	NCT04185883	Phase 1	RECRUITING	NSW, QLD, SA, WA	2019-12-03	2019-12-17	2027-12-05	AMG 404; AMG 404 + Sotorasib; Afatinib; Afatinib + Sotorasib; Atezolizumab; Atezolizumab + Sotorasib; BI 1701963; BI 1701963 + Sotorasib; Bevacizumab; Bevacizumab + Sotorasib; Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Docetaxel; Everolimus; Everolimus + Sotorasib; Paclitaxel; Palbociclib; Palbociclib + Sotorasib; Panitumumab; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab; Pembrolizumab + Sotorasib; Pemetrexed; Sotorasib; Sotorasib + TNO155; Sotorasib + Vociprotafib; TNO155; Trametinib; Vociprotafib	anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; mTORC1_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C_inhibitor; SOS1-KRAS_inhibitor; KRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; ERBB2_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; CDK4/6_inhibitor; KRAS_G12C_inhibitor; antimetabolite; ERBB2_inhibitor,second_generation; CDK4/6_inhibitor + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + mTORC1_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; taxane; KRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,second_generation + KRAS_G12C_inhibitor; MEK_inhibitor; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; BI 1701963 + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; Sotorasib; Sotorasib + TNO155; Sotorasib + Vociprotafib	CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; CDK4/6_inhibitor + KRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C_inhibitor; ERBB2_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; ERBB2_inhibitor,second_generation + KRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SOS1-KRAS_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + mTORC1_inhibitor	20190135	A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation	2065 - St Leonards - GenesisCare -North Shore Oncology; 2747 - Kingswood - Nepean Cancer Centre; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 5011 - Woodville South - The Queen Elizabeth Hospital; 6008 - Subiaco - St John of God Healthcare - (TERMINATED)	https://clinicaltrials.gov/ct2/show/NCT04185883
NCT04221035	HR-NBL2	Phase 3	RECRUITING	NSW, NZ, VIC, WA	2020-01-06	2019-11-05	2032-11	Busulfan; Busulfan + Melphalan + Thiotepa; Carboplatin; Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Dinutuximab + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Temozolomide + Vincristine; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Dinutuximab + Radiotherapy; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Melphalan; Radiotherapy; Temozolomide; Thiotepa; Vincristine	alkylating_agent + anthracycline + anti-GD2_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; anti-GD2_monoclonal_antibody; radiotherapy; platinum-based_antineoplastic_agent; doxorubicin; alkylating_agent; anti-GD2_monoclonal_antibody + radiotherapy; topoisomerase_inhibitor; vinca_alkaloid	Busulfan + Melphalan + Thiotepa; Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Dinutuximab + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Temozolomide + Vincristine; Dinutuximab + Radiotherapy	alkylating_agent; alkylating_agent + anthracycline + anti-GD2_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; anti-GD2_monoclonal_antibody + radiotherapy; doxorubicin	2019-001068-31	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy	NSW, 2031 - Sydney - Australian and New Zealand Children's Hematology/oncology Group; NSW, 2031 - Sydney - Sydney children Hospital; NSW, 2031 - Sydney - sydney children Hospital; NSW, 2145, - Westmead - Cancer Centre for Children, The Children's Hospital - (SUSPENDED); NSW, 2305 - New Lambton Heights - Children's Cancer & Haematology Services, John Hunter Children's Hospital; VIC 3168 - Clayton - Children's Cancer Centre, Monash Children's Hospital; WA, 6009 - Nedlands - Oncology/Haematology Department, Perth Children's Hospital - (SUSPENDED)	https://clinicaltrials.gov/ct2/show/NCT04221035
NCT04221542	NCT04221542	Phase 1	RECRUITING	NSW, VIC	2020-01-06	2020-03-04	2032-03-04	Abiraterone; Abiraterone + Enzalutamide + Xaluritamig; Abiraterone + Xaluritamig; Enzalutamide; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor + bispecific_T-cell_engager,STEAP1-targeting	Abiraterone + Enzalutamide + Xaluritamig; Abiraterone + Xaluritamig; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor + bispecific_T-cell_engager,STEAP1-targeting; bispecific_T-cell_engager,STEAP1-targeting	20180146	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04262466	IMC-F106C-101	Phase 1 / Phase 2	RECRUITING	NSW, NZ, VIC, WA	2020-02-07	2020-02-25	2026-08	Bevacizumab; Bevacizumab + Pembrolizumab; Bevacizumab + Tebentafusp; IMC-F106C; Pembrolizumab; Tebentafusp	anti-VEGF_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; anti-VEGF_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; bispecfic_T-cell_engager,gp100-targeting	Bevacizumab + Pembrolizumab; Bevacizumab + Tebentafusp; Pembrolizumab; IMC-F106C	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; bispecific_T-cell_engager,PRAME-targeting	IMC-F106C-101	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers	Select Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research - (COMPLETED); 2065 - Wollstonecraft - Melanoma Institute Australia (MIA) - The Poche Centre; 3004 - Melbourne - The Alfred Hospital; 6009 - Nedlands - Linear Clinical Research; 92697 - Auckland - New Zealand Clinical Research-Auckland	https://clinicaltrials.gov/ct2/show/NCT04262466
NCT04423029	DF6002	Phase 1	RECRUITING	VIC	2020-06-05	2020-07-13	2027-11-30	DF6002; DF6002 + Nivolumab; Nivolumab	IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IL-12_Fc-fusion_protein	DF6002; DF6002 + Nivolumab	IL-12_Fc-fusion_protein; IL-12_Fc-fusion_protein + anti-PD-1_monoclonal_antibody	DF6002 - 001	A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Solid Tumors	3084 - Heidelberg - Local Institution - 0022 - (WITHDRAWN); 3128 - Box Hill - Local Institution - 0023 - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT04423029
NCT04429542	BCA101X1101	Phase 1	RECRUITING	NSW, VIC	2020-06-11	2020-06-01	2027-06-01	BCA101; BCA101 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + bifunctional_EGFR/TGF-beta_fusion_protein; anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein	BCA101; BCA101 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bifunctional_EGFR/TGF-beta_fusion_protein; bifunctional_EGFR/TGF-beta_fusion_protein	BCA101X1101	First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors	Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Colorectal Cancer; Squamous Cell Carcinoma of the Lung; EGFR Amplification; Epithelial Ovarian Cancer; Pancreas Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck	2050 - Camperdown - Chris O'Brien Lifehouse; 2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT04429542
NCT04464226	NCT04464226	Phase 3	RECRUITING	SA	2020-07-07	2020-10-20	2028-06-26	Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	20321	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park - Adelaide Cancer Centre Research Pty Ltd - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04503278	BNT211-01	Phase 1	RECRUITING	VIC	2020-08-04	2020-09-16	2041-01	CLDN6 CAR-T; CLDN6 RNA-LPX	mRNA_vaccine,CLDN6-targeting; autologous_CAR-T-cell_therapy,CLDN6-targeting	CLDN6 CAR-T; CLDN6 RNA-LPX	autologous_CAR-T-cell_therapy,CLDN6-targeting; mRNA_vaccine,CLDN6-targeting	BNT211-01	Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors	Solid Tumor	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04503278
NCT04516447	ZN-c3-002	Phase 1	RECRUITING	QLD, SA, VIC, WA	2020-08-14	2020-10-26	2027-02-28	Azenosertib; Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Pegylated liposomal doxorubicin; Bevacizumab; Carboplatin; Gemcitabine; Paclitaxel; Pegylated liposomal doxorubicin	WEE1_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; WEE1_inhibitor + anthracycline; gemcitabine; taxane; platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; anthracycline; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + antimetabolite; WEE1_inhibitor	Azenosertib + Bevacizumab; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Pegylated liposomal doxorubicin	WEE1_inhibitor + anthracycline; WEE1_inhibitor + anti-VEGF_monoclonal_antibody; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; gemcitabine	ZN-c3-002	A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	3121 - Melbourne - Site 2716; 3144 - Melbourne - Site 2706; 4101 - South Brisbane - Site 2707; 4556 - Sunshine Coast - Site 2708; 5000 - Adelaide - Site 2709; 6009 - Nedlands - Site 2705	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04524871	MORPHEUS-LIVER	Phase 1 / Phase 2	RECRUITING	NZ	2020-08-21	2020-11-01	2026-12-31	ADG126; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + NKT2152; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab; Bevacizumab + Tobemstomig; NKT2152; TPST-1120; Tiragolumab; Tobemstomig; Tocilizumab	anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-CTLA4_monoclonal_antibody; HIF2a_inhibitor; HIF2a_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; PPAR-alpha_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; bispecific_PD-1/LAG3_antibody	ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + NKT2152; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + Tobemstomig	HIF2a_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	GO42216	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	1023 - Auckland - Auckland City Hospital	https://clinicaltrials.gov/ct2/show/NCT04524871
NCT04534205	AHEAD-MERIT	Phase 2 / Phase 3	RECRUITING	NSW, QLD, SA, VIC	2020-08-27	2021-01-07	2029-04	BNT113; BNT113 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + vaccine_therapy,HPV-E6/HPV-E7-targeting; anti-PD-1_monoclonal_antibody; vaccine_therapy,HPV-E6/HPV-E7-targeting	BNT113 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + vaccine_therapy,HPV-E6/HPV-E7-targeting	BNT113-01	An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1	Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 2200 - Bankstown - Bankstown-Lidcombe Hospital - (WITHDRAWN); 2450 - Coffs Harbour - Coffs Harbour Hospital - (WITHDRAWN); 2500 - Wollongong - Southern Medical Day Care Centre; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Cancer Research SA; 5042 - Bedford Park - Flinders Medical Centre; VIC 3065 - Fitzroy - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT04534205
NCT04585750	PMV-586-101	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2020-10-07	2020-10-29	2026-07-14	Pembrolizumab; Pembrolizumab + Rezatapopt; Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody; mutant_p53_reactivator,Y220C-selective	Pembrolizumab + Rezatapopt; Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective	PMV-586-101	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer; Gall Bladder Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Small Cell Lung Carcinoma; NSCLC; NSCLC (Non-small Cell Lung Cancer); SCLC; Non-Small Cell Lung Carcinoma; Triple Negative Breast Cancer; TNBC; HER2+ Breast Cancer; Non-Small Cell Lung Cancer; ER/PR Positive Breast Cancer; HER2- Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; ER/PR(+), Her2(-) Breast Cancer	Bedford Park - Flinders Medical Center; Camperdown - Chris O'Brien Lifehouse Hospital; Clayton - Monash Medical Centre; Nedlands - Linear Clinical Research; South Brisbane - Mater Cancer Care Centre	https://clinicaltrials.gov/ct2/show/NCT04585750
NCT04597411	PSMA-617-100	Phase 1	RECRUITING	NSW	2020-10-16	2021-04-01	2027-01-01	225Ac-PSMA-617; 225Ac-PSMA-617 + Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan; Abiraterone; Enzalutamide; Lu-177 vipivotide tetraxetan	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; CYP17A1_inhibitor; radioligand,PSMA-targeting; radioconjugate,PSMA-targeting	225Ac-PSMA-617; 225Ac-PSMA-617 + Abiraterone + Enzalutamide + Lu-177 vipivotide tetraxetan; 225Ac-PSMA-617 + Lu-177 vipivotide tetraxetan	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; radioconjugate,PSMA-targeting + radioligand,PSMA-targeting; radioligand,PSMA-targeting	PSMA-617-100	AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy	Prostatic Neoplasms, Castration-Resistant	Darlinghurst - St. Vincent's Hospital Research Office-Translational Research Center	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04606446	KAT6	Phase 1	RECRUITING	NSW, SA, VIC, WA	2020-10-22	2020-11-16	2029-09-22	Fulvestrant; Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole; Letrozole + PF-07248144 + Palbociclib; PF-07220060; PF-07248144; PF-07248144 + Vepdegestrant; Palbociclib; Vepdegestrant	CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader; ER_PROTAC_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor; KAT6_inhibitor; ER_PROTAC_degrader + KAT6_inhibitor; CDK4/6_inhibitor	Fulvestrant + PF-07220060 + PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib; PF-07248144; PF-07248144 + Vepdegestrant	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + KAT6_inhibitor + selective_estrogen_receptor_degrader; ER_PROTAC_degrader + KAT6_inhibitor; KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader	C4551001	A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS	Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse - (TERMINATED); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Western Health-Sunshine & Footscray Hospitals; 3050 - Parkville - Royal Melbourne Hospital; 5000 - Adelaide - Cancer Research South Australia; 6008 - Subiaco - St. John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT04606446
NCT04612751	TROPION-Lung04	Phase 1	ACTIVE_NOT_RECRUITING		Help: Date registered 2020-11-03	2021-02-02		AZD7789; AZD7789 + Datopotamab deruxtecan; Carboplatin; Carboplatin + Datopotamab deruxtecan + Durvalumab; Carboplatin + Datopotamab deruxtecan + Rilvegostomig; Carboplatin + Datopotamab deruxtecan + Volrustomig; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Datopotamab deruxtecan + Rilvegostomig; Datopotamab deruxtecan + Volrustomig; Durvalumab; Rilvegostomig; Volrustomig	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; bispecific_PD-1/TIM3_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIM3_antibody; bispecific_PD-L1/CTLA4_antibody; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody	AZD7789 + Datopotamab deruxtecan; Carboplatin + Datopotamab deruxtecan + Durvalumab; Carboplatin + Datopotamab deruxtecan + Rilvegostomig; Carboplatin + Datopotamab deruxtecan + Volrustomig; Datopotamab deruxtecan + Durvalumab; Datopotamab deruxtecan + Rilvegostomig; Datopotamab deruxtecan + Volrustomig	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIM3_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	2023-505992-54-00  D926FC00001	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)	Advanced or Metastatic NSCLC		https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04613596	CA239-0009	Phase 2 / Phase 3	RECRUITING	ACT, NSW, NZ, QLD, SA, VIC	2020-10-30	2020-12-02	2029-10-31	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib; Adagrasib + Pembrolizumab; Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CA239-0009	A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer	2444 - Port Macquarie - Local Institution - 007-1002; 2500 - Wollongong - Cancer Care Wollongong; 2605 - Garran - Canberra Hospital; 3168 - Clayton - Local Institution - 007-004 - (WITHDRAWN); 3350 - Ballarat - Ballarat Regional Integrated Cancer Center; 4102 - Woolloongabba - Princess Alexandra Hospital; 4414 - Palmerston North - Local Institution - Anderson, M.; 4812 - Hyde Park - Local Institution - 007-1003; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04613596
NCT04614103	IOV-LUN-202	Phase 2	RECRUITING	NSW, WA	2020-10-28	2021-05-07	2031-12	Cyclophosphamide; Fludarabine	antimetabolite; alkylating_agent	Cyclophosphamide; Fludarabine	alkylating_agent; antimetabolite	IOV-LUN-202	A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer	Metastatic Non Small Cell Lung Cancer	2010 - Darlinghurst - St. Vincent's Hospital; 2145 - Westmead - Westmead Hospital; 6009 - Nedlands - Hollywood Private Hospital Ramsay	https://clinicaltrials.gov/ct2/show/NCT04614103
NCT04665206	VT3989-001	Phase 1 / Phase 2	RECRUITING	VIC, WA	2020-12-10	2021-03-24	2027-06-02	Ipilimumab; Ipilimumab + Nivolumab + Osimertinib + VT3989; Nivolumab; Osimertinib; VT3989	EGFR_inhibitor,third_generation; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; TEAD_palmitoylation_inhibitor; EGFR_inhibitor,third_generation + TEAD_palmitoylation_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab + Osimertinib + VT3989; VT3989	EGFR_inhibitor,third_generation + TEAD_palmitoylation_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; TEAD_palmitoylation_inhibitor	VT3989-001	Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumor, Adult; Mesothelioma; NSCLC	3000 - Melbourne - Peter MacCullum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04684108	CSG-301-101	Phase 1	ACTIVE_NOT_RECRUITING		Help: Date registered 2020-12-24	2021-11-04		SG301	anti-CD38_monoclonal_antibody	SG301	anti-CD38_monoclonal_antibody	CSG-301-101	A Phase 1 Study of SG301 in Subjects With Hematological Malignancies	Hematological Malignancy; Relapsed or Refractory Multiple Myeloma		https://clinicaltrials.gov/ct2/show/NCT04684108
NCT04686305	DL03	Phase 1	RECRUITING	SA, VIC, WA	2020-12-22	2021-03-09	2027-06-30	Carboplatin; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan + Volrustomig; Cisplatin; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Pemetrexed; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Volrustomig; Volrustomig	anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate; bispecific_PD-L1/CTLA4_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Carboplatin + Rilvegostomig + Trastuzumab Deruxtecan; Carboplatin + Trastuzumab Deruxtecan + Volrustomig; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Volrustomig	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	D967YC00001	A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	3084 - Heidelberg - Research Site - (WITHDRAWN); 5000 - Adelaide - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04686305
NCT04728893	1026-003	Phase 2	RECRUITING	NSW, VIC, WA	2021-01-25	2021-04-05	2027-03-19	Nemtabrutinib	BTK_inhibitor	Nemtabrutinib	BTK_inhibitor	1026-003	A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies	Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia	2747 - Sydney - Nepean Hospital-Nepean Cancer Care Centre ( Site 0204) - (COMPLETED); 3128 - Box Hill - Box Hill Hospital ( Site 0203); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 0200)	https://clinicaltrials.gov/ct2/show/NCT04728893
NCT04739670	BELLA	Phase 2	RECRUITING	NSW, QLD, VIC	2021-02-01	2021-03-01	2025-09-30	Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	anti-VEGF_monoclonal_antibody; gemcitabine; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	19/002	A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer	2065 - St Leonards - Royal North Shore; 4101 - South Brisbane - Mater Health; Melbourne - Monash Health; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04740424	FS222-19101	Phase 1	RECRUITING	NSW, WA	2021-02-03	2020-12-14	2027-10-30	FS222	bispecific_PD-L1/CD137_antibody; bispecific_PD-L1/4-1BB_antibody	FS222	bispecific_PD-L1/4-1BB_antibody; bispecific_PD-L1/CD137_antibody	FS222-19101	A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies	Advanced Cancer; Metastatic Cancer	2298 - Waratah - Calvary Mater Newcastle; 6150 - Perth - One Clinical Research Perth	https://clinicaltrials.gov/ct2/show/NCT04740424
NCT04745689	TAZMAN	Phase 2	ACTIVE_NOT_RECRUITING		Help: Date registered 2021-02-09	2021-02-23		Barasertib; Barasertib + Durvalumab; Carboplatin; Cisplatin; Durvalumab; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor; platinum-based_antineoplastic_agent; AURKB_inhibitor; anti-PD-L1_monoclonal_antibody	Barasertib + Durvalumab; Carboplatin; Cisplatin; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2024-511887-10-00  D6132C00001	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04771130	BGB-11417-103	Phase 1 / Phase 2	RECRUITING	NSW, NZ, QLD, VIC, WA	2021-02-23	2021-05-24	2028-02-08	Azacitidine; Azacitidine + Posaconazole + Sonrotoclax; Azacitidine + Sonrotoclax; Posaconazole; Sonrotoclax	Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; azole_antifungal; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor	Azacitidine + Posaconazole + Sonrotoclax; Azacitidine + Sonrotoclax; Sonrotoclax	Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal	BGB-11417-103	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm	0622 - Auckland - North Shore Hospital; 2025 - Auckland - Aotearoa Clinical Trials; 6021 - Wellington - Wellington Regional Hospital (Ccdhb); NSW 2139 - Concord - Concord Repatriation General Hospital; NSW 2217 - Kogarah - St George Hospital; NSW 2800 - Orange - Orange Health Hospital; QLD 4215 - Southport - Gold Coast University Hospital; VIC 3004 - Melbourne - The Alfred Hospital; VIC 3065 - Fitzroy - St Vincents Hospital Melbourne; VIC 3084 - Heidelberg - Austin Health; VIC 3168 - Clayton - Monash Health; WA 6009 - Nedlands - Linear Clinical Research; WA 6009 - Nedlands - One Clinical Research; WA 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04784715	2023-507904-30-00--D967UC00001	Phase 3	NOT_RECRUITING		Help: Date registered 2021-03-05	2021-04-26		Docetaxel; Docetaxel + Paclitaxel + Pertuzumab + Trastuzumab; Paclitaxel; Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; taxane; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Docetaxel + Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; placebo	2023-507904-30-00  D967UC00001	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	Metastatic; Breast Cancer; HER2-positive		https://clinicaltrials.gov/ct2/show/NCT04784715
NCT04794699	IDE397-001	Phase 1	RECRUITING	NSW, SA	2021-03-09	2021-04-14	2027-03-30	Docetaxel; Docetaxel + IDE397 + Paclitaxel; IDE397; IDE397 + Sacituzumab Govitecan; Paclitaxel; Sacituzumab Govitecan	MAT2A_inhibitor + taxane; taxane; anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor; MAT2A_inhibitor + anti-Trop2_antibody-drug_conjugate	Docetaxel + IDE397 + Paclitaxel; IDE397; IDE397 + Sacituzumab Govitecan	MAT2A_inhibitor; MAT2A_inhibitor + anti-Trop2_antibody-drug_conjugate; MAT2A_inhibitor + taxane	IDE397-001	An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors	Solid Tumor	02010 - Darlinghurst - The Kinghorn Cancer Centre, St Vincent's Health Network Sydney; 05042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04794699
NCT04802759	CO42867	Phase 1 / Phase 2	RECRUITING	SA, VIC, WA	2021-03-16	2021-06-22	2027-11-30	Abemaciclib; Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Abemaciclib + Giredestrant + Inavolisib; Atezolizumab; Atezolizumab + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Inavolisib + Palbociclib; Giredestrant + Inavolisib + Ribociclib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Inavolisib; Ipatasertib; Palbociclib; Pertuzumab; Ribociclib; Samuraciclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; mTORC1_inhibitor; selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; CDK7_inhibitor; CDK7_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Abemaciclib + Atezolizumab + Giredestrant; Abemaciclib + Giredestrant; Abemaciclib + Giredestrant + Inavolisib; Atezolizumab + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Inavolisib + Palbociclib; Giredestrant + Inavolisib + Ribociclib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Pertuzumab	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-PD-L1_monoclonal_antibody + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	CO42867	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3199 - Frankston - Peninsula Health-Frankston Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04830202	C20-503		NO_LONGER_AVAILABLE	WA	2021-04-05			Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	C20-503	Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	6005 - West Perth	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04862663	CAPItello-292	Phase 3	RECRUITING	NSW, WA	2021-04-23	2021-05-10	2029-08-14	Abemaciclib; Abemaciclib + Capivasertib + Fulvestrant; Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Palbociclib + Ribociclib; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor	Abemaciclib + Capivasertib + Fulvestrant; Capivasertib + Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib + Ribociclib; Capivasertib + Fulvestrant + Ribociclib; Fulvestrant + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D361DC00001	A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2076 - Wahroonga - Research Site - (WITHDRAWN); 2228 - Miranda - Research Site - (WITHDRAWN); 2298 - Waratah - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04868604	SECuRE	Phase 1 / Phase 2	RECRUITING	NSW	2021-04-27	2021-08-11	2026-09					CLP05	A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2010 - Darlinghurst - St Vincent's Public Hospital	https://clinicaltrials.gov/ct2/show/NCT04868604
NCT04870944	PEPN2111	Phase 1 / Phase 2	RECRUITING	NSW	2021-04-28	2022-01-28	2026-12-31	CBL0137	curaxin,FACT_complex-targeting	CBL0137	curaxin,FACT_complex-targeting	PEPN2111	A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma	Diffuse Midline Glioma, H3 K27-Altered; Metastatic Malignant Neoplasm in the Central Nervous System; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma, H3 K27-Altered; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Primary Malignant Central Nervous System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm	2031 - Randwick - Sydney Children's Hospital - (SUSPENDED)	https://clinicaltrials.gov/ct2/show/NCT04870944
NCT04876651	177Lu-TLX591-002	Phase 3	RECRUITING	NSW, NZ, QLD, VIC, WA	2021-05-03	2023-08-29	2028-12-01	177Lu-DOTA-rosopatamab; 177Lu-TLX591	radioligand,PSMA-targeting; 177Lu-anti-PSMA-radioconjugate	177Lu-DOTA-rosopatamab; 177Lu-TLX591	177Lu-anti-PSMA-radioconjugate; radioligand,PSMA-targeting	177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	1023 - Auckland - Auckland City Hospital; 2145 - Westmead - Westmead Hospital; 3083 - Melbourne - Austin Health; 3168 - Clayton - Monash Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 6150 - Murdoch - 'GenesisCare Murdoch'	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04879329	RC48G001	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2021-05-07	2022-05-03	2029-04-14	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Disitamab vedotin; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	RC48G001	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Urothelial Carcinoma	2065 - St Leonards - GenesisCare - North Shore; 2109 - Sydney - Macquarie University; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4102 - Brisbane - Metro South Hospital and Health Service; 4102 - Woolloongabba - Princess Alexandra Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; QLD 4101 - South Brisbane - Mater Cancer Care Centre, Mater Misericordiae Limited	https://clinicaltrials.gov/ct2/show/NCT04879329
NCT04895709	CA052-002	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC, WA	2021-05-19	2021-05-27	2028-07-07	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody; taxane	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane	CA052-002	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Microsatellite Stable Colorectal Cancer; Non-Small-Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Urothelial Carcinoma; Pancreatic Adenocarcinoma; Melanoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms	2148 - Blacktown - Blacktown Hospital; 2170 - Liverpool - Liverpool Hospital; 3065 - Melbourne - St Vincent's Hospital; 3144 - Malvern - Cabrini Hospital - Malvern; 4102 - Brisbane - Princess Alexandra Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04895709
NCT04924075	6482-015	Phase 2	RECRUITING	NSW, VIC	2021-06-08	2021-08-12	2029-06-04	Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	6482-015	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations	Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers	2031 - Randwick - Prince of Wales Hospital-Medical Oncology ( Site 1601); 3050 - Parkville - The Royal Melbourne Hospital ( Site 1602)	https://clinicaltrials.gov/ct2/show/NCT04924075
NCT04925648	PICASSO	Phase 2	RECRUITING	NSW, VIC	2021-06-07	2021-10-18	2025-12-01	Darolutamide; Darolutamide + Dasatinib; Dasatinib	SRC_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; YES1_inhibitor; KIT_inhibitor + antiandrogen,nonsteroidal,second_generation; PDGFRA_inhibitor + antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor; YES1_inhibitor + antiandrogen,nonsteroidal,second_generation; BCR-ABL1_inhibitor,second_generation + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor	Darolutamide + Dasatinib; Dasatinib	BCR-ABL1_inhibitor,second_generation; BCR-ABL1_inhibitor,second_generation + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor; KIT_inhibitor + antiandrogen,nonsteroidal,second_generation; PDGFRA_inhibitor; PDGFRA_inhibitor + antiandrogen,nonsteroidal,second_generation; SRC_inhibitor; SRC_inhibitor + antiandrogen,nonsteroidal,second_generation; YES1_inhibitor; YES1_inhibitor + antiandrogen,nonsteroidal,second_generation	PICASSO	PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04928846	M18-868	Phase 3	RECRUITING	NSW, VIC	2021-06-14	2022-03-25	2028-03	Docetaxel; Telisotuzumab Vedotin	taxane; anti-cMET_antibody-drug_conjugate	Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	M18-868	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital /ID# 274447; 2444 - Port Macquarie - Port Macquarie Base Hospital /ID# 273654; 3084 - Heidelberg - Austin Health /ID# 247507; 3220 - Geelong - Barwon Health /ID# 241920	https://clinicaltrials.gov/ct2/show/NCT04928846
NCT04929223	WO42758	Phase 1	RECRUITING	VIC	2021-06-11	2021-10-22	2028-11-07	Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab; Bevacizumab + Divarasib; Bevacizumab + Inavolisib; Cetuximab; Cetuximab + Divarasib; Cetuximab + Inavolisib; Divarasib; Inavolisib; SY-5609; Tiragolumab	anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CDK7_inhibitor; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Divarasib; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib	CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody	WO42758	A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	Metastatic Colorectal Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04929223
NCT04938817	3475-B98	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC, WA	2021-06-21	2021-08-19	2029-12-10	Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-LAG3_monoclonal_antibody; VEGF_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	3475-B98	A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)	Small Cell Lung Carcinoma	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 4004) - (COMPLETED); 3168 - Clayton - Monash Health-Oncology Research ( Site 4005); 4032 - Brisbane - The Prince Charles Hospital-Oncology Clinical Trials ( Site 4003) - (COMPLETED); 6009 - Perth - Hollywood Private Hospital-Medical Oncology ( Site 4001)	https://clinicaltrials.gov/ct2/show/NCT04938817
NCT04939610	LuMIERE	Phase 1 / Phase 2	RECRUITING	SA, VIC	2021-06-17	2021-07-30	2028-06-30	177Lu-FAP-2286	radioligand,FAP-targeting	177Lu-FAP-2286	radioligand,FAP-targeting	CO-2286-114	LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor	Solid Tumor	3004 - Melbourne - Novartis Investigative Site; 5000 - Adelaide - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04939610
NCT04947189	4CAST	Phase 1 / Phase 2	RECRUITING	NSW	2021-06-26	2022-11-01	2027-12	Dexamethasone; Dexamethasone + Docetaxel + Seviteronel; Docetaxel; Seviteronel	CYP17A1_inhibitor; CYP17A1_inhibitor + glucocorticoid + taxane; glucocorticoid; taxane	Dexamethasone + Docetaxel + Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane	4CAST	4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04947189
NCT04950075	ChonDRAgon	Phase 2	RECRUITING	NSW, QLD, SA	2021-06-30	2021-09-23	2026-12	INBRX-109; Placebo	placebo; anti-DR5_agonistic_antibody	INBRX-109; Placebo	anti-DR5_agonistic_antibody; placebo	Ph2 INBRX-109 SA CS	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma	Conventional Chondrosarcoma	2050 - Camperdown - Chris O'Brien Lifehouse; 5000 - Adelaide - Royal Adelaide Hospital; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04950075
NCT04956640	LOXO-RAS-20001	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC, WA	2021-07-02	2021-07-19	2027-04	Carboplatin; Carboplatin + Cetuximab + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Olomorasib + Pembrolizumab; Cisplatin; Olomorasib; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; antimetabolite	Carboplatin + Cetuximab + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Cetuximab + Olomorasib + Pembrolizumab; Olomorasib	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	LOXO-RAS-20001	A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms	2010 - Sydney - St Vincent's Hospital Sydney; 2065 - St Leonards - Royal North Shore Hospital; 3199 - Frankston - Peninsula and Southeast Oncology; 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04956640
NCT04958239	1463-0001	Phase 1	RECRUITING	NSW, QLD, VIC	2021-07-01	2021-10-18	2028-11-19	Ezabenlimab; Pembrolizumab	anti-PD-1_monoclonal_antibody	Ezabenlimab; Pembrolizumab	anti-PD-1_monoclonal_antibody	1463-0001	An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)	Neoplasms	2010 - Darlinghurst - Kinghorn Cancer Centre; 2640 - Albury - Border Cancer Hospital - (COMPLETED); 3084 - Heidelberg - Austin Hospital; 4814 - Douglas - Townsville Hospital	https://clinicaltrials.gov/ct2/show/NCT04958239
NCT04986852	KEYNOTE-C14	Phase 2	RECRUITING	WA	2021-07-22	2021-09-30	2026-08-30	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_06 / KEYNOTE-C14	A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Metastatic Triple-Negative Breast Cancer	6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04986852
NCT04995523	ARTEMIDE-01	Phase 1 / Phase 2	RECRUITING	VIC	2021-07-29	2021-09-14	2028-03-16	Rilvegostomig	bispecific_PD-1/TIGIT_antibody	Rilvegostomig	bispecific_PD-1/TIGIT_antibody	D7020C00001	Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC	Non-Small-Cell Lung Carcinoma	3000 - Melbourne - Research Site - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT04996875	CGT9486-20-201	Phase 2	RECRUITING	NSW, QLD, VIC	2021-08-06	2021-11-09	2026-07	Bezuclastinib	KIT_inhibitor,type_1; KIT_D816V_inhibitor	Bezuclastinib	KIT_D816V_inhibitor; KIT_inhibitor,type_1	CGT9486-20-201	A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis	Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL); Aggressive Systemic Mastocytosis (ASM)	2747 - Kingswood - Nepean Hospital; 3051 - Melbourne N. - Peter MacCallum Cancer Centre; 4215 - Southport - Gold Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT04996875
NCT05007782	GS-US-570-6015	Phase 1	RECRUITING	NSW, VIC	2021-08-11	2021-08-18	2028-12	GS-1811; Zimberelimab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	Zimberelimab; GS-1811	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	GS-US-570-6015	A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Advanced Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05007782
NCT05053854	PARLuNET	Phase 1	RECRUITING	VIC	2021-09-20	2021-12-08	2029-06-30	Talazoparib	PARP_inhibitor	Talazoparib	PARP_inhibitor	PMC67199	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05067283	KANDLELIT-001	Phase 1	RECRUITING	NSW, NZ, VIC	2021-10-01	2021-12-17	2030-02-25	Carboplatin; Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; Fluorouracil; Leucovorin; MK-1084; MK-1084 + Pembrolizumab; Oxaliplatin; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; antimetabolite	Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Cetuximab + MK-1084; MK-1084; MK-1084 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; Fluorouracil	1084-001	A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris O'Brien Lifehouse ( Site 0002); 2145 - Westmead - Westmead Hospital ( Site 0006); 2170 - Liverpool - Liverpool Hospital-Medical Oncology ( Site 0001); 3168 - Clayton - Monash Health-Oncology Research ( Site 0003); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 0004) - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05067283
NCT05081609	IL-Believe	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC	2021-10-05	2022-01-11	2029-08	Pembrolizumab; TransCon TLR7/8 agonist; Trastuzumab; Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate; TLR7/TLR8_agonist; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab; TransCon TLR7/8 agonist; Trastuzumab; Trastuzumab Emtansine	TLR7/TLR8_agonist; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody	ASND0029	IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung Cancer; Third Line or Later (3L+) HER2+ Breast Cancer; Second or Third Line (2L/3L) Cervical Cancer; Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)	04120 - Brisbane - Ascendis Pharma Investigational Site; 05065 - Toorak Gardens - Ascendis Pharma Investigational Site - (TERMINATED); 2298 - Waratah - Ascendis Pharma Investigational Site; 3199 - Frankston - Ascendis Pharma Investigational Site; 4215 - Southport - Ascendis Pharma Investigational Site; 5000 - Adelaide - Ascendis Pharma Investigational Site; 5042 - Adelaide - Ascendis Pharma Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05081609
NCT05086692	ABILITY-1	Phase 1 / Phase 2	RECRUITING	NSW, QLD	2021-10-07	2021-08-27	2026-12-30	MDNA11; MDNA11 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_superkine + anti-PD-1_monoclonal_antibody; IL-2_superkine	MDNA11 + Pembrolizumab	IL-2_superkine + anti-PD-1_monoclonal_antibody	MDNA11-01	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer; Viral Cancer; Cervical Cancers; Endometrial Cancer	2031 - Randwick - Scientia Clinical Research; 2109 - Sydney - Macquarie University; 4120 - Greenslopes - Gallipoli Medical Research Foundation; 4556 - Buderim - University of the Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05093231	PemOla	Phase 2	RECRUITING		2021-10-26			Olaparib; Olaparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody	PemOla	A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb	Pancreatic Cancer		https://clinicaltrials.gov/ct2/show/NCT05093231
NCT05094336	MTAPESTRY-101	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2021-10-14	2022-02-01	2028-11-27	AMG 193; AMG 193 + Docetaxel; Docetaxel	PRMT5_inhibitor; PRMT5_inhibitor + taxane; taxane	AMG 193; AMG 193 + Docetaxel	PRMT5_inhibitor; PRMT5_inhibitor + taxane	20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	Advanced MTAP-null Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse; 3002 - East Melbourne - Epworth Healthcare; 3050 - Parkville - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05094336
NCT05117476	MICA	Phase 1	RECRUITING	VIC, WA	2021-11-02	2021-10-29	2026-06	CLN-619; CLN-619 + Carboplatin + Paclitaxel + Pemetrexed; CLN-619 + Datopotamab deruxtecan; CLN-619 + Pembrolizumab; Carboplatin; Datopotamab deruxtecan; Paclitaxel; Pembrolizumab; Pemetrexed	anti-MICA/MICB_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-MICA/MICB_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; taxane; platinum-based_antineoplastic_agent; anti-MICA/MICB_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite	CLN-619; CLN-619 + Carboplatin + Paclitaxel + Pemetrexed; CLN-619 + Datopotamab deruxtecan; CLN-619 + Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-MICA/MICB_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	CLN-619-001	A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor; NSCLC	3004 - Melbourne - Alfred Health - (COMPLETED); 3168 - Clayton - Monash Health - (COMPLETED); 6009 - Nedlands - Linear Clinical Research - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05117476
NCT05118789	NVL-520-01	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2021-11-03	2022-01-04	2026-10-31	Tegafur-gimeracil-oteracil potassium; Zidesamtinib	DPD_inhibitor; ROS1_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	Zidesamtinib; Tegafur-gimeracil-oteracil potassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	NVL-520-01	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05118789
NCT05123482	D6900C00001	Phase 1 / Phase 2	RECRUITING	QLD, VIC, WA	2021-11-05	2021-10-18	2027-03-26	Puxitatug samrotecan; Puxitatug samrotecan + Rilvegostomig; Puxitatug samrotecan + Rilvegostomig + Saruparib; Rilvegostomig; Saruparib	PARP1-selective_inhibitor + anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-B7H4_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; PARP1-selective_inhibitor	Puxitatug samrotecan; Puxitatug samrotecan + Rilvegostomig; Puxitatug samrotecan + Rilvegostomig + Saruparib	PARP1-selective_inhibitor + anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody	D6900C00001	A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)	Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer; Endometrial Cancer; Squamous Non-Small Cell Lung Cancer	3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site - (WITHDRAWN); 6009 - Nedlands - Research Site; VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05128825	DENALI	Phase 2	RECRUITING	QLD, SA, VIC, WA	2021-11-09	2022-02-17	2027-06-30	Azenosertib	WEE1_inhibitor	Azenosertib	WEE1_inhibitor	ZN-c3-005	A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Fallopian tube carcinoma	3021 - Footscray - Site 2716 - Epworth Healthcare Freemasons; 4032 - Brisbane - Site 2715 - Icon Cancer Centre - Chermside; 4101 - South Brisbane - Site 2707 - Mater Brisbane; 5037 - Adelaide - Site 2709 - Icon Cancer Research Adelaide; 5065 - Toorak Gardens - Site 2702 - Burnside War Memorial Hospital - The Brian Fricker Oncology Centre; 6008 - Subiaco - Site 2717 - St John of God Hospital Subiaco; 6009 - Nedlands - Site 2701 - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT05128825
NCT05141149	PAUF-I	Phase 1 / Phase 2	RECRUITING	VIC	2021-11-18	2023-06-05	2026-12	Gemcitabine; Gemcitabine + PBP1510; PBP1510	anti-PAUF_monoclonal_antibody + antimetabolite; anti-PAUF_monoclonal_antibody; gemcitabine	Gemcitabine + PBP1510; PBP1510	anti-PAUF_monoclonal_antibody; anti-PAUF_monoclonal_antibody + antimetabolite; gemcitabine	PAUF-I	A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer	Pancreatic Cancer	Melbourne - Monash Health	https://clinicaltrials.gov/ct2/show/NCT05141149
NCT05142189	LuCa-MERIT-1	Phase 1	RECRUITING	NSW, SA, VIC	2021-11-24	2022-06-17	2031-11	Carboplatin; Carboplatin + Cemiplimab + Paclitaxel; Cemiplimab; Docetaxel; Paclitaxel	taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cemiplimab + Paclitaxel; Cemiplimab; Docetaxel	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane	BNT116-01	LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	2031 - Randwick - Scientia Clinical Research; 2065 - Sydney - Royal North Shore Hospital; 3168 - Clayton - Monash Health; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05142189
NCT05150457	BNA035-101	Phase 1	RECRUITING	NSW, QLD, VIC	2021-12-03	2022-02-08	2025-11	BNA35	bispecific_EGFR/4-1BB_antibody	BNA35	bispecific_EGFR/4-1BB_antibody	BNA035-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah - St George Private Hospital; 3065 - Fitzroy - St. Vincents Hospital Melbourne; 4217 - Benowa - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05150691	DB-1303-O-1001	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2021-11-26	2022-01-31	2027-10	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab; Itraconazole; Pertuzumab; Trastuzumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; SMO_inhibitor; anti-ERBB2_monoclonal_antibody; SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	DB-1303; DB-1303 + Itraconazole; DB-1303 + Pertuzumab; DB-1303 + Trastuzumab	SMO_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	DB-1303-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors	HER2-positive Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research LTD; 2109 - Sydney - Macquarie Clinical Trials Unit; 3168 - Melbourne - Monash Health; 4101 - South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05150691
NCT05155332	1456-0001	Phase 1	RECRUITING	SA, VIC	2021-12-10	2022-03-28	2028-10-31	VSV-GP	oncolytic_virus	VSV-GP	oncolytic_virus	1456-0001	Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors	Solid Tumors	3199 - Frankston - Peninsula Haematology & Oncology; 5062 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05155332
NCT05182931	I-FIRST	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2021-12-20	2022-07-14	2025-12-30	Dabrafenib; Dabrafenib + Trametinib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Dabrafenib + Trametinib; Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor	ONJ2021-006	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3084 - Heidelberg - Austin Health; 3128 - Box Hill - Eastern Health; 3168 - Clayton - Monash Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; Adelaide - Royal Adelaide Hsopital; Melbourne - Peter MacCallum Cancer Centre; Perth - Sir Charles Gairdner Hospital; Prahran - Alfred Hospital; Sydney - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05203172	C4221026	Phase 4	RECRUITING	VIC	2022-01-10	2022-07-05	2029-07-31	Binimetinib; Binimetinib + Cetuximab + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Ribociclib; Cetuximab; Encorafenib; Ribociclib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor	Binimetinib; Binimetinib + Cetuximab + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Ribociclib; Encorafenib	BRAF_V600_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor	C4221026	ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05203172
NCT05205109	ATG-037-001	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2022-01-11	2022-06-07	2028-02-28	ATG 037; ATG 037 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor	ATG 037 + Pembrolizumab	CD73_inhibitor + anti-PD-1_monoclonal_antibody	ATG-037-001	A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2298 - Sydney - Calvary Mater Newcastle; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4217 - Benowa - Pindara Private Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research Unit - (TERMINATED); WA6153 - Mount Pleasant - One Clinical Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT05205109
NCT05208944	THIO-101	Phase 2	RECRUITING	QLD, SA, VIC	2022-01-13	2022-06-08	2026-12-31	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	THIO-101	A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	3065 - Fitzroy - St. Vincent Hospital Melbourne - (SUSPENDED); 4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic - (SUSPENDED); 5000 - Adelaide - Cancer Research SA - (SUSPENDED)	https://clinicaltrials.gov/ct2/show/NCT05208944
NCT05215340	TROPION-Lung08	Phase 3	RECRUITING	NSW, SA, VIC	2022-01-18	2022-03-04	2028-04-30	Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	DS1062-A-U304	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Metastatic Non Small Cell Lung Cancer	2050 - Camperdown - Chris Obrien Lifehouse; 3084 - Heidelberg - Austin Hospital; 3149 - Mount Waverley - Peninsula and South Eastern Haematology and Oncology Group; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05215340
NCT05216432	RLY-2608-101	Phase 1	RECRUITING	NSW, VIC	2022-01-18	2021-12-08	2027-04-30	Fulvestrant; Fulvestrant + PF-07220060 + RLY-2608; Fulvestrant + Palbociclib + RLY-2608; Fulvestrant + RLY-2608; Fulvestrant + RLY-2608 + Ribociclib; PF-07220060; Palbociclib; RLY-2608; Ribociclib	CDK4_selective_inhibitor; PI3K_alpha_inhibitor,allosteric,mutant-selective; CDK4/6_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK4_selective_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	Fulvestrant + PF-07220060 + RLY-2608; Fulvestrant + Palbociclib + RLY-2608; Fulvestrant + RLY-2608; Fulvestrant + RLY-2608 + Ribociclib; RLY-2608	CDK4/6_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective; PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	RLY-2608-101	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor	2019 - Sydney - St Vincents Hospital; 3000 - Melbourne - Peter MacCallum Cancer Center; 3004 - Melbourne - The Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT05216432
NCT05245968	NCT05245968	Phase 1	RECRUITING	VIC	2022-02-17	2021-12-01	2025-12	Imatinib; Imatinib + Pimitespib; Pimitespib; Sunitinib	KIT_inhibitor,first_generation; PDGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; PDGFRA_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor; KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation	Imatinib + Pimitespib; Sunitinib	BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor	10058060	A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumors	Adelaide - Flinders Medical Center; Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05245968
NCT05253651	MOUNTAINEER-03	Phase 3	RECRUITING	NSW, QLD, VIC	2022-02-14	2022-10-24	2029-07-27	Bevacizumab; Bevacizumab + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin; Cetuximab; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib; Leucovorin; Oxaliplatin; Trastuzumab; Tucatinib	anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation	Bevacizumab + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	SGNTUC-029	An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer	Colorectal Neoplasms	2050 - Camperdown - Chris O'Brien Lifehouse; 3004 - Melbourne - Alfred Health; 3065 - Fitzroy - St Vincent's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4814 - Townsville - Townsville Hospital and Health Service	https://clinicaltrials.gov/ct2/show/NCT05253651
NCT05254171	ASPIRE	Phase 2 / Phase 3	RECRUITING	ACT, NSW, SA, VIC, WA	2022-02-21	2022-08-08	2027-01-01	Gemcitabine; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Ivospemin; Nab-paclitaxel; Placebo	gemcitabine; taxane; placebo; antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; antimetabolite; polyamine_analogue	Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; gemcitabine; placebo	CL-SBP-101-04	A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV	2485 - Tweed Heads - The Tweed Hospital - (WITHDRAWN); 2605 - Garran - Canberra Region Cancer Centre; 3084 - Heidelberg - Austin Hospital; 5307 - Kurralta Park - Ashford Cancer Centre Research; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05254171
NCT05261399	SAFFRON	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2022-02-25	2022-08-03	2026-12-17	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Osimertinib + Savolitinib; Pemetrexed; Savolitinib	platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_1; EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent	D5087C00001	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Carcinoma; Non-Small-Cell Lung	2145 - Westmead - Research Site; 2170 - Liverpool - Research Site; 2298 - Waratah NSW - Research Site; 3168 - Clayton - Research Site; 3220 - Geelong - Research Site - (WITHDRAWN); 4215 - Southport - Research Site; 6160 - Fremantle - Research Site	https://clinicaltrials.gov/ct2/show/NCT05261399
NCT05263180	EMB09X101	Phase 1	RECRUITING	NSW, VIC	2022-02-22	2022-07-25	2024-12-31	EMB-09	bispecific_PD-L1/OX40_antibody	EMB-09	bispecific_PD-L1/OX40_antibody	EMB09X101	A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	Frankston - Peninsula and South Eastern Haematology & Oncology Group; Leonards Hill - GenesisCareNorthShore; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05263180
NCT05267626	CP-AU-007-01	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC	2022-02-23	2022-04-04	2026-06-12	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin + Avelumab; AU-007 + Aldesleukin + Nivolumab; Aldesleukin; Avelumab; Nivolumab	IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IL-2_variant; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin + Avelumab; AU-007 + Aldesleukin + Nivolumab	IL-2_variant + anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-IL-2_monoclonal_antibody	CP-AU-007-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer	2228 - Miranda - Southside Cancer Care Centre; 3004 - Melbourne - The Alfred Hospital; 3021 - Saint Albans - Sunshine Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05267626
NCT05269316	IMP9064-101	Phase 1 / Phase 2	RECRUITING	NSW, WA	2022-03-03	2022-02-11	2026-12-31	IMP9064; Senaparib	PARP_inhibitor; ATR_inhibitor	IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064-101	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors	Solid Tumor; Advanced Solid Tumor	2148 - Blacktown - Blacktown Hospital - (COMPLETED); 6009 - Nedlands - Linear Clinical Research Limited - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05269316
NCT05277051	NCT05277051	Phase 1	RECRUITING	WA	2022-03-03	2022-03-22	2028-09-12	Dostarlimab; Dostarlimab + GSK4381562; Dostarlimab + GSK5764227; GSK4381562; GSK5764227	anti-B7H3_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-PVRIG_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PVRIG_monoclonal_antibody	Dostarlimab; Dostarlimab + GSK4381562; Dostarlimab + GSK5764227; GSK4381562	anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PVRIG_monoclonal_antibody; anti-PVRIG_monoclonal_antibody	217228	A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors	Neoplasms	6009 - Nedlands - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT05277051
NCT05279300	CS5001-101	Phase 1	RECRUITING	NSW, SA, VIC	2022-03-14	2022-03-28	2027-12-31	CS5001; CS5001 + Cyclophosphamide + Doxorubicin + Gemcitabine + Lenalidomide + Oxaliplatin + Prednisone + Rituximab + Vincristine; Cyclophosphamide; Doxorubicin; Gemcitabine; Lenalidomide; Oxaliplatin; Prednisone; Rituximab; Vincristine	alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + anti-ROR1_antibody-drug_conjugate + antimetabolite + glucocorticoid + immunomodulatory_imide_drug + platinum-based_antineoplastic_agent + vinca_alkaloid; glucocorticoid; gemcitabine; anti-ROR1_antibody-drug_conjugate; immunomodulatory_imide_drug; platinum-based_antineoplastic_agent; doxorubicin; anti-CD20_monoclonal_antibody; alkylating_agent; vinca_alkaloid	CS5001; CS5001 + Cyclophosphamide + Doxorubicin + Gemcitabine + Lenalidomide + Oxaliplatin + Prednisone + Rituximab + Vincristine	alkylating_agent + anthracycline + anti-CD20_monoclonal_antibody + anti-ROR1_antibody-drug_conjugate + antimetabolite + glucocorticoid + immunomodulatory_imide_drug + platinum-based_antineoplastic_agent + vinca_alkaloid; anti-ROR1_antibody-drug_conjugate; doxorubicin; gemcitabine	CS5001-101	A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas	Advanced Solid Tumor; Advanced Lymphoma	2031 - Randwick - Scientia Clinical Research Limited; Adelaide - Ashford Cancer Centre Research - (TERMINATED); Adelaide - Central Adelaide Local Health Network Incorporated; Adelaide - Royal Adelaide Hospital (RAH); East Melbourne - Epworth Freemasons Medical Centre; Melbourne - Epworth Foundation trading as Epworth HealthCare	https://clinicaltrials.gov/ct2/show/NCT05279300
NCT05290597	CIBI363A101	Phase 1	RECRUITING	NSW	2022-03-13	2022-08-22	2026-12-31	IBI363	anti-PD-1/IL-2-immunocytokine_conjugate	IBI363	anti-PD-1/IL-2-immunocytokine_conjugate	CIBI363A101	A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas	Solid Malignancies or Lymphomas	2109 - Sydney - Kate.Wilkinson1@health.nsw.gov.au; 2145 - Sydney - Westmead Hospital; 2170 - Sydney - Sydney Southwest Private Hospital; 2500 - Sydney - Cancer Care Wollongong	https://clinicaltrials.gov/ct2/show/NCT05290597
NCT05303532	ROSY-D	Phase 3	ENROLLING_BY_INVITATION	VIC	2022-03-21	2022-04-19	2026-12-31	Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	D4191C00137	ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment	Cancer	3000 - Melbourne - Research Site; 3128 - Box Hill - Research Site	https://clinicaltrials.gov/ct2/show/NCT05303532
NCT05304585	ARST2032	Phase 3	RECRUITING	NSW, NZ, WA	2022-03-28	2022-08-04	2030-06-30	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin; Dactinomycin + Vincristine; Radiotherapy; Vincristine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; radiotherapy; antineoplastic_antibiotic; alkylating_agent; vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid	ARST2032	A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma	1145 - Grafton - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT05304585
NCT05315700	ORIC-114-01	Phase 1 / Phase 2	RECRUITING	NSW, VIC, WA	2022-04-06	2022-03-10	2027-09	Carboplatin; ORIC-114	platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	ORIC-114; Carboplatin	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent	ORIC-114-01	An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Solid Tumors	Camperdown - Chris O'Brien Lifehouse; Melbourne - Peter MacCallum Cancer Centre; Nedlands - One Clinical Research, Hollywood Medical Centre; Sydney - Sydney Adventist Health	https://clinicaltrials.gov/ct2/show/NCT05315700
NCT05327686	SAMURAI	Phase 2	RECRUITING	VIC	2022-04-07	2023-02-01	2028-06-15	Avelumab; Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab; Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab + Radiotherapy; Axitinib; Cabozantinib; Ipilimumab; Lenvatinib; Nivolumab; Pembrolizumab; Radiotherapy	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; VEGFR2_inhibitor; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; VEGFR/PDGFR_inhibitor; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; radiotherapy; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGF_inhibitor; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab; Avelumab + Axitinib + Cabozantinib + Ipilimumab + Lenvatinib + Nivolumab + Pembrolizumab + Radiotherapy	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,ATP-competitive + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + MET_inhibitor,type_2 + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + RET_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + ROS1_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; RET_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + VEGFR/PDGFR_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + VEGFR2_inhibitor + VEGF_inhibitor + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + radiotherapy	NRG-GU012	Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)	Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05327686
NCT05352672	R3767-ONC-2011	Phase 3	RECRUITING	QLD, SA, TAS, VIC	2022-04-25	2022-07-14	2031-06-30	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Pembrolizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Pembrolizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	R3767-ONC-2011	A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	03004 - Melbourne - The Alfred Hospital; 03220 - Geelong - Barwon Health Andrew Love Cancer Centre, University Hospital Geelong; 03355 - Wendouree - Ballarat Oncology and Haematology Clinical Trials Unit; 04814 - Townsville - The Townsville Hospital and Health Service; 05006 - Adelaide - Calvary North Adelaide Hospital; 4215 - Southport - Gold Coast University Hospital - (SUSPENDED); 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT05352672
NCT05356741	VIR-5818-V101	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2022-04-26	2022-04-13	2027-08-16	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	VIR-5818-V101	A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Locally Advanced or Metastatic HER2-Expressing Cancers	2031 - Randwick - Investigational site number #101; 3000 - Melbourne - Investigational site number #100	https://clinicaltrials.gov/ct2/show/NCT05356741
NCT05367440	PETRANHA	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2022-05-05	2022-06-02	2031-04-17	Abiraterone; Abiraterone + Saruparib; Apalutamide; Apalutamide + Saruparib; Darolutamide; Darolutamide + Saruparib; Enzalutamide; Enzalutamide + Saruparib; Saruparib	antiandrogen,nonsteroidal,second_generation; PARP1-selective_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor	Abiraterone + Saruparib; Apalutamide + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib	CYP17A1_inhibitor + PARP1-selective_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	D9720C00003	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)	Metastatic Prostate Cancer	2010 - Darlinghurst - Research Site; 2050 - Camperdown - Research Site; 2065 - St Leonards - Research Site; 3002 - East Melbourne - Research Site; 3004 - Melbourne - Research Site; 3084 - Heidelberg - Research Site	https://clinicaltrials.gov/ct2/show/NCT05367440
NCT05384626	NVL-655-01	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2022-05-17	2022-06-09	2028-01	Lorlatinib; Lorlatinib + NVL-655 + Neladalkib; NVL-655; NVL-655 + Neladalkib; Neladalkib	ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation; ALK_inhibitor,fourth_generation + ROS1_inhibitor; ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation	Lorlatinib + NVL-655 + Neladalkib; NVL-655 + Neladalkib	ALK_inhibitor,fourth_generation; ALK_inhibitor,fourth_generation + ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation + ROS1_inhibitor	NVL-655-01	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Sydney - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05384626
NCT05393791	ANZadapt	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2022-05-23	2022-11-10	2027-11-10	Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	79835	ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - Genesis Care North Shore; 2076 - Wahroonga - Sydney Adventist Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 4101 - South Brisbane - Mater Hospital Brisbane; 5000 - Adelaide - Royal Adelaide Hospital; 6150 - Murdoch - Fiona Stanly Hospital; Adelaide - ICON Cancer Centre; Birtinya - Sunshine Coast University Hospital; Box Hill - Eastern Health Box Hill; Kogarah - St George Hospital	https://clinicaltrials.gov/ct2/show/NCT05393791
NCT05396833	2022-500287-35-00--MS201924-0020	Phase 1	STOPPED_EARLY	NSW, TAS	Help: Date registered 2022-05-31	2022-06-07		Avelumab; Avelumab + Tuvusertib; Lartesertib; Lartesertib + Tuvusertib; Tuvusertib	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATM_inhibitor + ATR_inhibitor; anti-PD-L1_monoclonal_antibody; ATR_inhibitor; ATM_inhibitor	Avelumab + Tuvusertib; Lartesertib + Tuvusertib	ATM_inhibitor + ATR_inhibitor; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	2022-500287-35-00  MS201924_0020	An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)	Metastatic or Locally Advanced Unresectable Solid Tumors	- Waratah; - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05396833
NCT05410145	D3S-001-100	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC, WA	2022-06-06	2022-08-03	2027-02	Carboplatin; Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab; Cetuximab + D3S-001; Cisplatin; D3S-001; D3S-001 + Pembrolizumab; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; antimetabolite	Carboplatin + Cisplatin + D3S-001 + Pemetrexed; Cetuximab + D3S-001; D3S-001; D3S-001 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	D3S-001-100	A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation	KRAS P.G12C	2109 - Sydney - D3 Bio Investigative Site; 3000 - Melbourne - D3 Bio Investigative Site; 3144 - Malvern - D3 Bio Investigative Site; 5042 - Bedford Park - D3 Bio Investigative Site; 6009 - Nedlands - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05410145
NCT05411133	A001	Phase 1	RECRUITING	NSW, VIC	2022-06-05	2022-05-30	2026-05	Cabotamig	bispecific_T-cell_engager,CDH17-targeting	Cabotamig	bispecific_T-cell_engager,CDH17-targeting	A001	A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies	Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Gastroesophageal Junction; Gastrointestinal Neuroendocrine Tumors	Adelaide - Southern Oncology Clinical Research Unit; Sydney - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05411133
NCT05413421	ORIC-944-01	Phase 1	RECRUITING	NSW, VIC	2022-06-07	2022-06-01	2026-09	Abiraterone; Abiraterone + Apalutamide + Darolutamide + Enzalutamide + ORIC-944; Apalutamide; Apalutamide + Darolutamide + ORIC-944; Darolutamide; Enzalutamide; ORIC-944	PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation; PRC2_complex_inhibitor	Abiraterone + Apalutamide + Darolutamide + Enzalutamide + ORIC-944; Apalutamide + Darolutamide + ORIC-944; ORIC-944	CYP17A1_inhibitor + PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation; PRC2_complex_inhibitor; PRC2_complex_inhibitor + antiandrogen,nonsteroidal,second_generation	ORIC-944-01	An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer	Metastatic Prostate Cancer	Bendigo - Bendigo Health; Frankston - Peninsula Health; Wahroonga - Sydney Adventist Health	https://clinicaltrials.gov/ct2/show/NCT05413421
NCT05417594	CERTIS1	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2022-06-09	2022-06-24	2027-02-19	Datopotamab deruxtecan; Datopotamab deruxtecan + Palacaparib; Palacaparib; Palacaparib + Temozolomide; Palacaparib + Trastuzumab Deruxtecan; Temozolomide; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; anti-Trop2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate; alkylating_agent	Datopotamab deruxtecan + Palacaparib; Palacaparib; Palacaparib + Temozolomide; Palacaparib + Trastuzumab Deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-Trop2_antibody-drug_conjugate	D8410C00001	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)	Advanced Solid Malignancies	2010 - Darlinghurst - Research Site; 2031 - Randwick - Research Site; 2050 - Camperdown - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05417594
NCT05450744	IPAX-2	Phase 1	UNKNOWN	NZ, QLD, SA, VIC	2022-07-06	2023-04-01	2025-06	131I-IPA; 131I-TLX-101	radioligand,LAT1/LAT2-targeting; radioiodine_conjugate	131I-IPA; 131I-TLX-101	radioiodine_conjugate; radioligand,LAT1/LAT2-targeting	131I-TLX-101-002 (IPAX-2)	A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	Adelaide - Royal Adelaide Hospital; Auckland - Mercy Hospital; Gold Coast - Gold Coast University Hospital; Melbourne - Olivia Newton John Cancer Research Institute/Austin Health	https://clinicaltrials.gov/ct2/show/NCT05450744
NCT05458219	CIBI343A101	Phase 1	RECRUITING	NSW, QLD	2022-07-11	2022-10-26	2025-12	IBI343	anti-CLDN18.2_antibody-drug_conjugate	IBI343	anti-CLDN18.2_antibody-drug_conjugate	CIBI343A101	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	2010 - Darlinghurst - St Vincent Hospital; 2500 - Wollongong - Cancer Care Wollongong; 4217 - Benowa - Pindara Private Hospital; 4575 - Birtinya - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05458219
NCT05462236	AUM001-2001-MK3475-D65	Phase 2	RECRUITING	NSW, QLD, VIC	2022-07-13	2023-04-14	2026-10-15	Irinotecan; Irinotecan + Pembrolizumab + Tinodasertib; Pembrolizumab; Tinodasertib	topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; MNK1/2_inhibitor; MNK1/2_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	Irinotecan + Pembrolizumab + Tinodasertib; Tinodasertib	MNK1/2_inhibitor; MNK1/2_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	AUM001-2001-MK3475-D65	A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2500 - Wollongong - Prince of Wales Hospital; 3144 - Malvern - Cabrini Hospital; 3355 - Wendouree - Ballarat Oncology and Haematology; 4217 - Benowa - Pindara Private Hospital, Gold Coast Cancer Care	https://clinicaltrials.gov/ct2/show/NCT05462236
NCT05466799	TRIPP-FFX	Phase 2	RECRUITING	SA, TAS, VIC	2022-07-18	2023-04-26	2025-09	Leucovorin; OncoSil	brachytherapy; folinic_acid	OncoSil; Leucovorin	brachytherapy; folinic_acid	ONCO01P04	An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.	Locally Advanced Pancreatic Cancer	Adelaide - Royal Adelaide Hospital; Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT05466799
NCT05483530	HLX60HLX10-FIH101	Phase 1	UNKNOWN	NSW	2022-08-01	2022-12-14	2025-08	HLX10; HLX10 + HLX60; HLX60	anti-GARP_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	HLX10 + HLX60	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	HLX60HLX10-FIH101	A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Efficacy of HLX60 (Anti-GARP Monoclonal Antibody) Combination With HLX10 (Anti-PD-1 Monoclonal Antibody) in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Sydney - Macquarie University Hospital & Nepean Hospital	https://clinicaltrials.gov/ct2/show/NCT05483530
NCT05498428	PALOMA-2	Phase 2	RECRUITING		Help: Date registered 2022-08-12	2022-11-11		Amivantamab; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Carboplatin + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Carboplatin; Lazertinib; Osimertinib; Pemetrexed; rHuPH20	platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase; antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; recombinant_human_hyaluronidase; antimetabolite	Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Carboplatin + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20	EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody + recombinant_human_hyaluronidase; antimetabolite + bispecific_cMET/EGFR_antibody + platinum-based_antineoplastic_agent	61186372NSC2002  CR109264	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer	Carcinoma, Non-small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT05498428
NCT05498597	AMT-151-01	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2022-08-10	2023-01-25	2024-10-30	AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151-01	First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	Advanced Solid Tumor; Advanced Cancer; Advanced Carcinoma; Ovarian Cancer; Ovarian Carcinoma; Ovarian Epithelial Cancer; Ovarian Endometrioid Adenocarcinoma; Endometrial Cancer; Endometrial Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Lung Adenocarcinoma; Triple Negative Breast Cancer; Pancreatic Ductal Adenocarcinoma; Malignant Pleural Mesothelioma; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Mucinous Adenocarcinoma	Adelaide - Cancer Research SA; Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital; Perth - One Clinical Research (OCR); South Brisbane - Mater Cancer Care Centre; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT05498597
NCT05501886	VIKTORIA-1	Phase 3	RECRUITING	NSW, QLD, TAS, VIC, WA	2022-08-12	2022-12-08	2026-12-31	Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Gedatolisib; Palbociclib	PI3K_alpha_inhibitor; pan-PI3K/mTORC1/mTORC2_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader	Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	CELC-G-301	Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy	Breast Cancer	Adelaide - Adelaide Oncology & Haematology; Fitzroy - St Vincent's Hospital (Melbourne) Ltd; Frankston - Peninsula & South Eastern Hematology and Oncology Group (PSEHOG) - (COMPLETED); Nedlands - Hollywood Private Hospital, Breast Cancer Research Centre; South Brisbane - Mater Hospital Brisbane, Mater Cancer Care Centre; Southport - Icon Cancer Centre- Southport; Wahroonga - Sydney Adventist Hospital; Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05501886
NCT05503797	F8394-201	Phase 2	RECRUITING	NSW, VIC	2022-08-15	2023-02-21	2026-12-28	Plixorafenib	RAF_dimer_inhibitor	Plixorafenib	RAF_dimer_inhibitor	F8394-201	A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations	Cancer Harboring BRAF Alterations; HGG; LGG; Solid Tumors	2031 - Randwick - Sydney Children's Hospital Network - Randwick; 2305 - New Lambton Heights - Newcastle Private Hospital; 2800 - Orange - Orange Health Service; 3004 - Melbourne - The Alfred	https://clinicaltrials.gov/ct2/show/NCT05503797
NCT05504291	ARET2121	Phase 2	RECRUITING	WA	2022-08-15	2022-11-04	2026-12-31	Carboplatin; Carboplatin + Etoposide + Melphalan + Vincristine; Etoposide; Melphalan; Vincristine	topoisomerase_inhibitor; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid; platinum-based_antineoplastic_agent; alkylating_agent; vinca_alkaloid	Carboplatin + Etoposide + Melphalan + Vincristine	alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor + vinca_alkaloid	ARET2121	Intravitreal Melphalan for Intraocular Retinoblastoma	Bilateral Retinoblastoma; Childhood Intraocular Retinoblastoma; Group D Retinoblastoma; Stage I Retinoblastoma; Unilateral Retinoblastoma	6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT05504291
NCT05519449	PSMA-007-001	Phase 1	RECRUITING	NSW, SA, WA	2022-08-25	2022-09-15	2028-12	Darolutamide; Darolutamide + JANX007; JANX007	PSMA-tumor-activated_T-cell_engager + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; PSMA-tumor-activated_T-cell_engager	Darolutamide + JANX007; JANX007	PSMA-tumor-activated_T-cell_engager; PSMA-tumor-activated_T-cell_engager + antiandrogen,nonsteroidal,second_generation	PSMA-007-001	A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse (COBLH); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SoCRU); 6009 - Nedlands - Linear Clinical Research Ltd.	https://clinicaltrials.gov/ct2/show/NCT05519449
NCT05521412	VIOLET	Phase 1 / Phase 2	RECRUITING	VIC	2022-08-26	2022-09-29	2026-12					21/028	EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05521412
NCT05523947	YH32367-101	Phase 1 / Phase 2	RECRUITING	NSW, VIC, WA	2022-08-29	2022-08-26	2026-12-01	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367-101	A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors	HER2-Positive Solid Tumor	Adelaide - Southern Oncology Clinical Research Unit; Melbourne - Austin Health; Perth - Breast Cancer Research Centre - WA - (WITHDRAWN); Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05523947
NCT05525247	SLC-3010-001	Phase 1 / Phase 2	RECRUITING	NSW, WA	2022-08-30	2022-12-21	2028-01	Gemcitabine; Gemcitabine + SLC3010; SLC3010	anti-IL-2_antibody_conjugate; gemcitabine; anti-IL-2_antibody_conjugate + antimetabolite	Gemcitabine + SLC3010; SLC3010	anti-IL-2_antibody_conjugate; anti-IL-2_antibody_conjugate + antimetabolite; gemcitabine	SLC-3010-001	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah - Selecxine Investigator site; 6153 - Brentwood - Selecxine Investigator site	https://clinicaltrials.gov/ct2/show/NCT05525247
NCT05527184	IMGN151-1001	Phase 1	RECRUITING	WA	2022-09-01	2023-01-11	2027-02	IMGN151	anti-FR-alpha_antibody-drug_conjugate	IMGN151	anti-FR-alpha_antibody-drug_conjugate	IMGN151-1001	A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers	Endometrial Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Cervical Cancer	6000 - Perth - Monash Health - Monash Medical Centre /ID# 268971	https://clinicaltrials.gov/ct2/show/NCT05527184
NCT05533697	mRNA-4359-P101	Phase 1 / Phase 2	RECRUITING	NSW, VIC, WA	2022-09-07	2022-08-18	2027-12-08	Pembrolizumab; Pembrolizumab + mRNA-4359; mRNA-4359	mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody	Pembrolizumab + mRNA-4359; mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	mRNA-4359-P101	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2065 - Wollstonecraft - Melanoma Institute Australia; 2228 - Miranda - Southside Cancer Center; 3084 - Melbourne - Austin Hospital; 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05533697
NCT05536141	ARC-20	Phase 1	RECRUITING	NSW, VIC	2022-09-07	2022-10-26	2027-07	AB-521; Cabozantinib; Zimberelimab	VEGFR2_inhibitor; RET_inhibitor; MET_inhibitor,type_2; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; anti-PD-1_monoclonal_antibody; ROS1_inhibitor; HIF2a_inhibitor; AXL_inhibitor; KIT_inhibitor	Cabozantinib; Zimberelimab; AB-521	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	ARC-20	A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors	Clear Cell Renal Cell Carcinoma; Solid Tumors	Camperdown - Chris O'Brien Lifehouse; Melbourne - Box Hill Hospital; Sydney - Ashford Cancer Centre Research/ICON; Sydney - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT05536141
NCT05538130	C4901001	Phase 1	RECRUITING	VIC	2022-09-09	2022-11-30	2029-04-29	Encorafenib; Encorafenib + PF-07799544; PF-07799544; PF-07799544 + PF-07799933; PF-07799933	MEK_inhibitor; BRAF_V600_inhibitor; BRAF_inhibitor,pan-mutant-selective + MEK_inhibitor; BRAF_inhibitor,pan-mutant-selective; BRAF_V600_inhibitor + MEK_inhibitor	Encorafenib + PF-07799544; PF-07799544 + PF-07799933	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_inhibitor,pan-mutant-selective + MEK_inhibitor	C4901001	A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS	Melanoma; Glioma; Thyroid Cancer; Non-Small Cell Lung Cancer; Malignant Neoplasms; Brain Neoplasms; Colorectal Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT05538130
NCT05544552	SURF301	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC, WA	2022-09-15	2022-11-22	2027-06	TYRA-300	FGFR3_inhibitor	TYRA-300	FGFR3_inhibitor	TYR300-101	A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcinoma; Solid Tumor, Adult; Bladder Cancer; Non-muscle-invasive Bladder Cancer; FGFR3 Gene Mutation; FGFR3 Gene Alteration; Advanced Solid Tumor; Advanced Urothelial Carcinoma; Urinary Tract Cancer; Urinary Tract Tumor; Urinary Tract Carcinoma	2109 - Macquarie Park - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Research Unit; 3084 - Heidelberg - Austin Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4215 - Southport - Tasman Oncology; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05544552
NCT05549297	IMCgp100-203	Phase 3	RECRUITING	NSW, QLD, VIC	2022-09-19	2022-12-19	2028-07	Pembrolizumab; Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; anti-PD-1_monoclonal_antibody; bispecfic_T-cell_engager,gp100-targeting	Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; bispecfic_T-cell_engager,gp100-targeting	IMCgp100-203	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	Advanced Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia; 3004 - Melbourne - Alfred Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 4120 - Greenslopes - Gallipoli Medical Research Foundation (GMRF)	https://clinicaltrials.gov/ct2/show/NCT05549297
NCT05555732	DS1062-A-U303	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2022-09-22	2023-01-11	2027-08-01	Carboplatin; Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Pemetrexed	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Datopotamab deruxtecan + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	DS1062-A-U303	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Metastatic Non Small Cell Lung Cancer	2217 - Kogarah - St George Public Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 3199 - Frankston - PSEHOG (Peninsula and South Eastern Haematology and Oncology Group); 5000 - Adelaide - CRSA/ St Andrews Hospital - (TERMINATED); 5042 - Bedford Park - Flinders Medical Centre (Fmc); QLD 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05555732
NCT05563220	ELEVATE	Phase 1 / Phase 2	RECRUITING	NSW	2022-09-28	2023-01-24	2028-12-28	Abemaciclib; Abemaciclib + Elacestrant + Palbociclib + Ribociclib; Abemaciclib + Elacestrant + Ribociclib; Alpelisib; Alpelisib + Elacestrant; Capivasertib; Capivasertib + Elacestrant; Elacestrant; Elacestrant + Everolimus; Everolimus; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; mTORC1_inhibitor; selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor	Abemaciclib + Elacestrant + Palbociclib + Ribociclib; Abemaciclib + Elacestrant + Ribociclib; Alpelisib + Elacestrant; Capivasertib + Elacestrant; Elacestrant + Everolimus	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	STML-ELA-0222	A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	Breast Cancer; Metastatic Breast Cancer	2113 - Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05563220
NCT05577416	AB-218-IIT-201	Phase 1	RECRUITING	VIC	2022-10-11	2022-10-11	2025-12-01	Safusidenib	IDH1_R132_inhibitor	Safusidenib	IDH1_R132_inhibitor	2022.003	A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma	Glioma	Melbourne - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT05577416
NCT05581004	GO43860	Phase 1	RECRUITING	NSW, VIC, WA	2022-10-12	2022-10-20	2027-02-28	Atezolizumab; Atezolizumab + Pembrolizumab + RO7502175; Atezolizumab + RO7502175; Pembrolizumab; RO7502175	unknown_drug_class; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Pembrolizumab + RO7502175; Atezolizumab + RO7502175; RO7502175	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	GO43860	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; NSCLC; HNSCC; Melanoma; TNBC; Esophageal Cancer; Gastric Cancer; Cervical Cancer; Colorectal Cancer; Urothelial Carcinoma; Clear Cell RCC; HCC	2010 - Darlinghurst - Kinghorn Cancer Centre; 3168 - Clayton - Monash Health Monash Medical Centre; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05581004
NCT05598151	HM-EZHI-101	Phase 1	RECRUITING	SA, VIC	2022-10-24	2023-01-11	2028-06	HM97662	EZH1/2_inhibitor	HM97662	EZH1/2_inhibitor	HM-EZHI-101	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Adelaide - Cancer Research SA; Ballarat - Grampians Health; Clayton - Monash Medical Centre; Frankston - Peninsula and Southeast Oncology	https://clinicaltrials.gov/ct2/show/NCT05598151
NCT05599984	M23-385	Phase 1	RECRUITING	NSW, VIC	2022-10-28	2022-12-05	2026-06	ABBV-706; ABBV-706 + Budigalimab; ABBV-706 + Carboplatin + Cisplatin; Budigalimab; Carboplatin; Cisplatin	anti-PD-1_monoclonal_antibody + antibody-drug_conjugate,SEZ6-targeting; platinum-based_antineoplastic_agent; antibody-drug_conjugate,SEZ6-targeting + platinum-based_antineoplastic_agent; antibody-drug_conjugate,SEZ6-targeting; anti-PD-1_monoclonal_antibody	ABBV-706; ABBV-706 + Budigalimab; ABBV-706 + Carboplatin + Cisplatin	anti-PD-1_monoclonal_antibody + antibody-drug_conjugate,SEZ6-targeting; antibody-drug_conjugate,SEZ6-targeting; antibody-drug_conjugate,SEZ6-targeting + platinum-based_antineoplastic_agent	M23-385	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 260874; 2050 - Camperdown - Chris O'Brien Lifehouse /ID# 259087; 3000 - Melbourne - Peter MacCallum Cancer Ctr /ID# 259197; 3084 - Heidelberg - Austin Health and Ludwig Institute for Cancer Research /ID# 255174	https://clinicaltrials.gov/ct2/show/NCT05599984
NCT05607498	EMB07X101	Phase 1	RECRUITING	VIC, WA	2022-11-03	2023-03-01	2026-03-31	EMB-07	bispecific_T-cell_engager,ROR1-targeting	EMB-07	bispecific_T-cell_engager,ROR1-targeting	EMB07X101	A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma	Frankston - Peninsula and South Eastern Haematology and Oncology Group; Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05607498
NCT05609968	3475-D46	Phase 3	RECRUITING	NSW, SA, VIC	2022-11-02	2023-02-06	2028-08-23	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	3475-D46	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Carcinoma, Non-Small-Cell Lung	2800 - Orange - Orange Hospital-Clinical Trials Unit ( Site 0600); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 0601); 5000 - Adelaide - Cancer Research SA-St Andrews Hospital ( Site 0603)	https://clinicaltrials.gov/ct2/show/NCT05609968
NCT05611931	XPORT-EC-042	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC	2022-11-03	2023-04-18	2028-01-31	Placebo; Selinexor	placebo; XPO1_inhibitor	Selinexor; Placebo	XPO1_inhibitor; placebo	XPORT-EC-042	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Endometrial Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Wentworthville - Westmead Hospital; 2250 - Gosford - Central Coast LHD - Gosford & Wyong Hospitals; 2305 - New Lambton Heights - Newcastle Private Hospital; 2560 - Campbelltown - Macarthur Cancer Therapy Centre; 2640 - Albury East - Border Medical Oncology and Haematology; 3000 - Melbourne - Peter MacCallum Cancer Centre/RWH/RMH - (WITHDRAWN); 3128 - Box Hill - Box Hill Hospital - Eastern Health (Oncology); 3144 - Malvern - Cabrini Health; 3168 - Clayton - Monash Health; 3199 - Frankston - Frankston Hospital; 4215 - Southport - ICON Cancer Centre Southport; 4350 - Toowoomba - Toowoomba Hospital; 5000 - Southport - The Royal Adelaide Hospital; 7000 - Hobart - Royal Hobart Hospital; Saint Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT05611931
NCT05614258	ADG206-1001	Phase 1	RECRUITING	SA, VIC	2022-11-09	2023-02-13	2025-10	ADG206	anti-4-1BB_agonistic_antibody	ADG206	anti-4-1BB_agonistic_antibody	ADG206-1001	A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	3168 - Clayton - Monash Health; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05614258
NCT05614739	FORAGER-1	Phase 1	RECRUITING	NSW	2022-11-07	2023-01-12	2027-06	Enfortumab Vedotin; Enfortumab Vedotin + LOXO-435 + Pembrolizumab; LOXO-435; LOXO-435 + Pembrolizumab; Pembrolizumab	FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate; FGFR3_inhibitor; anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Enfortumab Vedotin + LOXO-435 + Pembrolizumab; LOXO-435; LOXO-435 + Pembrolizumab	FGFR3_inhibitor; FGFR3_inhibitor + anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	18594	FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations	Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms	2065 - St Leonards - GenesisCare North Shore; 2109 - Sydney - Macquarie University; 2310 - Hunter Region, NSW - Calvary Mater Newcastle; NSW 2010 - Darlinghurst - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT05614739
NCT05619913	EPOCH	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2022-11-09	2023-05-22	2026-12	Eribulin; Eribulin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody	Eribulin; Eribulin + Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue	ANZGOG 1828/2021	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Ovarian Carcinosarcoma; Uterine Carcinosarcoma	8006 - Melbourne - Peter MacCallum Cancer Centre; Clayton - Monash Health; Herston - Royal Brisbane and Women's Hospital; Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT05619913
NCT05642780	SKB264-II-06	Phase 2	RECRUITING	NSW, QLD, SA	2022-11-30	2023-01-17	2027-12-31	Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Pembrolizumab + Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	SKB264-II-06	A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors	Solid Tumor	4066 - Auchenflower - Icon Cancer Centre Wesley; Bedford Park - Flinders Medical Centre; Kogarah - Wollongong Hospital	https://clinicaltrials.gov/ct2/show/NCT05642780
NCT05642949	MHB036C-CP001EN	Phase 1 / Phase 2	NOT_YET_RECRUITING	QLD, SA, VIC	2022-11-30	2023-01-23	2026-06-30	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C-CP001EN	Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05642949
NCT05647122	EGRET	Phase 1	RECRUITING	NSW, VIC	2022-12-02	2022-12-22	2027-10-06	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib; Bevacizumab; Fluorouracil; Leucovorin; Osimertinib	anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti_EGFR/cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; Fluorouracil; folinic_acid; anti_EGFR/cMET_antibody-drug_conjugate; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti_EGFR/cMET_antibody-drug_conjugate	AZD9592; AZD9592 + Bevacizumab + Fluorouracil + Leucovorin; AZD9592 + Osimertinib	EGFR_inhibitor,third_generation + anti_EGFR/cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + anti_EGFR/cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; anti_EGFR/cMET_antibody-drug_conjugate; Fluorouracil	D9350C00001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumours; Carcinoma Non-small Cell Lung; Head and Neck Neoplasms; Colorectal Neoplasms	2217 - Kogarah - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05647122
NCT05652855	MHB088C-CP001EN	Phase 1 / Phase 2	NOT_YET_RECRUITING	QLD, SA, VIC	2022-12-07	2023-01-23	2026-07-31	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C-CP001EN	Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3144 - Melbourne - Cabrini Health; 4217 - Gold Coast - Pindara Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT05652855
NCT05652868	MYTX-011-01	Phase 1	RECRUITING	NSW, SA	2022-12-07	2023-03-23	2027-12	MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011-01	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01	NSCLC; NSCLC Stage IV; NSCLC Stage IIIB; Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Advanced Non-Small Cell Lung Cancer; Advanced Non-Small Cell Non-Squamous Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2148 - Blacktown - Blacktown Hospital; 5000 - Adelaide - Queen Elizabeth Hospital; 5011 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT05652868
NCT05668988	DZ2022E0005	Phase 3	RECRUITING	NSW, VIC, WA	2022-12-20	2022-12-13	2027-10-31	Carboplatin; Carboplatin + Pemetrexed; Pemetrexed; Sunvozertinib	platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; ERBB2_inhibitor,exon_20_selective	Carboplatin + Pemetrexed; Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent	DZ2022E0005	A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation	Non-small Cell Lung Cancer	Concord - Concord Cancer Centre Medical Oncology Clinical Trials Unit Concord Repatriation General Hospital; Melbourne - Peter MacCallum Cancer Centre; Nedlands - Sir Charles Gairdner Hospital, Heart Research Insititute; Randwick - Prince of Wales Hospital	https://clinicaltrials.gov/ct2/show/NCT05668988
NCT05671510	PRESERVE-003	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2022-12-31	2023-06-28	2027-06-30	Docetaxel; ONC392	anti-CTLA4_monoclonal_antibody; taxane	Docetaxel; ONC392	taxane; anti-CTLA4_monoclonal_antibody	PRESERVE-003	Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors	Non Small Cell Lung Cancer	2200 - Bankstown - Bankstown Hospital - 3305 - (COMPLETED); 4006 - Newstead - Mater - 3301 - (COMPLETED); 5000 - Adelaide - Cancer Research SA - 3303 - (COMPLETED); New Lambton Heights - Newcastle Private Hospital - 3302 - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT05671510
NCT05676931	EDGE-Lung	Phase 2	RECRUITING	NSW, QLD, SA, WA	2023-01-05	2023-02-21	2027-12	Docetaxel; Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Quemliclustat + Zimberelimab; Domvanalimab; Domvanalimab + Quemliclustat + Zimberelimab; Domvanalimab + Zimberelimab; Quemliclustat; Quemliclustat + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-TIGIT_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + taxane; taxane; CD73_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CD73_inhibitor	Docetaxel + Domvanalimab + Zimberelimab; Docetaxel + Quemliclustat + Zimberelimab; Domvanalimab + Quemliclustat + Zimberelimab; Domvanalimab + Zimberelimab; Quemliclustat + Zimberelimab	CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	EDGE-Lung	A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Cancer	2450 - Coffs Harbour - Coffs Harbour Health Campus - (WITHDRAWN); 4217 - Benowa - Pindara Private Hospital; 5000 - Adelaide - Cancer Research SA Pty Ltd; 6009 - Nedlands - Sir Charles Gairdner Hospital; Albury - The Border Cancer Hospital	https://clinicaltrials.gov/ct2/show/NCT05676931
NCT05691478	NCI-2022-08567	Phase 2 / Phase 3	RECRUITING	NSW, NZ, QLD, VIC, WA	2023-01-18	2023-03-03	2030-03-20	Cabozantinib; Cabozantinib + Cisplatin + Doxorubicin + Methotrexate; Cisplatin; Cisplatin + Doxorubicin + Methotrexate; Doxorubicin; Methotrexate	RET_inhibitor; anthracycline + antifolate + platinum-based_antineoplastic_agent; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; RET_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; RET_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; KIT_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; AXL_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + anthracycline + antifolate + platinum-based_antineoplastic_agent; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; VEGFR2_inhibitor; anthracycline + antimetabolite + platinum-based_antineoplastic_agent; ROS1_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; KIT_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; ROS1_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; AXL_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; VEGFR2_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; antifolate; platinum-based_antineoplastic_agent; doxorubicin; VEGFR2_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; ROS1_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; AXL_inhibitor	Cabozantinib + Cisplatin + Doxorubicin + Methotrexate; Cisplatin + Doxorubicin + Methotrexate	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; AXL_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; AXL_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; KIT_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; KIT_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + anthracycline + antifolate + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; RET_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; RET_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; ROS1_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; ROS1_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; VEGFR2_inhibitor + anthracycline + antifolate + platinum-based_antineoplastic_agent; VEGFR2_inhibitor + anthracycline + antimetabolite + platinum-based_antineoplastic_agent; anthracycline + antifolate + platinum-based_antineoplastic_agent; anthracycline + antimetabolite + platinum-based_antineoplastic_agent; doxorubicin	NCI-2022-08567	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma	High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma	1145 - Grafton - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital - (SUSPENDED); 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT05691478
NCT05694936	VADER	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2023-01-19	2023-01-23	2027-06	Cetuximab; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Panitumumab; Sodium Valproate	HDAC_inhibitor; anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody	Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody	VADER	A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (VADER Study).	Metastatic Colorectal Cancer	2065 - Saint Leonards - Royal North Shore Hospital; 2145 - Westmead - Western Sydney Local Health District; 3000 - Melbourne - Peter MacCallum Cancer Institute; 3084 - Melbourne - Austin Health; 3128 - Box Hill - Eastern Health; 3199 - Frankston - Peninsula Health; 3280 - Warrnambool - South West Healthcare; 3350 - Ballarat Central - Grampians Health; 4029 - Herston - Royal Brisbane and Women's Hospital; 5000 - Adelaide - Queen Elizabeth Hospital; 5042 - Bedford Park - Southern Adelaide Local Health Network Incorporated	https://clinicaltrials.gov/ct2/show/NCT05694936
NCT05696626	ELAINEIII	Phase 3	RECRUITING	NSW, QLD	2023-01-13	2023-10-31	2028-04	Abemaciclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Lasofoxifene + Palbociclib + Ribociclib; Fulvestrant; Lasofoxifene; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_modulator; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_modulator	Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Lasofoxifene + Palbociclib + Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_modulator	SMX 22-002	An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Metastatic Breast Cancer	Blacktown - Blacktown Hospital; Concord - Concord Repatriation General Hospital; South Brisbane - Mater Misericordiae Ltd, South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05696626
NCT05712356	BOLSTER	Phase 2	ACTIVE_NOT_RECRUITING		Help: Date registered 2023-02-03	2023-08-24		Certepetide; Cisplatin; Durvalumab; Gemcitabine; Placebo	gemcitabine; tumor-homing_peptide_iRGD; platinum-based_antineoplastic_agent; placebo; anti-PD-L1_monoclonal_antibody; antimetabolite	Certepetide; Cisplatin; Durvalumab; Gemcitabine; Placebo	tumor-homing_peptide_iRGD; anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent	2023-503740-14  LSTA1-P02	A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)	Gall Bladder Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Extrahepatic Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Gall Bladder Cancer; Gallbladder Carcinoma; Bile Duct Cancer		https://clinicaltrials.gov/ct2/show/NCT05712356
NCT05718895	CLINCH	Phase 1	RECRUITING	QLD, SA, VIC	2023-01-30	2023-03-27	2026-06-30	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG-022-ST-001	An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	Adelaide - Cancer Research SA Pty Ltd - (COMPLETED); Malvern - Cabrini Health Limited; South Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon)	https://clinicaltrials.gov/ct2/show/NCT05718895
NCT05720130	TheraPb-ADVC001	Phase 1 / Phase 2	RECRUITING	QLD	2023-02-07	2023-03-15	2029-12-31	212Pb-ADVC001	radioligand,PSMA-targeting	212Pb-ADVC001	radioligand,PSMA-targeting	TheraPb-ADVC001	Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	4029 - Brisbane - Royal Brisbane & Women's Hospital; 4102 - Brisbane - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT05720130
NCT05725291	AMT-116-01	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2023-02-02	2023-07-25	2026-12-30	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116-01	First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Sydney - Macquarie University Hospital; 3004 - Victoria Park - Alfred Hospital; 3084 - Victoria Park - Austin Health; 3144 - Victoria Park - Cabrini Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit; Brisbane - ICON Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05725291
NCT05727176	FOENIX-CCA4	Phase 2	RECRUITING	NSW, VIC, WA	2023-02-03	2023-07-05	2026-12	Futibatinib	pan-FGFR_inhibitor,irreversible	Futibatinib	pan-FGFR_inhibitor,irreversible	TAS-120-205	Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements	Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement	2010 - Sydney - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre; 3004 - Melbourne - Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT05727176
NCT05727904	IOV-MEL-301	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2023-02-06	2023-03-30	2030-03-01	Lifileucel; Lifileucel + Pembrolizumab; Pembrolizumab	autologous_tumor-infiltrating_lymphocytes_therapy; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_tumor-infiltrating_lymphocytes_therapy	Lifileucel + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_tumor-infiltrating_lymphocytes_therapy	IOV-MEL-301	A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma	Metastatic Melanoma; Unresectable Melanoma; Melanoma	3000 - Melbourne - Peter MacCallum Cancer Centre; 4120 - Greenslopes - Greenslopes Private Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6150 - Murdoch - Fiona Stanley Hospital; NSW 2145 - Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05727904
NCT05735080	INX-315-01	Phase 1 / Phase 2	RECRUITING	QLD, VIC	2023-02-09	2023-03-28	2026-06	Abemaciclib; Abemaciclib + Fulvestrant + INX-315; Fulvestrant; Fulvestrant + INX-315; INX-315	CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader	Abemaciclib + Fulvestrant + INX-315; Fulvestrant + INX-315; INX-315	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	INX-315-01	A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer	Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer	3052 - Parkville - Peter MacCallum Cancer Center; 4101 - South Brisbane - Mater Hospital	https://clinicaltrials.gov/ct2/show/NCT05735080
NCT05756907	SB221	Phase 1 / Phase 2	RECRUITING	NSW, SA	2023-02-23	2023-09-15	2025-05-30	Atezolizumab; Atezolizumab + SON-1010; SON-1010	IL-12_variant; IL-12_variant + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + SON-1010; SON-1010	IL-12_variant; IL-12_variant + anti-PD-L1_monoclonal_antibody	SB221	A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer	Advanced Solid Tumor; Platinum-resistant Ovarian Cancer	2148 - Blacktown - Blacktown Mt Druitt Hospital; 2640 - Albury - The Border Cancer Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT05756907
NCT05759728	CNA3103-001	Phase 1 / Phase 2	RECRUITING	SA	2023-02-26	2023-10-24	2027-12	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103-001	A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	5000 - Adelaide - Carina Biotech Investigators	https://clinicaltrials.gov/ct2/show/NCT05759728
NCT05763004	IOS-1002-201	Phase 1	RECRUITING	SA, VIC, WA	2023-02-28	2023-03-15	2025-05-31	IOS1002; IOS1002 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting; anti-PD-1_monoclonal_antibody; fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting	IOS1002; IOS1002 + Pembrolizumab	anti-PD-1_monoclonal_antibody + fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting; fusion_protein,LILRB2/LILRB2/KIR3DL1-targeting	IOS-1002-201	A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors	Solid Tumor, Adult	Clayton - Monash Health Medical Center; Heidelberg - Austin Health / Cancer Clinical Trials Center; Melbourne - Alfread Health; Melbourne - Peter MacCallum Cancer Center; Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05763004
NCT05774873	CIBI334A101	Phase 1 / Phase 2	RECRUITING	NSW	2023-03-07	2023-08-09	2026-06-30	IBI334	bispecific_EGFR/B7H3_antibody	IBI334	bispecific_EGFR/B7H3_antibody	CIBI334A101	A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	2145 - Waratah - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT05774873
NCT05785754	DCSZ11-101	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2023-03-14	2023-06-28	2026-12	DCSZ11; DCSZ11 + Doxorubicin + Tebentafusp; DCSZ11 + Pembrolizumab; Doxorubicin; Pembrolizumab; Tebentafusp	anti-CD93_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; doxorubicin; anti-PD-1_monoclonal_antibody; anthracycline + anti-CD93_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; bispecfic_T-cell_engager,gp100-targeting	DCSZ11; DCSZ11 + Doxorubicin + Tebentafusp; DCSZ11 + Pembrolizumab	anthracycline + anti-CD93_monoclonal_antibody + bispecfic_T-cell_engager,gp100-targeting; anti-CD93_monoclonal_antibody; anti-CD93_monoclonal_antibody + anti-PD-1_monoclonal_antibody; doxorubicin	DCSZ11-101	A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	2010 - Sydney - St Vincent's Hospital; 2031 - Randwick - Scientia Clinical Research; 3144 - Malvern - Cabrini Hospital - (COMPLETED); 3168 - Clayton - Monash Health; 4556 - Buderim - University of Sunshine Coast - (WITHDRAWN); 5011 - Woodville South - The Queen Elizabeth Hospital (TQEH); 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research Limited; NSW2170 - Liverpool - Liverpool Hospital - (COMPLETED); QLD4101 - South Brisbane - Mater Misericordiae Health Services Brisbane Ltd; QLD4810 - Douglas - Townsville Hospital; Wahroonga - Sydney Adventist Hospital - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT05785754
NCT05785767	R3767-ONC-2235	Phase 2 / Phase 3	RECRUITING	NSW, VIC	2023-03-14	2023-06-30	2032-02-05	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	R3767-ONC-2235	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%	Advanced Non-Small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 2500 - Wollongong - Southern Medical Day Care Centre; 2650 - Wagga Wagga - Riverina Cancer Care Centre (RCCC); 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital	https://clinicaltrials.gov/ct2/show/NCT05785767
NCT05789082	KRAScendo-170	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2023-03-28	2023-06-20	2032-01-29	Carboplatin; Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Cisplatin; Divarasib; Divarasib + Pembrolizumab; Pembrolizumab; Pemetrexed	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; antimetabolite	Carboplatin + Cisplatin + Divarasib + Pembrolizumab + Pemetrexed; Divarasib + Pembrolizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	BO44426	A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Non-Small Cell Lung Cancer	2139 - Concord - Concord Repatriation General Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05789082
NCT05797168	FONTANA	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2023-03-21	2023-06-05	2028-01-06	AZD5335; AZD5335 + Bevacizumab; AZD5335 + Bevacizumab + Carboplatin; AZD5335 + Palacaparib; AZD5335 + Saruparib; Bevacizumab; Carboplatin; Palacaparib; Saruparib	anti-VEGF_monoclonal_antibody; PARP1-selective_inhibitor; platinum-based_antineoplastic_agent; anti-FR-alpha_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody	AZD5335; AZD5335 + Bevacizumab; AZD5335 + Bevacizumab + Carboplatin; AZD5335 + Palacaparib; AZD5335 + Saruparib	PARP1-selective_inhibitor + anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent	D8990C00001	A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors	Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer	2170 - Liverpool - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05797168
NCT05800015	R3767-ONC-2236	Phase 2 / Phase 3	RECRUITING	NSW, VIC, WA	2023-03-23	2023-08-08	2031-12-23	Carboplatin; Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed; Cemiplimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed	anti-LAG3_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	R3767-ONC-2236	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels	Non-small Cell Lung Cancer	2109 - Macquarie Park - Macquarie University Health Science Center (MQ Health); 2500 - Wollongong - Southern Medical Day Care Centre; 3065 - Fitzroy - St Vincents Hospital Melbourne; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (BRICC); 3550 - Bendigo - Bendigo Hospital; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05800015
NCT05800665	GO44537	Phase 1	_COHORTS_FULL	NSW, VIC	2023-03-24	2023-05-02	2026-07-30	RO-7656594	unknown_drug_class; AR_PROTAC_degrader	RO-7656594	AR_PROTAC_degrader; unknown_drug_class	GO44537	A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer	Advanced Prostate Cancer; Metastatic Prostate Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney; 2162 - New South Wales - Macquarie University Hospital; 3084 - Heidelberg - Austin Hospital; 3168 - Clayton - Monash Health Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05800665
NCT05800964	NCT05800964	Phase 1	RECRUITING	NSW, VIC	2023-03-24	2023-06-13	2028-02-12	AMG 305	bispecific_T-cell_engager,MSLN-targeting	AMG 305	bispecific_T-cell_engager,MSLN-targeting	20220073	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown - Chris OBrien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05800964
NCT05805501	BO43936	Phase 2	_PAUSED	QLD	2023-03-28	2023-04-21	2025-10-31	Axitinib; Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig; Pembrolizumab; Tiragolumab; Tobemstomig	VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody	Axitinib + Pembrolizumab; Axitinib + Tiragolumab + Tobemstomig; Axitinib + Tobemstomig	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	BO43936	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	4575 - Birtinya - Sunshine Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT05805501
NCT05807035	CAN001	Phase 1	RECRUITING	SA	2023-04-07	2023-02-10	2028-02-10	Radvax	autologous_anticancer_vaccine	Radvax	autologous_anticancer_vaccine	CAN001	A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers	Solid Tumor	5046 - Adelaide - ARASMI	https://clinicaltrials.gov/ct2/show/NCT05807035
NCT05818683	CR109321	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2023-04-06	2023-04-26	2027-09-01	Abiraterone; Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone; Apalutamide; Cabazitaxel; Cetrelimab; Darolutamide; Docetaxel; Enzalutamide; JNJ-78278343; Prednisone	antiandrogen,nonsteroidal,second_generation; bispecific_T-cell_engager,KLK2-targeting; glucocorticoid; taxane; anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane	Abiraterone + Apalutamide + Cabazitaxel + Cetrelimab + Darolutamide + Docetaxel + Enzalutamide + JNJ-78278343 + Prednisone	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,KLK2-targeting + glucocorticoid + taxane	CR109321	A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer	2109 - Macquarie University - Macquarie University; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05818683
NCT05852691	CO44194	Phase 2	_PAUSED	VIC	2023-05-02	2023-07-18	2026-12-18	Nab-paclitaxel; Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; Pembrolizumab; RO7247669; Tobemstomig	bispecific_PD-1/LAG3_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; taxane	Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel + Tobemstomig; RO7247669	anti-PD-1_monoclonal_antibody + taxane; bispecific_PD-1/LAG3_antibody + taxane	CO44194	A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer	Breast Cancer	St Albans - Sunshine Hospital	https://clinicaltrials.gov/ct2/show/NCT05852691
NCT05867251	AVZO-021-1001	Phase 1 / Phase 2	RECRUITING	NSW	2023-05-17	2023-08-30	2030-01-31	AVZO-021; AVZO-021 + Abemaciclib + Carboplatin + Fulvestrant + Letrozole + Palbociclib + Ribociclib + Sacituzumab Govitecan; Abemaciclib; Carboplatin; Fulvestrant; Letrozole; Palbociclib; Ribociclib; Sacituzumab Govitecan	CDK2_inhibitor; selective_estrogen_receptor_degrader; platinum-based_antineoplastic_agent; aromatase_inhibitor; anti-Trop2_antibody-drug_conjugate; CDK2_inhibitor + CDK4/6_inhibitor + anti-Trop2_antibody-drug_conjugate + aromatase_inhibitor + platinum-based_antineoplastic_agent + selective_estrogen_receptor_degrader; CDK4/6_inhibitor	AVZO-021; AVZO-021 + Abemaciclib + Carboplatin + Fulvestrant + Letrozole + Palbociclib + Ribociclib + Sacituzumab Govitecan	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + anti-Trop2_antibody-drug_conjugate + aromatase_inhibitor + platinum-based_antineoplastic_agent + selective_estrogen_receptor_degrader	AVZO-021-1001	A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer; CCNE1 Amplification; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer	Macquarie University - Macquarie University Hospital; Wollongong - Cancer Care Wollongong	https://clinicaltrials.gov/ct2/show/NCT05867251
NCT05868174	177Lu-TLX250-001	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2023-05-11	2023-05-23	2026-12	177Lu-TLX250; 177Lu-TLX250 + Peposertib; Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate	177Lu-TLX250 + Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250-001	A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors	Solid Tumor, Adult; Advanced Solid Tumor; Advanced Renal Cell Carcinoma	Adelaide - Ashford (Icon) Cancer Centre; Brisbane - Princess Alexandra Hospital; Melbourne - Austin Health; North Ryde - Macquarie University; Perth - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT05868174
NCT05872295	IKS014-01	Phase 1	RECRUITING	NSW, VIC, WA	2023-05-14	2023-09-14	2027-09	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014-01	A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	Breast Cancer; Gastric Cancer; Gastroesophageal-junction Cancer	2109 - Sydney - Macquarie University; 2139 - Concord - Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit; 2145 - Westmead - Westmead Hospital; 3004 - Melbourne - Alfred Health; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group (PSEHOG); 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05872295
NCT05886868	BL0020-101	Phase 1	RECRUITING	NSW, QLD	2023-05-24	2023-10-24	2025-02	BL0020	unknown_drug_class	BL0020	unknown_drug_class	BL0020-101	A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Birtinya - Sunshine Coast University Private Hospital; Sydney - Cancer Care Foundation Limited; Sydney - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05886868
NCT05894239	INAVO122	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-06-07	2023-09-08	2032-12-28	Inavolisib; Placebo	placebo; PI3K_alpha_inhibitor	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	WO44263	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Metastatic Breast Cancer	2010 - Darlinghurst - Kinghorn Cancer Centre; 2250 - Gosford - Gosford Hospital; 3168 - Clayton - Monash Health; 4556 - Sippy Downs - University of the Sunshine Coast; 6009 - Perth - Sir Charles Gairdner Hospital; NSW 2148 - Blacktown - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05894239
NCT05906862	AMT-253-01	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2023-06-07	2023-11-06	2026-12-30	AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253	anti-MUC18_antibody-drug_conjugate	AMT-253-01	First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	Adelaide - Southern Oncology Clinical Research; Brisbane - ICON Cancer Centre; Malvern - Cabrini Malvern Hospital; Sydney - Blacktown; Sydney - Chris O'Brien Lifehouse; Sydney - Maquarie University Hospital; VIC 3004 - Melbourne - Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT05906862
NCT05907954	IDE196-009	Phase 2	RECRUITING	NSW, VIC	2023-06-14	2023-07-03	2029-01-31	Darovasertib	PKC_inhibitor	Darovasertib	PKC_inhibitor	IDE196-009	(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Uveal Melanoma	2010 - Sydney - St. Vincent's Health Sydney; 3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT05907954
NCT05910827	HMBD-001-103	Phase 1 / Phase 2	_COHORTS_FULL	NSW, QLD, SA, VIC, WA	2023-06-16	2024-02-05	2026-03-01	Cetuximab; Cetuximab + Docetaxel + HMBD-001; Cetuximab + HMBD-001; Docetaxel; Docetaxel + HMBD-001; HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody; taxane; anti-ERBB3_monoclonal_antibody,third_generation; anti-ERBB3_monoclonal_antibody,third_generation + taxane	Cetuximab + Docetaxel + HMBD-001; Cetuximab + HMBD-001; Docetaxel + HMBD-001	anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation; anti-EGFR_monoclonal_antibody + anti-ERBB3_monoclonal_antibody,third_generation + taxane; anti-ERBB3_monoclonal_antibody,third_generation + taxane	HMBD-001-103	A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers	Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma	2065 - Sydney - GenesisCare North Shore; 2145 - Westmead - Westmead Hospital; 3144 - Malvern - Cabrini Health - (WITHDRAWN); 4101 - Brisbane - ICON Cancer Centre South Brisbane - (WITHDRAWN); 4120 - Greenslopes - Greenslopes Private Hospital; 5042 - Adelaide - Southern Oncology Clinical Research Unit; 6009 - Perth - Linear Clinical Research; Frankston - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT05910827
NCT05911295	SGNDV-001	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2023-06-09	2023-09-22	2029-04-30	Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	SGNDV-001	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)	Urothelial Carcinoma	2010 - Darlinghurst - Saint Vincents Hospital Sydney - Human Research Ethics Committee; 2010 - Darlinghurst - St Vincent's Clinic; 2031 - Randwick - Prince of Wales Hospital; 2065 - St Leonards - North Shore Private Hospital; 2065 - St Leonards - Royal North Shore Hospital; 2109 - Macquarie University - Macquarie University Hospital; 2109 - North Ryde - Macquarie University; 2139 - Concord - Concord Repatriation General Hospital; 2229 - Caringbah - South Eastern Sydney Local Health District; 2444 - Port Macquarie - Port Macquarie Base Hospital; 3084 - Melbourne - Austin Health; 3144 - Malvern - Cabrini.; 3199 - Frankston - Peninsula & South Eastern Hematology and Oncology Group (PASO); 3199 - Frankston - Peninsula And South East Oncology; 4029 - Herston - Icon Cancer Centre Chermside; 4101 - Brisbane - Mater Misericordiae - Mater Hospital Brisbane; 4101 - South Bribane - Mater Research; 4101 - South Brisbane - Mater Cancer Care Centre; 5112 - Elizabeth Vale - Lyell McEwin Hospital; NSW 2450 - NSW - Mid North Coast Local Health District	https://clinicaltrials.gov/ct2/show/NCT05911295
NCT05914116	DB-1311-O-1001	Phase 1 / Phase 2	RECRUITING	NSW, QLD, WA	2023-06-13	2023-08-17	2028-01	DB-1311; DB-1311 + Itraconazole; Itraconazole	anti-B7H3_antibody-drug_conjugate; SMO_inhibitor + anti-B7H3_antibody-drug_conjugate; SMO_inhibitor	DB-1311; DB-1311 + Itraconazole	SMO_inhibitor + anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate	DB-1311-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors	Advanced Solid Tumors	2031 - Sydney - Research Site 201; 2050 - Camperdown - Research Site 215; 2109 - Sydney - Research Site 205; 2139 - Concord - Research Site 212; 2148 - Blacktown - Research Site 208; 2228 - Sydney - Research Site 206; 2298 - Waratah - Research Site 216; 2305 - New Lambton Heights - Research Site 217; 4102 - Brisbane - Research Site 203; 4224 - Gold Coast - Research Site 210; 4575 - Birtinya - Research Site 209; 6009 - Nedlands - Research Site 202; 6009 - Nedlands - Research Site 207	https://clinicaltrials.gov/ct2/show/NCT05914116
NCT05923008	CIBI130A101	Phase 1 / Phase 2	RECRUITING	QLD	2023-06-19	2023-11-14	2026-10-31	IBI130	anti-Trop2_antibody-drug_conjugate; anti-Trop2_monoclonal_antibody	IBI130	anti-Trop2_antibody-drug_conjugate; anti-Trop2_monoclonal_antibody	CIBI130A101	A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	4575 - Birtinya - Sunshine Coast University	https://clinicaltrials.gov/ct2/show/NCT05923008
NCT05947851	1026-010	Phase 3	RECRUITING	SA, VIC	2023-07-07	2023-08-08	2035-03-14	Nemtabrutinib; Nemtabrutinib + Venetoclax; Rituximab; Rituximab + Venetoclax; Venetoclax	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor; anti-CD20_monoclonal_antibody; Bcl2_inhibitor + anti-CD20_monoclonal_antibody; Bcl2_inhibitor	Nemtabrutinib + Venetoclax; Rituximab + Venetoclax	BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor + anti-CD20_monoclonal_antibody	1026-010	A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)	Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL	3021 - Melbourne - Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103); 5000 - Adelaide - Royal Adelaide Hospital ( Site 1104)	https://clinicaltrials.gov/ct2/show/NCT05947851
NCT05950945	DS8201-0001-CIS-MA	Phase 3	RECRUITING	NSW, VIC, WA	2023-07-10	2023-12-30	2027-10-01	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	DS8201-0001-CIS-MA	A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)	Breast Cancer	2065 - North Sydney - Mater Hospital Sydney; 3165 - East Bentleigh - Monash Medical Centre Moorabbin; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05950945
NCT05957081	MarkV-01	Phase 1	NOT_YET_RECRUITING	QLD, VIC	2023-07-19	2023-11-28	2028-10-04	PMC-309; PMC-309 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-VISTA_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VISTA_monoclonal_antibody	PMC-309; PMC-309 + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VISTA_monoclonal_antibody; anti-VISTA_monoclonal_antibody	MarkV-01	A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3004 - Melbourne - Alfred Health; 3144 - Malvern - Cabrini Health Limited; 3350 - Ballarat - Ballarat Regional Integrated Cancer Centre (Grampians Health); 4217 - Benowa - Australian Hospital Care (Pindara) PTY LTD. Trading as Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05957081
NCT05957536	D3L-001-100	Phase 1	RECRUITING	NSW, VIC	2023-07-20	2023-09-19	2026-03-11	D3L-001	bispecific_ERBB2/CD47_antibody	D3L-001	bispecific_ERBB2/CD47_antibody	D3L-001-100	A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.	HER-2 Positive Advanced Solid Tumors	2109 - Sydney - D3 Bio Investigative Site; 3144 - Malvern - D3 Bio Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05957536
NCT05967689	REZILIENT2	Phase 2	RECRUITING	NSW, WA	2023-07-21	2023-07-31	2026-08-31	Zipalertinib	EGFR_inhibitor,exon_20_selective	Zipalertinib	EGFR_inhibitor,exon_20_selective	TAS6417-201	An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.	Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	2065 - Saint Leonards - Genesis Care North Shore; 2200 - Bankstown - Bankstown-Lidcombe Hospital; 6027 - Joondalup - Joondalup Hospital Pharmacy	https://clinicaltrials.gov/ct2/show/NCT05967689
NCT05969041	MYE-Symphony	Phase 1	RECRUITING	NSW, SA, VIC, WA	2023-07-28	2023-08-02	2028-08-31	MT-302	Trop2-targeting_lipid-nanoparticles	MT-302	Trop2-targeting_lipid-nanoparticles	MTX-TROP2-302	MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors	Epithelial Tumors, Malignant	2010 - Darlinghurst - St Vincent's Public Hospital Sydney; 2031 - Randwick - Scientia Clinical Research Ltd; 2145 - Westmead - Westmead Hospital; 3144 - Malvern - Cabrini Health; 5042 - Bedford Park - Souther Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT05969041
NCT05975073	NCT05975073	Phase 1 / Phase 2	_COHORTS_FULL	SA, VIC	2023-07-27	2023-08-01	2026-01-05	AMG 193; AMG 193 + IDE397; IDE397	PRMT5_inhibitor; MAT2A_inhibitor + PRMT5_inhibitor; MAT2A_inhibitor	AMG 193 + IDE397	MAT2A_inhibitor + PRMT5_inhibitor	20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors	3168 - Clayton - Monash Medical Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05975073
NCT05981703	BGB-A317-26808-101	Phase 1	RECRUITING	NSW, NZ, SA, WA	2023-07-31	2023-09-21	2027-09-30	BGB-26808; BGB-26808 + Tislelizumab; Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HPK1_inhibitor	BGB-26808 + Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-26808-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Solid Tumor	1023 - Auckland - Auckland City Hospital; 1023 - Auckland - Harbour Cancer and Wellness; 3010 - Rotorua - Health New Zealand Te Whatu Ora Lakes Rotorua Hospital; NSW 2109 - North Ryde - Macquarie University; NSW 2228 - Miranda - Southside Cancer Care - (COMPLETED); SA 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT05981703
NCT05983198	SatisfACtion	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2023-08-08	2023-11-07	2029-11-05	225Ac-PSMA-R2; 225Ac-PSMA-R2 + Bicalutamide + Flutamide; Bicalutamide; Flutamide; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; radioconjugate,PSMA-targeting; antiandrogen,nonsteroidal,first_generation; antiandrogen,nonsteroidal,first_generation + radioligand,PSMA-targeting	225Ac-PSMA-R2; 225Ac-PSMA-R2 + Bicalutamide + Flutamide; Lu-177 vipivotide tetraxetan	antiandrogen,nonsteroidal,first_generation + radioligand,PSMA-targeting; radioligand,PSMA-targeting; radioconjugate,PSMA-targeting	CAAA802A12101	SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy	Prostate Cancer	2010 - Darlinghurst - Novartis Investigative Site; 3004 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT05983198
NCT05984277	eVOLVE-Lung02	Phase 3	RECRUITING	NSW, QLD, VIC	2023-08-02	2023-10-24	2029-03-23	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed + Volrustomig; Paclitaxel; Pembrolizumab; Pemetrexed; Volrustomig	bispecific_PD-L1/CTLA4_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed + Volrustomig	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent + taxane	D798AC00001	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).	Metastatic Non-small Cell Lung Cancer	3065 - Fitzroy - Research Site; 3084 - Heidelberg - Research Site; 3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site; NSW 2145 - Sydney - Research Site	https://clinicaltrials.gov/ct2/show/NCT05984277
NCT05985083	IMM47-201	Phase 1	RECRUITING		2023-08-14	2023-08-18		IMM47	anti-CD24_monoclonal_antibody	IMM47	anti-CD24_monoclonal_antibody	IMM47-201	A Phase I, Open-Label, Multicenter, Dose-Escalation And Cohort-Expansion Study Of IMM47 In Subjects With Advanced Solid Tumors	Advanced or Metastatic Solid Tumors; Oncology		https://clinicaltrials.gov/ct2/show/NCT05985083
NCT05987332	IDE196-002	Phase 2 / Phase 3	RECRUITING	NSW, QLD, VIC, WA, Washington	2023-08-03	2023-10-31	2028-01-15	Crizotinib; Crizotinib + Darovasertib; Dacarbazine; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Darovasertib; Ipilimumab; Nivolumab; Pembrolizumab	ALK_inhibitor,first_generation; PKC_inhibitor + ROS1_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; alkylating_agent + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; alkylating_agent; MET_inhibitor,type_1; ROS1_inhibitor; PKC_inhibitor	Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IDE196-002	IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)	Metastatic Uveal Melanoma	2145 - Sydney - Westmead Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Melbourne - Alfred Health; 4102 - Brisbane - Princess Alexander Hospital; 6009 - Perth - Sir Charles Gairdner Hospital; Adelaide - Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT05987332
NCT05991349	CIBI129A101	Phase 1 / Phase 2	RECRUITING	NSW	2023-08-06	2024-03-12	2025-05-31	IBI129	anti-B7H3_antibody-drug_conjugate	IBI129	anti-B7H3_antibody-drug_conjugate	CIBI129A101	A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2050 - Camperdown - Chris O'Brien Lifehouse; 2217 - Kogarah - St George private Hospital; 2500 - Wollongong - Wollongong Hospital	https://clinicaltrials.gov/ct2/show/NCT05991349
NCT05997615	VIR-5500-V101	Phase 1	RECRUITING	NSW, VIC	2023-08-11	2023-08-10	2027-09-29	AMX-500; Darolutamide; Darolutamide + Enzalutamide; Enzalutamide	unknown_drug_class; antiandrogen,nonsteroidal,second_generation	Darolutamide + Enzalutamide; AMX-500	antiandrogen,nonsteroidal,second_generation; unknown_drug_class	VIR-5500-V101	A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer	Hormone-refractory Prostate Cancer	2010 - Sydney - Investigational Site Number: 101; 3000 - Melbourne - Investigational Site Number: 100	https://clinicaltrials.gov/ct2/show/NCT05997615
NCT06007690	CoMpass	Phase 3	RECRUITING	NZ, QLD, VIC	2023-08-17	2023-12-06	2027-03-01	Belzupacap Sarotalocan	viral_nanoparticle_drug_conjugates	Belzupacap Sarotalocan	viral_nanoparticle_drug_conjugates	AU-011-301	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma	1050 - Auckland - Auckland Eye Ltd; 3002 - East Melbourne - Eye Research Australia; 4000 - Brisbane - Terrace Eye Centre	https://clinicaltrials.gov/ct2/show/NCT06007690
NCT06016738	OPERA-01	Phase 3	RECRUITING	NSW, SA, VIC, WA	2023-08-29	2023-11-16	2027-09-30	Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Exemestane; Fulvestrant; Letrozole; Palazestrant	selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist; aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Palazestrant	aromatase_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	OP-1250-301	A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma	2145 - Westmead - Clinical Trial Site; 2250 - Gosford - Clinical Trial Site; 3168 - Clayton - Clinical Trial Site; 3355 - Ballarat Central - Clinical Trial Site; 3630 - Shepparton - Clinical Trial Site; 5000 - Adelaide - Clinical Trial Site; 6009 - Nedlands - Clinical Trial Site	https://clinicaltrials.gov/ct2/show/NCT06016738
NCT06018337	DB-1303-O-3002	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2023-08-25	2024-01-18	2028-07	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Nab-paclitaxel; Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine; taxane; fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane	DB-1303-O-3002	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Metastatic Breast Cancer	2050 - Camperdown - Research Site 6108-0; 2109 - Sydney - Research Site 6102-0; 2155 - Adelaide - Research Site 6110-0; 2170 - Liverpool - Research Site 6109-0; 2747 - Kingswood - Research Site 6116-0; 3021 - St Albans - Research Site 6105-0; 3550 - Bendigo - Research Site 6103-0; 3844 - Traralgon - Research Site 6113-0; 4101 - South Brisbane - Research Site 6101-0; 4215 - Southport - Research Site 6107-0; 4575 - Birtinya - Research Site 6106-0; 4814 - Townsville - Research Site 6104-0; 6009 - Perth - Research Site 6114-0	https://clinicaltrials.gov/ct2/show/NCT06018337
NCT06029270	NCI-2023-06678--NCI-2023-06678	Phase 2	RECRUITING	VIC	Help: Date registered 2023-09-08	2024-07-15		Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Nivolumab; Cisplatin; Gemcitabine; Nivolumab; Nivolumab + Relatlimab; Relatlimab	gemcitabine; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite	Carboplatin + Cisplatin + Gemcitabine + Nivolumab; Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	NCI-2023-06678  NCI-2023-06678	A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)	Metastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06029270
NCT06031441	GO44431	Phase 1	RECRUITING	NSW, VIC	2023-09-04	2023-11-27	2027-12-31	Atezolizumab; Atezolizumab + RO7566802; RO7566802	unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody	Atezolizumab + RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class	GO44431	A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumors; Recurrent Solid Tumors; Metastatic Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06031441
NCT06051942	CSP0003	NA	RECRUITING	NZ	2023-09-18	2022-11-22	2026-05					CSP0003	PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Benign Prostatic Hyperplasia; Localized Prostate Cancer	Tauranga - Tauranga Urology Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06051942
NCT06063681	StingrayTx	Phase 1	RECRUITING	NSW, VIC	2023-09-23	2023-10-12	2025-12	SR-8541A	ENPP1_inhibitor	SR-8541A	ENPP1_inhibitor	StingrayTx	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors	Advanced / Metastatic Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula & South Eastern Haematology & Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06063681
NCT06064097	NCI-2023-07208	Phase 2	RECRUITING	NZ	2023-09-29	2024-06-25	2026-12-31	Cisplatin; Cisplatin + Gemcitabine + Nivolumab + Radiotherapy; Gemcitabine; Nivolumab; Radiotherapy	gemcitabine; radiotherapy; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; antimetabolite	Cisplatin + Gemcitabine + Nivolumab + Radiotherapy	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; gemcitabine	NCI-2023-07208	A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)	Stage II Nasopharyngeal Carcinoma AJCC v8; Stage III Nasopharyngeal Carcinoma AJCC v8; Stage IV Nasopharyngeal Carcinoma AJCC v8	1145 - Grafton - Starship Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT06064097
NCT06064877	FIERCE-HN	Phase 3	RECRUITING	NSW, QLD, WA	2023-09-26	2024-01-11	2027-11	Cetuximab; Cetuximab + Ficlatuzumab; Ficlatuzumab; Placebo	placebo; anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Cetuximab + Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo	AV-299-23-301	A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)	Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma	2010 - Sydney - St. Vincent's Hospital; 2217 - Kogarah - St George Hospital; 4102 - Brisbane - Princess Alexandra Hospital; 6150 - Murdoch - St. John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT06064877
NCT06065748	CO44657	Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC	2023-09-26	2023-12-11	2028-12-30	Abemaciclib; Abemaciclib + Fulvestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + LHRH Agonist + Palbociclib + Ribociclib; Fulvestrant; Giredestrant; LHRH Agonist; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; LHRH_agonist	Abemaciclib + Fulvestrant + LHRH Agonist + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + LHRH Agonist + Palbociclib + Ribociclib	CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader	CO44657	A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	0110 - Whangarei - Whangarei Hospital; 2060 - North Sydney - Mater Hospital; 2086 - Frenchs Forest - Northern Beaches Hospital; 2747 - Kingswood - Nepean Hospital; 3021 - St Albans - Sunshine Hospital; 3220 - Geelong - Barwon Health; 3280 - Warrnambool - South West Healthcare; 4101 - South Brisbane - Mater Misericordiae Limited; 4442 - Palmerston North - Palmerston North Hospital; 4556 - Sippy Downs - University of the Sunshine Coast; Adelaide - Cancer Research SA; Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT06065748
NCT06072781	RAMP-301	Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2023-10-02	2024-03-18	2031-02-09	Anastrozole; Anastrozole + Letrozole + Paclitaxel + Pegylated liposomal doxorubicin; Avutometinib; Avutometinib + Defactinib; Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin	FAK_inhibitor; taxane; FAK_inhibitor + RAF/MEK_clamp; aromatase_inhibitor; RAF/MEK_clamp; anthracycline + aromatase_inhibitor + taxane; anthracycline	Anastrozole + Letrozole + Paclitaxel + Pegylated liposomal doxorubicin; Avutometinib + Defactinib	FAK_inhibitor + RAF/MEK_clamp; anthracycline + aromatase_inhibitor + taxane	VS-6766-301	A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)	Low Grade Serous Ovarian Cancer	1023 - Auckland - Auckland City Hospital; 2031 - Randwick - Prince of Wales Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4066 - Auchenflower - Icon Cancer Centre Wesley; 5000 - Adelaide - Cancer Research South Australia; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06072781
NCT06074588	2870-004	Phase 3	RECRUITING	NSW, VIC	2023-10-03	2023-11-12	2030-03-11	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Docetaxel; Docetaxel + Pemetrexed; Pemetrexed; Sacituzumab tirumotecan	glucocorticoid; taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane; anti-Trop2_antibody-drug_conjugate; antimetabolite	Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed	anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane	2870-004	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital ( Site 3000); 2217 - Kogarah - St. George Private Hospital ( Site 3004); 3021 - Melbourne - Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 3003); 3168 - Clayton - Monash Health-Oncology Research ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06074588
NCT06084481	M24-427	Phase 1	RECRUITING	NSW, VIC	2023-10-10	2023-11-09	2026-07	Itraconazole; Itraconazole + Telisotuzumab adizutecan; Telisotuzumab adizutecan	SMO_inhibitor + anti-cMET_antibody-drug_conjugate; anti-cMET_antibody-drug_conjugate; SMO_inhibitor	Itraconazole + Telisotuzumab adizutecan; Telisotuzumab adizutecan	SMO_inhibitor + anti-cMET_antibody-drug_conjugate; anti-cMET_antibody-drug_conjugate	M24-427	A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications	Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer	2050 - Camperdown - Chris O'Brien Lifehouse /ID# 262765; 3084 - Heidelberg - Austin Health /ID# 256635	https://clinicaltrials.gov/ct2/show/NCT06084481
NCT06092580	AWT020-001	Phase 1	RECRUITING	QLD, SA, VIC	2023-10-18	2023-09-15	2026-09-30	AWT020	anti-PD1-IL2_fusion_protein	AWT020	anti-PD1-IL2_fusion_protein	AWT020-001	A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer	Advanced Cancer	3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - ICON Cancer Center South Brisbane; 5042 - Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT06092580
NCT06097728	eVOLVE-Meso	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-10-18	2023-11-09	2028-03-13	Carboplatin; Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed + Volrustomig; Cisplatin; Ipilimumab; Nivolumab; Pemetrexed; Volrustomig	bispecific_PD-L1/CTLA4_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed + Volrustomig	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA4_antibody + platinum-based_antineoplastic_agent	D7988C00001	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Unresectable Pleural Mesothelioma	2145 - Westmead - Research Site; 3000 - Melbourne - Research Site; 3168 - Clayton - Research Site; 4032 - Chermside - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06097728
NCT06103864	D7630C00001	Phase 3	RECRUITING	NSW, VIC, WA	2023-10-23	2023-11-23	2029-04-30	Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab	gemcitabine; taxane; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; gemcitabine	D7630C00001	A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Breast Cancer	2010 - Darlinghurst - Research Site; 2050 - Camperdown - Research Site; 2298 - Waratah - Research Site; 3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06103864
NCT06108479	DF6215-001	Phase 1	RECRUITING	SA, VIC	2023-10-25	2023-11-28	2027-12	DF6215; DF6215 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant	DF6215; DF6215 + Pembrolizumab	IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody	DF6215-001	A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors	Solid Tumor, Adult; Solid Tumor Cancer	3199 - Frankston - Peninsula and South East Oncology Medical (PASO); 5000 - Adelaide - Cancer Research SA (CRSA)	https://clinicaltrials.gov/ct2/show/NCT06108479
NCT06112314	PRISM-MEL-301	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-10-31	2024-06-05	2027-10-16	IMC-F106C; Nivolumab; Nivolumab + Relatlimab; Relatlimab	bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; IMC-F106C	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting	IMC-F106C-301	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301	Advanced Melanoma	02298 - Waratah - Calvary Mater Newcastle Hospital; 06009 - Nedlands - Linear Clinical Research; 06009 - Nedlands - One Clinical Research - Nedlands; 3051 - North Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Hospital; 4120 - Greenslopes - Gallipoli Medical Research Foundation (Greenslopes Private Hospital) - (COMPLETED); Wollstonecraft - University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre; Woolloongabba - The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT06112314
NCT06116136	CL1-95029-002	Phase 1 / Phase 2	RECRUITING	SA	2023-10-30	2024-08-31	2029-06-01	Pembrolizumab; Pembrolizumab + S095029; S095029	anti-NKG2A_monoclona_antibody; anti-PD-1_monoclonal_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody	Pembrolizumab + S095029	anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody	CL1-95029-002	Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer	MSI-H/dMMR Gastroesophageal-junction Cancer; MSI-H/dMMR Gastric Cancer	5011 - Woodville South - The Queen Elizabeth Hospital - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT06116136
NCT06117774	DeLLphi-306	Phase 3	RECRUITING	NSW, SA, VIC, WA	2023-10-31	2024-02-20	2030-03-31	Placebo; Radiotherapy; Tarlatamab	placebo; bispecific_T-cell_engager,DLL3-targeting; radiotherapy	Tarlatamab; Placebo; Radiotherapy	bispecific_T-cell_engager,DLL3-targeting; placebo; radiotherapy	20230016	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital; 2444 - Port Macquarie - Port Macquarie Base Hospital; 3168 - Clayton - Monash Medical Centre; 5042 - Bedford Park - Flinders Medical Centre; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT06117774
NCT06119581	SUNRAY-01	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2023-11-01	2023-12-21	2029-10	Carboplatin; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Olomorasib; Olomorasib + Pembrolizumab; Pembrolizumab; Pemetrexed; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; antimetabolite	Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	18612	SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	2250 - Gosford - Gosford Hospital; 3065 - Melbourne - St Vincent's Hospital; 3350 - Ballarat Central - Ballarat Health Services; 3630 - Shepparton - Goulburn Valley Health; 4066 - Auchenflower - Icon Cancer Centre Wesley; 4215 - Southport - Gold Coast University Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 4740 - Mackay - Mackay Base Hospital; 4814 - Townsville - The Townsville Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6009 - Perth - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06119581
NCT06120075	ARC-27	Phase 1	RECRUITING		Help: Date registered 2023-11-07	2024-01-19		AB-801; AB-801 + Docetaxel; Docetaxel	AXL_inhibitor + taxane; AXL_inhibitor; taxane	AB-801; AB-801 + Docetaxel	AXL_inhibitor; AXL_inhibitor + taxane	ARC-27	A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Advanced Cancer		https://clinicaltrials.gov/ct2/show/NCT06120075
NCT06120283	BGB-43395-101	Phase 1	RECRUITING	NSW, NZ, QLD, SA, VIC	2023-11-01	2023-12-01	2028-06	BGB-43395; BGB-43395 + Elacestrant + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant + Letrozole; Elacestrant; Fulvestrant; Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; aromatase_inhibitor; selective_estrogen_receptor_degrader	BGB-43395 + Elacestrant + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant + Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	BGB-43395-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer	1023 - Auckland - Harbour Cancer and Wellness; 8011 - Christchurch - Nzcr Christchurch; NSW 2109 - North Ryde - Macquarie University; NSW 2139 - Concord - Concord Repatriation General Hospital; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; NSW 2576 - Bowral - Southern Highlands Private Hospital; QLD 4814 - Douglas - Townsville University Hospital; SA 5000 - Adelaide - Genesiscare St Andrews; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06120283
NCT06120491	EvoPAR-PR01	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2023-11-06	2023-11-21	2031-04-30	Abiraterone; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Darolutamide; Enzalutamide; Placebo; Saruparib	antiandrogen,nonsteroidal,second_generation; PARP1-selective_inhibitor; placebo; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Placebo	CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	D9723C00001	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Metastatic Castration-Sensitive Prostate Cancer	2010 - Darlinghurst - Research Site - (TERMINATED); 2031 - Randwick - Research Site - (WITHDRAWN); 3000 - Melbourne - Research Site; 4032 - Chermside - Research Site; 4101 - South Brisbane - Research Site; 4812 - Hyde Park - Research Site; 5037 - Kurralta Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT06120491
NCT06127407	CHONQUER	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2023-11-07	2024-07-09	2030-11-26	Ivosidenib; Placebo	placebo; IDH1_R132_inhibitor	Ivosidenib; Placebo	IDH1_R132_inhibitor; placebo	CL3-95031-007	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen	Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen	2050 - Camperdown - Chris O'Brien Lifehouse; 3065 - Fitzroy - St Vincent'S Hospital Melbourne; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06127407
NCT06130553	PRIMROSE	Phase 1 / Phase 2	RECRUITING	VIC	2023-11-08	2024-01-18	2026-05-27	AZD3470	PRMT5_inhibitor	AZD3470	PRMT5_inhibitor	D9970C00001	PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumors That Are MTAP Deficient	Advanced Solid Tumors That Are MTAP Deficient	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06130553
NCT06131398	NCT06131398	Phase 1	RECRUITING	NSW, SA	2023-11-09	2024-03-07	2028-12-22	AMG-355; AMG-355 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody	AMG-355; AMG-355 + Pembrolizumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody	20220028	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - St Vincents Hospital Sydney; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT06131398
NCT06132958	TroFuse-005	Phase 3	RECRUITING	NSW, QLD, VIC	2023-11-10	2023-12-06	2028-01-10	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin; Doxorubicin + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Sacituzumab tirumotecan	anthracycline + taxane; glucocorticoid; taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin; anti-Trop2_antibody-drug_conjugate	Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Nab-paclitaxel + Paclitaxel	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin	2870-005	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Endometrial Cancer	2065 - St Leonards - GenesisCare North Shore ( Site 1103); 2148 - Sydney - Blacktown Hospital ( Site 1101); 3002 - East Melbourne - Epworth Freemasons ( Site 1104); 3199 - Frankston - Frankston Hospital ( Site 1105); 4029 - Brisbane - Royal Brisbane and Women's Hospital ( Site 1102)	https://clinicaltrials.gov/ct2/show/NCT06132958
NCT06136624	OMAHA-003	Phase 3	RECRUITING	NSW, NZ, QLD, VIC	2023-11-13	2023-12-31	2028-08-02	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Dexamethasone + Opevesostat; Enzalutamide; Opevesostat; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; glucocorticoid; CYP17A1_inhibitor; CYP11A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Dexamethasone + Opevesostat	CYP11A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	5684-003	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)	Prostate Cancer Metastatic	2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0234); 2145 - Westmead - Westmead Hospital ( Site 0232); 2830 - Dubbo - Dubbo Hospital ( Site 0235); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230); 3112 - Tauranga - Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201); 4102 - Brisbane - Princess Alexandra Hospital-Cancer Care Serices ( Site 0237); 9016 - Dunedin - Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203)	https://clinicaltrials.gov/ct2/show/NCT06136624
NCT06151574	1479-0008	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2023-11-22	2022-08-04	2028-01-28	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Zongertinib	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite; ERBB2_inhibitor,second_generation	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Zongertinib	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	1479-0008	Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations	Lung Cancer, Non-squamous, Non-small Cell	2031 - Randwick - Prince of Wales Hospital-Randwick-66496; 2065 - St Leonards - Royal North Shore Hospital-St Leonards-20807; 3084 - Heidelberg - Austin Health; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06151574
NCT06157541	TCaP	Phase 1 / Phase 2	RECRUITING	QLD, VIC	2023-11-26	2024-02-08	2028-01	Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody; alkylating_agent	Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; alkylating_agent	P3894 / MSD-MK3475-E78	Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme	Glioblastoma Multiforme; Astrocytoma, Grade IV	3084 - Heidelberg - Austin Hospital; 4006 - Bowen Hills - Newro Foundation; 4006 - Herston - Royal Brisbane and Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT06157541
NCT06157892	SGNDV-004	Phase 2	RECRUITING	VIC	2023-11-27	2024-05-20	2029-07-28	Disitamab vedotin; Disitamab vedotin + Tucatinib; Tucatinib	anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	SGNDV-004	A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors	Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Metastatic Breast Cancer; Metastatic Gastric Cancer; Advanced Breast Cancer; Advanced Gastric Cancer	3149 - Mount Waverley - Slade Health; 3199 - Frankston - Peninsula & South Eastern Hematology and Oncology Group (PASO); 3199 - Frankston - Slade Pharmacy Frankston; Frankston - Peninsula & South Eastern Hematology and Oncology Group (PASO)	https://clinicaltrials.gov/ct2/show/NCT06157892
NCT06161025	DS6000-109	Phase 2 / Phase 3	RECRUITING	NSW, SA	2023-12-06	2024-02-27	2029-12-31	Gemcitabine; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Paclitaxel; Pegylated liposomal doxorubicin; Raludotatug deruxtecan; Topotecan	anti-CDH6_antibody-drug_conjugate; topoisomerase_inhibitor; gemcitabine; taxane; anthracycline; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Raludotatug deruxtecan	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; anti-CDH6_antibody-drug_conjugate; gemcitabine	DS6000-109	A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Solid Cancer	5000 - Adelaide - GenesisCare St Andrews Hospital; St Leonards - GenesisCare North Shore (Oncology)	https://clinicaltrials.gov/ct2/show/NCT06161025
NCT06161441	R3767-ONC-2266	Phase 2	RECRUITING	VIC, WA	2023-11-29	2024-07-16	2029-04-19	Carboplatin; Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed; Cemiplimab; Cisplatin; Fianlimab; Paclitaxel; Pemetrexed	anti-LAG3_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cemiplimab + Cisplatin + Fianlimab + Paclitaxel + Pemetrexed; Carboplatin + Cemiplimab + Cisplatin + Paclitaxel + Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	R3767-ONC-2266	A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC	Resectable Non-small Cell Lung Cancer	3065 - Fitzroy - St Vincent's Hospital; 3128 - Box Hill - Eastern Health; 6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT06161441
NCT06162572	SPLFIO-174	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC	2023-12-07	2024-08-07	2027-07	Cemiplimab; Cemiplimab + S095018; Cemiplimab + S095024; Cemiplimab + S095029; S095018; S095024; S095029	anti-TIM3_monoclona_antibody; anti-NKG2A_monoclona_antibody; anti-PD-1_monoclonal_antibody; anti-CD73_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclona_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclona_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + S095018; Cemiplimab + S095024; Cemiplimab + S095029	anti-CD73_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-NKG2A_monoclona_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclona_antibody	SPLFIO-174	A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression	Non-small Cell Lung Cancer (NSCLC)	2640 - Albury - Border Medical Oncology Research Unit; 3021 - St Albans - Sunshine Hospital; 3844 - Traralgon - Latrobe Regional Health; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06162572
NCT06170190	CIBI133A101	Phase 1 / Phase 2	RECRUITING	NSW	2023-12-06	2024-01-16	2026-12-30	IBI133	anti-ERBB3_monoclonal_antibody	IBI133	anti-ERBB3_monoclonal_antibody	CIBI133A101	A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours	Locally Advanced Unresectable or Metastatic Solid Tumors	2170 - Liverpool - Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT06170190
NCT06170788	TroFuse-007	Phase 3	RECRUITING	NSW, VIC	2023-12-06	2023-12-15	2030-05-27	Dexamethasone; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; glucocorticoid	Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	2870-007	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead - Westmead Hospital ( Site 3000); 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002); 3076 - Epping - Northern Hospital ( Site 3003); 3350 - Ballarat Central - Grampians Health-Medical Oncology ( Site 3001) - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT06170788
NCT06172478	U31402-277	Phase 2	RECRUITING	NSW, QLD, TAS, VIC	2023-12-07	2024-02-26	2028-10-10	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	U31402-277	HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer; Ovarian Carcinoma; Cervical Cancer; Endometrial Cancer; Bladder Cancer; Esophageal Cancer; Pancreatic Carcinoma; Prostate Cancer; Non-small Cell Lung Cancer (NSCLC); Lung Cancer; Breast Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 3168 - Clayton - Monash Medical Centre Clayton; 4032 - Chermside - Icon Cancer Centre Chermside; 4812 - Hyde Park - Icon Cancer Centre Townsville; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT06172478
NCT06174987	ROMast-001	Phase 3	RECRUITING	SA, VIC	2023-12-08	2024-01-05	2026-08-03	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	ROMast-001	A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Advanced Cancer; Metastatic Cancer	3168 - Melbourne - Monash Medical Center - (WITHDRAWN); 5042 - Bedford Park - Flinders Medical Center	https://clinicaltrials.gov/ct2/show/NCT06174987
NCT06179160	INCB161734-101	Phase 1	RECRUITING	NSW, VIC, WA	2023-12-20	2024-01-04	2027-01-01	Cetuximab; Cetuximab + INCB161734 + Retifanlimab; INCB161734; Retifanlimab	KRAS_G12D_inhibitor; anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cetuximab + INCB161734 + Retifanlimab; INCB161734	KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	INCB161734-101	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Solid Tumors	02010 - Darlinghurst - St Vincent'S Hospital Sydney; 02050 - Camperdown - Chris Obrien Lifehouse; 03004 - Melbourne - The Alfred Hospital; 06009 - Nedlands - Linear Clinical Research; 3051 - North Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06179160
NCT06179511	D9470C00001	Phase 1 / Phase 2	RECRUITING	VIC	2023-12-19	2024-01-31	2027-01-07	AZD9829	anti-CD123_antibody-drug_conjugate	AZD9829	anti-CD123_antibody-drug_conjugate	D9470C00001	A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies	Hematological Malignancies	3084 - Heidelberg - Research Site; VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06179511
NCT06184035	Tumorad	Phase 1 / Phase 2	RECRUITING	SA, VIC	2023-12-14	2023-11-30	2027-12-31	177Lu-SN201	nanoparticle_radiopharmaceutics	177Lu-SN201	nanoparticle_radiopharmaceutics	Tumorad-01	A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors	Solid Tumor; Metastatic Cancer; Unresectable Solid Tumor; Recurrent Solid Tumor; Locally Advanced Solid Tumor; Refractory Cancer	3065 - Melbourne - St Vincent Hospital Melbourne; 5000 - Adelaide - Cancer Research South Adelaide	https://clinicaltrials.gov/ct2/show/NCT06184035
NCT06188208	VVD-130850-01	Phase 1	RECRUITING	NSW, QLD, TAS, VIC	2023-12-31	2024-01-05	2027-12	Pembrolizumab; Pembrolizumab + VVD-130850; VVD-130850	anti-PD-1_monoclonal_antibody; STAT3_inhibitor; STAT3_inhibitor + anti-PD-1_monoclonal_antibody	Pembrolizumab + VVD-130850; VVD-130850	STAT3_inhibitor; STAT3_inhibitor + anti-PD-1_monoclonal_antibody	VVD-130850-01	A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors	Advanced Solid Tumors; Advanced Hematologic Tumors	Adelaide - Cancer Research South Australia; Blacktown - Blacktown Hospital; Orange - Orange Health Service; South Brisbane - ICON Cancer Research; Southport - Gold Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT06188208
NCT06188520	CYCAD-1	Phase 1 / Phase 2	RECRUITING	VIC	2023-12-18	2023-12-05	2026-06-17	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; Abemaciclib; Camizestrant; Palbociclib; Ribociclib	CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D8470C00001	A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06188520
NCT06188702	CL1-95035-001	Phase 1 / Phase 2	RECRUITING	NSW, QLD, TAS, VIC	2024-01-02	2024-04-29	2031-10-31	S095035	MAT2A_inhibitor	S095035	MAT2A_inhibitor	CL1-95035-001	A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	MTAP-deleted Solid Tumors	2031 - Randwick - Scientia Clinical Research; 3004 - Prahran - The Alfred; 4812 - Douglas - Townsville University Hospital; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT06188702
NCT06198426	CIBI3004A101	Phase 1 / Phase 2	RECRUITING	NSW	2024-01-08	2024-08-19	2026-05-01	IBI3004	unknown_drug_class	IBI3004	unknown_drug_class	CIBI3004A101	A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2170 - Sydney - Liverpool Hospital - (TERMINATED); 2170 - Sydney - Westmead Hospital - (TERMINATED); 2770 - Randwick - Scientia Clinical Research Ltd - (TERMINATED)	https://clinicaltrials.gov/ct2/show/NCT06198426
NCT06199908	AMT-562-01	Phase 1	RECRUITING	NSW, SA, VIC	2024-01-08	2024-05-20	2025-12-31	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562-01	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Malvern - Cabrini Malvern Hospital; North Ryde - Macquarie University Hospital	https://clinicaltrials.gov/ct2/show/NCT06199908
NCT06203210	IDeate-Lung02	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-01-02	2024-05-21	2029-02-22	Amrubicin; Amrubicin + Lurbinectedin + Topotecan; Ifinatamab Deruxtecan; Lurbinectedin; Topotecan	anti-B7H3_antibody-drug_conjugate; topoisomerase_inhibitor; anthracycline; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; DNA_minor_groove-binding_agent	Amrubicin + Lurbinectedin + Topotecan; Ifinatamab Deruxtecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; anti-B7H3_antibody-drug_conjugate	DS7300-188	A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)	Small Cell Lung Cancer	2050 - Camperdown - Chris O Brien Lifehouse; 3021 - St Albans - Sunshine Hospital; 3350 - Ballarat - Ballarat Base Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4814 - Townsville - Townsville Cancer Centre; 5042 - Bedford Park - Flinders Medical Centre (Fmc); 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06203210
NCT06208657	OPTIMISE	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA, Washington	2024-01-05	2024-07-10	2035-12	Irinotecan; Irinotecan + Paxalisib + Temozolomide; Paxalisib; Temozolomide	alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; topoisomerase_inhibitor; dual_PI3K/mTOR_inhibitor; alkylating_agent	Irinotecan + Paxalisib + Temozolomide	alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor	OPTIMISE	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Recurrent Cancer; Refractory Cancer	Adelaide - Women's and Children's Hospital; Brisbane - Queensland Children's Hospital; Melbourne - Monash Children's Hospital; Melbourne - Royal Children's Hospital; Newcastle - John Hunter Children's Hospital; Perth - Perth Children's Hospital; Sydney - Sydney Children's Hospital, Randwick; Sydney - The Children's Hospital at Westmead	https://clinicaltrials.gov/ct2/show/NCT06208657
NCT06211036	DeLLphi-305	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-01-08	2024-06-05	2028-10-14	Durvalumab; Durvalumab + Tarlatamab; Etoposide; Tarlatamab	bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Tarlatamab; Etoposide	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; topoisomerase_inhibitor	20200041	A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)	Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 2500 - Wollongong - Wollongong Hospital; 3168 - Clayton - Monash Medical Centre; 4120 - Greenslopes - Greenslopes Private Hospital; 5000 - Adelaide - Cancer Research South Australia; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06211036
NCT06219941	D9800C00001	Phase 2	RECRUITING	NSW, VIC, WA	2024-01-12	2023-12-13	2026-12-31	AZD0901; AZD0901 + Fluorouracil + Gemcitabine + Irinotecan + Leucovorin + Liposomal Irinotecan; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	anti-CLDN18.2_antibody-drug_conjugate + antimetabolite + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; topoisomerase_inhibitor; folinic_acid; gemcitabine; anti-CLDN18.2_antibody-drug_conjugate	AZD0901; AZD0901 + Fluorouracil + Gemcitabine + Irinotecan + Leucovorin + Liposomal Irinotecan	anti-CLDN18.2_antibody-drug_conjugate; anti-CLDN18.2_antibody-drug_conjugate + antimetabolite + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; gemcitabine	D9800C00001	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)	Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma	2031 - Randwick - Research Site; 3000 - Melbourne - Research Site; WA6150 - Murdoch - Research Site	https://clinicaltrials.gov/ct2/show/NCT06219941
NCT06220864	SNV1521-101	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-01-23	2024-02-23	2026-12	SNV1521; SNV1521 + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate; PARP1-selective_inhibitor	SNV1521; SNV1521 + Trastuzumab Deruxtecan	PARP1-selective_inhibitor; PARP1-selective_inhibitor + anti-ERBB2_antibody-drug_conjugate	SNV1521-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research; 3004 - Melbourne - The Alfred Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 6009 - Crawley - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06220864
NCT06225596	BT8009-230	Phase 2 / Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-01-24	2024-01-24	2030-12	Avelumab; Avelumab + Carboplatin + Cisplatin + Gemcitabine; BT8009; BT8009 + Pembrolizumab; Carboplatin; Cisplatin; Gemcitabine; Pembrolizumab	anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody	Avelumab + Carboplatin + Cisplatin + Gemcitabine; BT8009; BT8009 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bicycle_toxin_conjugate,NECTIN4-targeting; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; bicycle_toxin_conjugate,NECTIN4-targeting; gemcitabine	BT8009-230	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Metastatic Urothelial Cancer	2031 - Randwick - Prince of Wales Hospital; 2148 - New South Wales - Blacktown Hospital; 2310 - Hunter - Calvary Mater Newcastle; 3220 - Geelong - Barwon Health; 4066 - South Brisbane - Icon Cancer Centre; 4101 - Brisbane - Mater Misericordiae Ltd, South Brisbane; 4102 - Woolloongabba - Princess Alexandra Hospital; 4215 - Southport - Gold Coast University Hospital; 4814 - Douglas - Townsville Hospital and Health Service; 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06225596
NCT06233942	BG-C9074-101	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-01-23	2024-04-12	2028-05-15	BG-C9074; BG-C9074 + Tislelizumab; Tislelizumab	anti-B7H4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7H4_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	BG-C9074; BG-C9074 + Tislelizumab	anti-B7H4_antibody-drug_conjugate; anti-B7H4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	BG-C9074-101	Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	NSW 2109 - North Ryde - Macquarie University; NSW 2500 - Wollongong - Cancer Care Wollongong; QLD 4102 - Woolloongabba - Princess Alexandra Hospital; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3168 - Clayton - Monash Health; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06233942
NCT06236438	LIVIGNO-4	Phase 2 / Phase 3	RECRUITING	ACT, NSW	2024-01-24	2024-04-10	2031-10	Budigalimab; Budigalimab + Carboplatin + Cisplatin + Livmoniplimab + Pemetrexed; Budigalimab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Livmoniplimab; Pembrolizumab; Pemetrexed	anti-GARP_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite	Budigalimab + Carboplatin + Cisplatin + Livmoniplimab + Pemetrexed; Budigalimab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	M23-721	A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital /ID# 261894; 2605 - Garran - Canberra Hospital /ID# 261891; 2747 - Kingswood - Nepean Hospital /ID# 262157	https://clinicaltrials.gov/ct2/show/NCT06236438
NCT06238479	EXCEED	Phase 1	RECRUITING	SA, VIC	2024-01-26	2024-03-05	2027-03	LY4101174	anti-NECTIN4_antibody-drug_conjugate	LY4101174	anti-NECTIN4_antibody-drug_conjugate	18836	A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer	3084 - Heidelberg - Austin Health; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06238479
NCT06242470	CP-MGC026-01	Phase 1	RECRUITING	QLD, SA, VIC	2024-02-01	2024-03-06	2028-10	MGC026	anti-B7H3_antibody-drug_conjugate	MGC026	anti-B7H3_antibody-drug_conjugate	CP-MGC026-01	A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors	Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC)	3084 - Heidelberg - Austin Health- Olivia Newton John Cancer Center; 4066 - Auchenflower - ICON Cancer Centre Wesley; 5037 - Kurralta Park - ICON Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06242470
NCT06244771	PROSPER	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2024-01-29	2024-02-12	2028-04	FMC-376	KRAS_G12C_inhibitor	FMC-376	KRAS_G12C_inhibitor	FMC-376-CL101	An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors	Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer	2109 - Macquarie Park - Macquarie University; 3128 - Box Hill - Eastern Health - Box Hill Hospital; 4215 - Southport - Tasman Health Care; 5006 - North Adelaide - GenesisCare North Adelaide; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06244771
NCT06247995	NeoB-Cap1	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2024-02-07	2024-08-14	2031-09-09	177Lu-NeoB; 177Lu-NeoB + Capecitabine; Capecitabine	fluoropyrimidine + radioligand,GRPR-targeting; radioligand,GRPR-targeting; fluoropyrimidine	177Lu-NeoB + Capecitabine	fluoropyrimidine + radioligand,GRPR-targeting	CAAA603D12101	A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.	Breast Cancer	2010 - Darlinghurst - Novartis Investigative Site; 3144 - Malvern - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT06247995
NCT06252649	CodeBreaK-301	Phase 3	RECRUITING	NSW, QLD, SA, VIC	2024-02-08	2024-07-17	2031-08-31	Bevacizumab; Panitumumab; Panitumumab + Sotorasib; Sotorasib	anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor	Bevacizumab; Panitumumab + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody	20210081	Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)	Metastatic Colorectal Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3084 - Heidelberg - Austin Health, Austin Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4350 - Toowoomba - Toowoomba Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06252649
NCT06253130	IMP1734-101	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2024-02-02	2023-12-11	2026-12-01	IMP1734	PARP1-selective_inhibitor	IMP1734	PARP1-selective_inhibitor	EIK1003-001 (IMP1734-101)	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 2109 - Sydney - Macquarie University; 3199 - Frankston - Peninsula and south eastern haematology and oncology group; 4101 - South Brisbane - Mater Cancer Care Centre, Mater Misericordiae Limited; 4102 - Woolloongabba - Princess Alexandra Hospital; 4125 - Southport - Gold Coast Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06253130
NCT06256588	JADE	Phase 3	RECRUITING	NSW, QLD, VIC	2024-02-05	2024-03-21	2029-07-13	Dostarlimab; Placebo	placebo; anti-PD-1_monoclonal_antibody	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	221530	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	2148 - Blacktown - GSK Investigational Site; 3004 - Melbourne - GSK Investigational Site; 3220 - Geelong - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 4029 - Herston - GSK Investigational Site; 4814 - Douglas - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06256588
NCT06257264	BG-68501-101	Phase 1	RECRUITING	NSW, NZ, QLD, SA, VIC	2024-02-05	2024-03-11	2028-02-28	BG-68501; BG-68501 + BGB-43395 + Fulvestrant; BG-68501 + Fulvestrant; BGB-43395; Fulvestrant	CDK4_selective_inhibitor; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor; selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader	BG-68501; BG-68501 + BGB-43395 + Fulvestrant; BG-68501 + Fulvestrant	CDK2_inhibitor; CDK2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	BG-68501-101	A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer	1023 - Auckland - Auckland City Hospital; NSW 2010 - Darlinghurst - Saint Vincents Hospital Sydney; NSW 2065 - St Leonards - Genesiscare North Shore; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; NSW 2747 - Kingswood - Nepean Hospital; QLD 4102 - Woolloongabba - Princess Alexandra Hospital; SA 5000 - Adelaide - Cancer Research South Australia; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3168 - Clayton - Monash Health	https://clinicaltrials.gov/ct2/show/NCT06257264
NCT06267729	APOLLO	Phase 1 / Phase 2	RECRUITING	VIC	2024-02-19	2024-03-12	2027-06-30	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	D9660C00001	A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO	Metastatic Prostate Cancer	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06267729
NCT06295731	HexAgon-HN	Phase 2 / Phase 3	RECRUITING	SA	2024-02-28	2024-05-14	2029-05	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	INBRX106-01-201	A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)	Head and Neck Squamous Cell Carcinoma (HNSCC)	5000 - Adelaide - Royal Adelaide Hospital	https://clinicaltrials.gov/ct2/show/NCT06295731
NCT06302426	INI-4001-101	Phase 1	NOT_YET_RECRUITING	NSW, VIC	2024-03-04	2024-03-29	2026-04-30	Atezolizumab; Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab; Avelumab; Cemiplimab; Durvalumab; INI-4001; Nivolumab; Pembrolizumab	TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; TLR7/TLR8_agonist; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Avelumab + Cemiplimab + Durvalumab + INI-4001 + Nivolumab + Pembrolizumab	TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	INI-4001-101	An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours	Advanced Solid Tumor	2640 - Albury - The Border Cancer Hospital; 3144 - Malvern - Cabrini Hospital	https://clinicaltrials.gov/ct2/show/NCT06302426
NCT06305962	177Lu-RAD204.2023.0001	Phase 1	RECRUITING	NSW, QLD, SA, WA	2024-03-07	2024-06-03	2025-10	177Lu-RAD204	radioconjugate,PD-L1-targeting	177Lu-RAD204	radioconjugate,PD-L1-targeting	177Lu-RAD204.2023.0001	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours	PDL1 Gene Mutation; Non Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); TNBC, Triple Negative Breast Cancer; Cutaneous Melanoma; HNSCC; Endometrial Cancer	2500 - Wollongong - Wollongong Hospital; 2747 - Kingswood - Nepean Hospital; 4215 - Southport - Gold Coast University Hospital; 4509 - North Lakes - Icon Cancer Centre North Lakes; 5000 - Adelaide - Cancer Research SA (CRSA); 6150 - Murdoch - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT06305962
NCT06312176	2870-010	Phase 3	RECRUITING	NSW, NZ, VIC, WA	2024-03-07	2024-04-14	2031-04-12	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Nab-paclitaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anthracycline + fluoropyrimidine + taxane; anthracycline; fluoropyrimidine	Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anthracycline + fluoropyrimidine + taxane; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	2870-010	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer	Breast Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 2031); 2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 2002); 2145 - Westmead - Westmead Hospital ( Site 2000); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 2003) - (COMPLETED); 6150 - Murdoch - Fiona Stanley Hospital-Medical Oncology ( Site 2004)	https://clinicaltrials.gov/ct2/show/NCT06312176
NCT06318273	M24-742	Phase 1	RECRUITING	NSW, VIC	2024-03-13	2024-03-08	2027-05	ABBV-969	anti-PSMA∕STEAP1_antibody-drug_conjugate	ABBV-969	anti-PSMA∕STEAP1_antibody-drug_conjugate	M24-742	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	2050 - Camperdown - Chris O'Brien Lifehouse /ID# 261731; 3065 - Fitzroy - St Vincent's Hospital /ID# 264293; 3350 - Ballarat - Ballarat Base Hospital /ID# 264294	https://clinicaltrials.gov/ct2/show/NCT06318273
NCT06325748	SENTI-202-101	Phase 1	RECRUITING	NSW, VIC	2024-03-19	2024-04-22	2040-08	SENTI-202	allogeneic_CAR-NK-cell_therapy,CD33/FLT3-targeting	SENTI-202	allogeneic_CAR-NK-cell_therapy,CD33/FLT3-targeting	SENTI-202-101	SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies	AML/MDS; CD33 Expressing Hematological Malignancies; FLT3 Expressing Hematological Malignancies	2050 - Camperdown - Royal Prince Alfred Hospital; 3000 - Melbourne - Peter MacCallum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06325748
NCT06326411	NST-628	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2024-03-21	2024-04-09	2029-11	NST-628	pan-RAF/MEK_glue	NST-628	pan-RAF/MEK_glue	NST-628-001	A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation	120 - Greenslopes - Gallipoli Medical Research Centre- Greenslopes Private Hospital; 2010 - Darlinghurst - The Kinghorn Cancer Center, St. Vincent's Health Network; 2031 - Randwick - Scientia Clinical Research, Ltd; 3144 - Malvern - Cabrini Health Limited; 3144 - Malvern - Cabrini Hospital; 5042 - Adelaide - Southern Oncology Research Unit	https://clinicaltrials.gov/ct2/show/NCT06326411
NCT06330064	DS7300-203	Phase 2	RECRUITING	NSW, QLD, WA	2024-03-19	2024-04-10	2028-07-25	Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate	Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate	DS7300-203	A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Recurrent or Metastatic Solid Tumors	2065 - St Leonards - Genesiscare North Shore Oncology; 2080 - Mount Kuring-Gai - St Vincent'S Hospital Sydney; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06330064
NCT06333951	NCT06333951	Phase 1	RECRUITING	NSW, SA	2024-03-21	2024-09-17	2031-10-27	AMG 193; AMG 193 + Carboplatin + Paclitaxel + Pembrolizumab; AMG 193 + Carboplatin + Pembrolizumab + Pemetrexed; AMG 193 + Pembrolizumab; AMG 193 + Sotorasib; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor + PRMT5_inhibitor; taxane; platinum-based_antineoplastic_agent; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; PRMT5_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + PRMT5_inhibitor; antimetabolite; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	AMG 193; AMG 193 + Carboplatin + Paclitaxel + Pembrolizumab; AMG 193 + Carboplatin + Pembrolizumab + Pemetrexed; AMG 193 + Pembrolizumab; AMG 193 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + PRMT5_inhibitor; KRAS_G12C_inhibitor + PRMT5_inhibitor; PRMT5_inhibitor; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; PRMT5_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	20230167	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)	Thoracic Tumors; Non-small Cell Lung Cancer	2800 - Orange - Orange Health Service; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT06333951
NCT06336148	ACTM-838-01	Phase 1	RECRUITING	NSW, SA, VIC	2024-03-22	2024-06-05	2026-07	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838-01	A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors	Solid Tumor	2145 - Westmead - Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200 - (COMPLETED); 3004 - Melbourne - Alfred Hospital, 55 Commercial Road, Site No: 201 - (COMPLETED); 5042 - Bedford Park - Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202 - (COMPLETED)	https://clinicaltrials.gov/ct2/show/NCT06336148
NCT06340568	Fern-EC-01	Phase 3	RECRUITING	NSW, VIC	2024-03-25	2025-06-10	2029-11	DB-1303; Doxorubicin; Doxorubicin + Paclitaxel; Paclitaxel	doxorubicin; anti-ERBB2_antibody-drug_conjugate; anthracycline + taxane; taxane	DB-1303; Doxorubicin + Paclitaxel	anthracycline + taxane; anti-ERBB2_antibody-drug_conjugate; doxorubicin	BNT323-01	A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer	Endometrial Cancer	2250 - Gosford - Gosford Hospital; 2500 - Wollongong - Wollongong Hospital; 3021 - Saint Albans - Sunshine Hospital	https://clinicaltrials.gov/ct2/show/NCT06340568
NCT06343402	TBBO8520-101	Phase 1	RECRUITING	NSW, SA, VIC	2024-04-01	2024-05-22	2028-02	BBO-8520; BBO-8520 + Pembrolizumab; Pembrolizumab; Tegafur-gimeracil-oteracil potassium	DPD_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	BBO-8520; BBO-8520 + Pembrolizumab; Tegafur-gimeracil-oteracil potassium	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	TBBO8520-101	A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study	Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma	2010 - Darlinghurst - Kinghorn Cancer Centre; 3051 - Melbourne - Peter MacCallum Cancer Centre; 3199 - Frankston - Peninsula & South Eastern Hematology and Oncology Group (PAS); 5011 - Woodville South - The Queen Elizabeth Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06343402
NCT06345079	STOPNET	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2024-04-01	2024-10-14	2028-06	Octreotide	somatostatin_analog	Octreotide	somatostatin_analog	AG0219NET	A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)	Neuroendocrine Tumors	2065 - Sydney - Royal North Shore Hospital; 2502 - Wollongong - Wollongong Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4006 - Brisbane - Royal Brisbane and Womens Hospital; 5000 - Adelaide - The Queen Elizabeth Hospital; 6150 - Perth - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT06345079
NCT06345729	1084-004	Phase 3	RECRUITING	NSW, NZ, VIC, WA	2024-03-28	2024-05-24	2031-02-18	MK-1084; MK-1084 + Pembrolizumab; Pembrolizumab; Placebo	placebo; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	MK-1084 + Pembrolizumab; Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	1084-004	A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)	Non-small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital ( Site 3400); 2050 - Camperdown - Chris O'Brien Lifehouse ( Site 3000); 3199 - Frankston - Frankston Hospital ( Site 3002); 6009 - Nedlands - One Clinical Research ( Site 3001)	https://clinicaltrials.gov/ct2/show/NCT06345729
NCT06346067	ERAS-254-02	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2024-03-28	2024-04-29	2028-12	Dacarbazine; Dacarbazine + Temozolomide + Trametinib; Naporafenib; Naporafenib + Trametinib; Temozolomide; Trametinib	MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + alkylating_agent; RAF_dimer_inhibitor; alkylating_agent	Dacarbazine + Temozolomide + Trametinib; Naporafenib + Trametinib; Trametinib	MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + alkylating_agent	ERAS-254-02	A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]	Advanced or Metastatic NRAS-mutant Melanoma	2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Institute; 3004 - Melbourne - Alfred Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4215 - Southport - Tasman Health Care; 6009 - Nedlands - Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT06346067
NCT06349408	CIBI3001A101	Phase 1	RECRUITING	NSW, SA	2024-04-01	2025-01-10	2027-12-31	IBI3001	bispecific_EGFR/B7H3_antibody-drug_conjugate	IBI3001	bispecific_EGFR/B7H3_antibody-drug_conjugate	CIBI3001A101	A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumor	2500 - Wollongong - Wollongong Public; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT06349408
NCT06350097	TROPION-Lung14	Phase 3	RECRUITING	NSW, QLD, VIC	2024-04-02	2024-04-29	2032-05-25	Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib	EGFR_inhibitor,third_generation; anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Osimertinib; Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate	D516NC00001	A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	2050 - Camperdown - Research Site; 2145 - Westmead - Research Site; 2217 - Kogarah - Research Site; 3168 - Clayton - Research Site; 4101 - South Brisbane - Research Site	https://clinicaltrials.gov/ct2/show/NCT06350097
NCT06351904	RAG-01-01	Phase 1	RECRUITING	NSW, VIC	2024-04-02	2024-04-03	2028-08-31	Bacillus Calmette-Guérin; RAG-01	saRNA_therapy,CDKN1A-targeting; BCG_vaccine	RAG-01; Bacillus Calmette-Guérin	saRNA_therapy,CDKN1A-targeting; BCG_vaccine	RAG-01-01	A Phase Ⅰ, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy	Non-Muscle-Invasive Bladder Cancer (NMIBC)	2065 - St Leonards - GenesisCare North Shore; 3050 - Melbourne - The Royal Melbourne Hospital; 3199 - Melbourne - Peninsula & South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT06351904
NCT06353386	5684-01A	Phase 1 / Phase 2	RECRUITING	NSW, NZ, QLD, VIC	2024-04-03	2024-05-20	2028-03-31	Cabazitaxel; Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat; Docetaxel; Olaparib; Opevesostat; Prednisone	CYP11A1_inhibitor + glucocorticoid + taxane; CYP11A1_inhibitor + glucocorticoid; glucocorticoid; taxane; PARP_inhibitor; CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor	Cabazitaxel + Dexamethasone + Opevesostat + Prednisone; Dexamethasone + Docetaxel + Opevesostat + Prednisone; Dexamethasone + Olaparib + Opevesostat; Dexamethasone + Opevesostat	CYP11A1_inhibitor + PARP_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid; CYP11A1_inhibitor + glucocorticoid + taxane	5684-01A	MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Prostatic Neoplasms, Castration-Resistant	1023 - Auckland - Auckland City Hospital ( Site 1333); 2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0108); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0110); 4120 - Greenslopes - Gallipoli Medical Research Ltd-GMRF CTU ( Site 0107)	https://clinicaltrials.gov/ct2/show/NCT06353386
NCT06357533	TROPION-Lung10	Phase 3	RECRUITING	NSW, QLD, VIC	2024-04-05	2024-04-11	2030-05-24	Datopotamab deruxtecan; Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig	anti-Trop2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody	Datopotamab deruxtecan + Rilvegostomig; Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; bispecific_PD-1/TIGIT_antibody	D7632C00001	A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Non-Small Cell Lung Cancer	2148 - Blacktown - Research Site; 2250 - Gosford - Research Site; 3000 - Melbourne - Research Site; 3168 - Clayton - Research Site; 3690 - Wodonga - Research Site; 4215 - Southport - Research Site - (WITHDRAWN); 4575 - Birtinya - Research Site; QL 4101 - South Brisbane - Research Site	https://clinicaltrials.gov/ct2/show/NCT06357533
NCT06360354	MTAPESTRY-103	Phase 1	RECRUITING	NSW, SA, VIC	2024-04-08	2024-05-29	2029-02-25	AMG 193; AMG 193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; AMG 193 + Gemcitabine + Nab-paclitaxel; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Nab-paclitaxel; Oxaliplatin	Fluorouracil; topoisomerase_inhibitor; folinic_acid; gemcitabine; taxane; platinum-based_antineoplastic_agent; PRMT5_inhibitor; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	AMG 193; AMG 193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; AMG 193 + Gemcitabine + Nab-paclitaxel	PRMT5_inhibitor; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; gemcitabine	20230223	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion	Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers	2050 - Camperdown - Chris OBrien Lifehouse; 2065 - St Leonards - GenesisCare -North Shore Oncology; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Epworth Healthcare; 3084 - Heidelberg - Austin Health, Austin Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT06360354
NCT06365853	IMGN853-0424	Phase 2	RECRUITING	NSW, VIC	2024-04-10	2024-07-29	2027-06	Mirvetuximab Soravtansine; Mirvetuximab Soravtansine + Prednisolone; Prednisolone	anti-FR-alpha_antibody-drug_conjugate; glucocorticoid; anti-FR-alpha_antibody-drug_conjugate + glucocorticoid	Mirvetuximab Soravtansine; Mirvetuximab Soravtansine + Prednisolone	anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + glucocorticoid	IMGN853-0424	A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression	Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive	2148 - Blacktown - Blacktown Hospital /ID# 269305; 2305 - Lambton Heights - Newcastle Private Hosptial /ID# 269306; 3168 - Clayton - Monash Health - Monash Medical Centre /ID# 269304	https://clinicaltrials.gov/ct2/show/NCT06365853
NCT06380751	EvoPAR-BR01	Phase 3	RECRUITING	NSW, VIC	2024-04-18	2024-08-01	2030-10-18	Abemaciclib; Abemaciclib + Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Ribociclib; Abemaciclib + Camizestrant + Palbociclib + Ribociclib; Anastrozole; Camizestrant; Camizestrant + Saruparib; Exemestane; Fulvestrant; Letrozole; Palbociclib; Ribociclib; Saruparib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader; PARP1-selective_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Ribociclib; Abemaciclib + Camizestrant + Palbociclib + Ribociclib; Camizestrant + Saruparib	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; PARP1-selective_inhibitor + selective_estrogen_receptor_degrader	D9722C00001	A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)	Advanced Breast Cancer	2010 - Darlinghurst - Research Site; 2139 - Darlinghurst - Research Site; 3144 - Malvern - Research Site - (WITHDRAWN); VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06380751
NCT06384352	YL211-INT-101-01	Phase 1	RECRUITING	VIC	2024-04-22	2024-05-01	2029-04-07	YL211	anti-cMET_antibody-drug_conjugate	YL211	anti-cMET_antibody-drug_conjugate	YL211-INT-101-01	A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Melbourne - Monash Health	https://clinicaltrials.gov/ct2/show/NCT06384352
NCT06388733	IVY-P3-24-021	Phase 3	RECRUITING	VIC	2024-04-24	2024-06-19	2028-03	Niraparib; Temozolomide	PARP_inhibitor; alkylating_agent	Niraparib; Temozolomide	PARP_inhibitor; alkylating_agent	IVY P3-24-021	A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma	Glioblastoma; GBM; Brain Neoplasms, Adult, Malignant; Brain Tumor	3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St Vincent's Hospital Melbourne	https://clinicaltrials.gov/ct2/show/NCT06388733
NCT06400472	NCT06400472	Phase 1	RECRUITING	QLD, SA	2024-05-01	2024-05-20	2027-04	Bevacizumab; Bevacizumab + LY4170156; Carboplatin; Carboplatin + LY4170156; LY4170156	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody	Bevacizumab + LY4170156; Carboplatin + LY4170156; LY4170156	anti-FR-alpha_antibody-drug_conjugate; anti-FR-alpha_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-FR-alpha_antibody-drug_conjugate + platinum-based_antineoplastic_agent	18863	A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors	Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms	4101 - QLD - Icon Cancer Centre South Brisbane; 5000 - Adelaide, SA - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT06400472
NCT06400485	AMT-676-01	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-05-01	2024-06-18	2026-02-14	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676-01	First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Greenslopes - Gallipoli Medical Research Foundation; Macquarie - Macquarie University Hospital; Melbourne - Cabrini Hospital; Nedlands - Linear Research; Randwick - SCIENTIA Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06400485
NCT06417814	TROPION-Lung15	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-05-13	2024-10-04	2028-05-29	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib; Pemetrexed	antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; anti-Trop2_antibody-drug_conjugate; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib	EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent	D516KC00001	A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)	Metastatic Non-small Cell Lung Cancer	2065 - St Leonards - Research Site; 2145 - Westmead - Research Site; 2170 - Liverpool - Research Site; 2217 - Kogarah - Research Site; 2444 - Port Macquarie - Research Site; 3084 - Heidelberg - Research Site; 4102 - Woolloongabba - Research Site; 5011 - Woodville - Research Site; 6009 - Nedlands - Research Site; VIC3065 - Fitzroy - Research Site	https://clinicaltrials.gov/ct2/show/NCT06417814
NCT06418061	CIBI3005A101	Phase 1	RECRUITING		2024-05-16	2025-01-08		IBI3005	unknown_drug_class,bispecific_antibody	IBI3005	unknown_drug_class,bispecific_antibody	CIBI3005A101	A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI3005 in Subjects With Advanced Malignant Solid Tumors	Unresectable; Locally Advanced or Metastatic Solid Tumors		https://clinicaltrials.gov/ct2/show/NCT06418061
NCT06421935	MS202659-0001	Phase 1	RECRUITING	NSW, VIC	2024-05-14	2024-08-07	2027-02-22	Abiraterone; Abiraterone + HRS-1167 + Prednisolone + Prednisone; HRS-1167; HRS-1167 + Tuvusertib; Prednisolone; Prednisone; Tuvusertib	ATR_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor + glucocorticoid; glucocorticoid; PARP1-selective_inhibitor; CYP17A1_inhibitor; ATR_inhibitor	Abiraterone + HRS-1167 + Prednisolone + Prednisone; HRS-1167; HRS-1167 + Tuvusertib	ATR_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor + glucocorticoid; PARP1-selective_inhibitor	MS202659_0001	An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors	Advanced Solid Tumor	Adelaide - Cancer Research SA; St Leonards - GenesisCare North Shore (Oncology)	https://clinicaltrials.gov/ct2/show/NCT06421935
NCT06422520	BGB-C354-101	Phase 1	RECRUITING	NSW, VIC, WA	2024-05-15	2024-07-08	2027-01-31	BGB-C354; BGB-C354 + Tislelizumab; Tislelizumab	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-C354; BGB-C354 + Tislelizumab	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	BGB-C354-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	NSW 2145 - Westmead - Westmead Hospital; VIC 3004 - Melbourne - The Alfred Hospital; VIC 3065 - Fitzroy - St Vincents Hospital Melbourne; WA 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06422520
NCT06427941	BGB-B2033-101	Phase 1	RECRUITING	NZ	2024-05-20	2024-07-23	2026-10-30	BGB-B2033; BGB-B2033 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-GPC3_monoclonal_antibody; anti-GPC3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-B2033; BGB-B2033 + Tislelizumab	anti-GPC3_monoclonal_antibody; anti-GPC3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-B2033-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors	Metastatic Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer; Extragonadal Yolk Sac Tumors; Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer; Metastatic Solid Tumor	1023 - Auckland - Auckland City Hospital	https://clinicaltrials.gov/ct2/show/NCT06427941
NCT06428409	9999-02A	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC, WA	2024-05-20	2024-06-20	2029-10-16	Cisplatin; Cisplatin + Pembrolizumab + Sacituzumab tirumotecan; Fluorouracil; Fluorouracil + Leucovorin + Sacituzumab tirumotecan; Leucovorin; Pembrolizumab; Sacituzumab tirumotecan	Fluorouracil; folinic_acid; anti-Trop2_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent	Cisplatin + Pembrolizumab + Sacituzumab tirumotecan; Fluorouracil + Leucovorin + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; Fluorouracil	9999-02A	A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers	Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer	2145 - Westmead - Westmead Hospital ( Site 0003); 3002 - East Melbourne - Epworth Freemasons ( Site 0005); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 0004); 4029 - Brisbane - Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001); 6009 - Nedlands - One Clinical Research ( Site 0002)	https://clinicaltrials.gov/ct2/show/NCT06428409
NCT06431594	BEHOLD-1	Phase 1	RECRUITING	NSW	2024-05-22	2024-07-02	2027-09-20	GSK5733584	anti-B7H4_antibody-drug_conjugate	GSK5733584	anti-B7H4_antibody-drug_conjugate	222730	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors	Solid Tumors; Neoplasms	2109 - Macquarie University - GSK Investigational Site; 2148 - Blacktown - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06431594
NCT06433219	MS201924-0002	Phase 2	RECRUITING	NSW	2024-05-22	2024-10-30	2028-01-25	Lartesertib; Lartesertib + Niraparib + Tuvusertib; Niraparib; Tuvusertib	PARP_inhibitor; ATR_inhibitor; ATM_inhibitor + ATR_inhibitor + PARP_inhibitor; ATM_inhibitor	Lartesertib + Niraparib + Tuvusertib; Tuvusertib	ATM_inhibitor + ATR_inhibitor + PARP_inhibitor; ATR_inhibitor	MS201924_0002	An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deﬁciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)	Ovarian Cancer	Liverpool - Liverpool Hospital - PARENT	https://clinicaltrials.gov/ct2/show/NCT06433219
NCT06435429	JZP598-303	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-05-24	2024-08-13	2031-11-26	Capecitabine; Capecitabine + Eribulin + Gemcitabine + Trastuzumab + Vinorelbine; Capecitabine + Eribulin + Gemcitabine + Vinorelbine + Zanidatamab; Eribulin; Gemcitabine; Trastuzumab; Trastuzumab Deruxtecan; Vinorelbine; Zanidatamab	anti-ERBB2_antibody-drug_conjugate; antimetabolite + bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; macrocyclic_ketone_analogue; gemcitabine; bispecific_ERBB2/ERBB2_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + antimetabolite + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; fluoropyrimidine; vinca_alkaloid	Capecitabine + Eribulin + Gemcitabine + Trastuzumab + Vinorelbine; Capecitabine + Eribulin + Gemcitabine + Vinorelbine + Zanidatamab; Trastuzumab Deruxtecan	anti-ERBB2_monoclonal_antibody + antimetabolite + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; antimetabolite + bispecific_ERBB2/ERBB2_antibody + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; anti-ERBB2_antibody-drug_conjugate; gemcitabine	JZP598-303	A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment	Metastatic HER2-positive Breast Cancer	2080 - Mount Kuring-Gai - The Kinghorn Cancer Centre; 3128 - Melbourne - Box Hill Hospital; 3149 - Mount Waverly - Peninsula and South Eastern Haematology and Oncology Group; 4575 - Birtinya - Sunshine Coast University Private Hospital; 5000 - Adelaide - HPS Pharmacies - Adelaide; 6008 - Subiaco - St John of God Hospital Subiaco	https://clinicaltrials.gov/ct2/show/NCT06435429
NCT06441747	BIL-PPP	Phase 2	RECRUITING	NSW, QLD, SA, VIC	2024-05-29	2024-09-23	2028-08	Durvalumab; Durvalumab + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody	BIL-PPP	Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)	Cholangiocarcinoma	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - Royal North Shore Hospital; 2145 - Westmead - Westmead Hospital; 2500 - Wollongong - Wollongong Hospital; 3084 - Melbourne - Austin Health; 3168 - Clayton - Monash Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06441747
NCT06449222	BNT327-02	Phase 2	RECRUITING	NSW, QLD, VIC	2024-06-03	2024-08-26	2029-06	BNT327; BNT327 + Carboplatin + Gemcitabine; BNT327 + Eribulin; BNT327 + Nab-paclitaxel; BNT327 + Paclitaxel; Carboplatin; Eribulin; Gemcitabine; Nab-paclitaxel; Paclitaxel	antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; macrocyclic_ketone_analogue; bispecific_PD-L1/VEGFA_antibody + taxane; gemcitabine; taxane; platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody; bispecific_PD-L1/VEGFA_antibody + macrocyclic_ketone_analogue	BNT327 + Carboplatin + Gemcitabine; BNT327 + Eribulin; BNT327 + Nab-paclitaxel; BNT327 + Paclitaxel	antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody + macrocyclic_ketone_analogue; bispecific_PD-L1/VEGFA_antibody + taxane; gemcitabine	BNT327-02	A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer	Locally Advanced Breast Cancer; Triple Negative Breast Cancer; Metastatic Triple Negative Breast Cancers	2065 - Sydney - Mater Hospital Sydney - (WITHDRAWN); 2145 - Westmead - Westmead Hospital - (WITHDRAWN); 3050 - Melbourne - Peter MacCallum Cancer Centre; 3199 - Frankston - Peninsula Oncology Centre; 4065 - Auchenflower - Icon Cancer Care, Wesley Clinic - (WITHDRAWN)	https://clinicaltrials.gov/ct2/show/NCT06449222
NCT06450106	STM-416p-201	Phase 1	RECRUITING	VIC	2024-06-06	2025-05-08	2026-03					STM-416p-201	A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy	Prostate Cancer	3051 - Melbourne N. - Australian Prostate Center; 3051 - Melbourne N. - Epworth HealthCare	https://clinicaltrials.gov/ct2/show/NCT06450106
NCT06452277	SOHO-02	Phase 3	RECRUITING	ACT, NSW, QLD, VIC	2024-06-05	2024-08-28	2029-04-26	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Sevabertinib	platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; EGFR/ERBB2_inhibitor,mutant-selective,non-covalent; antimetabolite	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Sevabertinib	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	22615	A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations	Advanced Non-small Cell Lung Cancer; HER2 Mutation	2139 - Concord - Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit; 2148 - Blacktown - Blacktown Cancer & Haematology Centre; 2298 - Waratah - Calvary Mater Hospital Newcastle; 2605 - Garran - The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC); 3084 - Heidelberg - Austin Hospital - Olivia Newton John Cancer Research Institute; 4556 - Buderim - University of the Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT06452277
NCT06459180	2870-020	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2024-06-10	2024-07-24	2028-10-23	Gemcitabine; Gemcitabine + Irinotecan + Pemetrexed + Tisotumab vedotin + Topotecan + Vinorelbine; Irinotecan; Pemetrexed; Sacituzumab tirumotecan; Tisotumab vedotin; Topotecan; Vinorelbine	anti-TF_antibody-drug_conjugate; topoisomerase_inhibitor; gemcitabine; anti-Trop2_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate + antimetabolite + topoisomerase_inhibitor + vinca_alkaloid; antimetabolite; vinca_alkaloid	Gemcitabine + Irinotecan + Pemetrexed + Tisotumab vedotin + Topotecan + Vinorelbine; Sacituzumab tirumotecan	anti-TF_antibody-drug_conjugate + antimetabolite + topoisomerase_inhibitor + vinca_alkaloid; anti-Trop2_antibody-drug_conjugate; gemcitabine	2870-020	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)	Cervical Cancer	2148 - Sydney - Blacktown Hospital ( Site 3006); 2560 - Sydney - Campbelltown Hospital-Macarthur Cancer Therapy Centre Medical Oncology ( Site 3000); 3000 - Melbourne - Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3005) - (COMPLETED); 3168 - Clayton - Monash Health-Oncology Research ( Site 3002); 4029 - Herston - Royal Brisbane and Women's Hospital ( Site 3001); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 3003)	https://clinicaltrials.gov/ct2/show/NCT06459180
NCT06460961	6837-001	Phase 1	RECRUITING	NSW, VIC	2024-06-11	2024-07-14	2029-07-13	MK-6837; MK-6837 + Pembrolizumab; Pembrolizumab	unknown_drug_class; anti-PD-1_monoclonal_antibody + unknown_drug_class; anti-PD-1_monoclonal_antibody	MK-6837; MK-6837 + Pembrolizumab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	6837-001	A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors	Neoplasm Metastasis	2145 - Westmead - Westmead Hospital ( Site 1002); 3004 - Melbourne - The Alfred Hospital ( Site 1001)	https://clinicaltrials.gov/ct2/show/NCT06460961
NCT06465069	NEXUS-01	Phase 1	RECRUITING	NSW, WA	2024-06-13	2024-07-01	2027-05	LY4052031	anti-NECTIN4_antibody-drug_conjugate	LY4052031	anti-NECTIN4_antibody-drug_conjugate	18882	A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors	Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer	2010 - Darlinghurst - St Vincent's Hospital; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06465069
NCT06467357	DESTINY-BTC01	Phase 3	RECRUITING	QLD, VIC, WA	2024-06-14	2024-08-12	2029-05-16	Cisplatin; Cisplatin + Durvalumab + Gemcitabine; Durvalumab; Gemcitabine; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody; antimetabolite	Cisplatin + Durvalumab + Gemcitabine; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	D781PC00001	DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	Biliary Tract Cancer	2139 - Concord - Research Site; 3168 - Clayton - Research Site; 4032 - Chermside - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06467357
NCT06475937	DM001001	Phase 1	RECRUITING	QLD, VIC	2024-06-20	2024-10-24	2027-02-13	DM001	bispecific-EGFR/Trop2_antibody-drug_conjugate	DM001	bispecific-EGFR/Trop2_antibody-drug_conjugate	DM001001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid Carcinoma	3168 - Clayton - Monash Health; 4101 - South Brisbane - Icon Cancer Centre South Brisbane; 4215 - Southport - Tasman Oncology Research	https://clinicaltrials.gov/ct2/show/NCT06475937
NCT06478693	MTX-GPC3-303	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-06-24	2024-07-01	2026-05-31	MT-303	GPC3-targeting_lipid-nanoparticles; GPC3-targeting_lipid-nanoparticle_CAR_mRNA	MT-303	GPC3-targeting_lipid-nanoparticle_CAR_mRNA; GPC3-targeting_lipid-nanoparticles	MTX-GPC3-303	A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma	Hepatocellular Carcinoma	2010 - Sydney - St Vincent's Hospital; 3004 - Melbourne - The Alfred Hospital; 4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd; 6150 - Murdoch - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06478693
NCT06486441	ASCENT-GYN-01	Phase 3	RECRUITING	ACT, NSW, QLD, VIC, WA	2024-06-27	2024-08-28	2029-06	Doxorubicin; Doxorubicin + Paclitaxel; Paclitaxel; Sacituzumab Govitecan	doxorubicin; anti-Trop2_antibody-drug_conjugate; anthracycline + taxane; taxane	Doxorubicin + Paclitaxel; Sacituzumab Govitecan	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate; doxorubicin	GS-US-682-6769	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	Endometrial Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2605 - Canberra - Canberra Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Health; 4101 - South Brisbane - Mater Cancer Care Centre; 6150 - Murdoch - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06486441
NCT06492122	FL-020-001	Phase 1	RECRUITING	NSW, QLD, WA	2024-07-01	2024-08-30	2026-12	225Ac-FL-020	anit-PSMA_radionucleotide-drug_conjugate,PSMA-targeting	225Ac-FL-020	anit-PSMA_radionucleotide-drug_conjugate,PSMA-targeting	FL-020-001	A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of [225Ac]Ac-FL-020 in Participants With mCRPC.	Metastatic Castration-resistant Prostate Cancer	Brisbane - Princess Alexandra Hospital; Murdoch - Genesiscare Murdoch; NSW 2109 - Sydney - MacQuarie University Clinical Trial Unit	https://clinicaltrials.gov/ct2/show/NCT06492122
NCT06496178	MCLA-158-CL02	Phase 3	RECRUITING	NSW, VIC, WA	2024-07-03	2024-06-25	2029-03	Petosemtamab	bispecific_EGFR/LGR5_antibody	Petosemtamab	bispecific_EGFR/LGR5_antibody	MCLA-158-CL02	A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2010 - Darlinghurst - Site 3; 2050 - Sydney - Site 73; 2065 - Saint Leonards - Site 11; 3000 - Melbourne - Site 38; 6009 - Nedlands - Site 30	https://clinicaltrials.gov/ct2/show/NCT06496178
NCT06501625	S095031-210	Phase 1 / Phase 2	RECRUITING	VIC	2024-07-09	2024-12-16	2027-09-13	Cisplatin; Cisplatin + Durvalumab + Gemcitabine + Ivosidenib; Durvalumab; Gemcitabine; Ivosidenib	platinum-based_antineoplastic_agent; IDH1_R132_inhibitor + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; IDH1_R132_inhibitor; gemcitabine; antimetabolite	Cisplatin + Durvalumab + Gemcitabine + Ivosidenib	IDH1_R132_inhibitor + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	S095031-210	A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	3004 - Melbourne - Alfred Health	https://clinicaltrials.gov/ct2/show/NCT06501625
NCT06515990	DM005001	Phase 1	RECRUITING	QLD	2024-07-17	2024-10-31	2027-03	DM005	bispecific-EGFR/cMET_antibody-drug_conjugate	DM005	bispecific-EGFR/cMET_antibody-drug_conjugate	DM005001	A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors	Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Solid Carcinoma	4101 - South Brisbane - ICON Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06515990
NCT06520345	177Lu-TLX591-203	Phase 3	RECRUITING	NSW, NZ, VIC, WA	2024-07-24	2024-07-26	2030-12	177Lu-TLX591; 177Lu-TLX591 + Abiraterone + Docetaxel + Enzalutamide; Abiraterone; Abiraterone + Docetaxel + Enzalutamide; Docetaxel; Enzalutamide	antiandrogen,nonsteroidal,second_generation; 177Lu-anti-PSMA-radioconjugate + CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; CYP17A1_inhibitor; 177Lu-anti-PSMA-radioconjugate	177Lu-TLX591 + Abiraterone + Docetaxel + Enzalutamide; Abiraterone + Docetaxel + Enzalutamide	177Lu-anti-PSMA-radioconjugate + CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane	177Lu-TLX591-203	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment	Metastatic Castration-resistant Prostate Cancer	2143 - Sydney - Westmead Hospital; 2500 - Wollongong - Wollongong Hospital; 2747 - Sydney - Nepean Hospital; 3051 - Melbourne - Australian Prostate Centre; 6150 - Perth - GenesisCare Murdoch; 92024 - Grafton - Auckland City Hospital	https://clinicaltrials.gov/ct2/show/NCT06520345
NCT06520449	NTA-476	Phase 0	NOT_YET_RECRUITING	VIC	2024-07-25	2024-09-13						2024-07-851	A Single-Arm Comparative Imaging Study of 68Ga-NTA-476 PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men With Prostate Cancer	Prostate Cancer	3051 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06520449
NCT06521554	NVL-330-01	Phase 1	RECRUITING	NSW	2024-07-25	2024-07-18	2026-03	NVL-330	ERBB2_inhibitor,exon_20_selective	NVL-330	ERBB2_inhibitor,exon_20_selective	NVL-330-01	A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	2065 - Saint Leonards - North Shore Health Hub; NSW 2050 - Camperdown - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT06521554
NCT06525220	MCLA-158-CL03	Phase 3	RECRUITING	NSW, VIC	2024-07-26	2024-09-25	2030-07	Pembrolizumab; Pembrolizumab + Petosemtamab; Petosemtamab	bispecific_EGFR/LGR5_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/LGR5_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab; Pembrolizumab + Petosemtamab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/LGR5_antibody	MCLA-158-CL03	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2065 - St Leonards - Site 24; 2148 - Blacktown - Site 11; 3004 - Melbourne - Site 151	https://clinicaltrials.gov/ct2/show/NCT06525220
NCT06532006	HLX22-GC-301	Phase 3	RECRUITING	Melbourne, NSW, QLD, Sydney, VIC	2024-07-31	2024-11-22	2028-09-01	Capecitabine; Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab; Oxaliplatin; Pembrolizumab; Trastuzumab	platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine	Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	HLX22-GC-301	A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer	Gastroesophageal-junction Cancer; Monoclonal Antibody; Gastric Cancer; HER2-positive Gastric Cancer	2109 - North Ryde - Macquarie University; 2250 - Gosford - Central Coast Local Health District (Gosford and Wyong Hospital); 2560 - Campbelltown - GenesisCare Research; 3065 - Fitzroy - St. Vincent Hospital Melbourne; 3940 - Frankston - Peninsula Health-Frankston hospital; 4556 - Sunshine Coast - University of the Sunshine Coast Clinical Trials, Sunshine Coast Haematology and Oncology Clinic; Sydney - Concord - Concord Repatriation General Hospital	https://clinicaltrials.gov/ct2/show/NCT06532006
NCT06533059	2618-001	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-07-29	2024-08-22	2027-12-29	ALTA2618	AKT1_E17K_inhibitor	ALTA2618	AKT1_E17K_inhibitor	2618-001	AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation	Cancer; Breast Cancer; Endometrial Cancer; Metastatic Cancer; Advanced Solid Tumor	2031 - Randwick - Research Site; 2148 - Blacktown - Research Site; 3144 - Malvern - Research Site; 4101 - South Brisbane - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06533059
NCT06533332	ERX-315-101	Phase 1	RECRUITING	NSW, SA	2024-07-29	2024-10-14	2026-06-30	ERX-315	benzamide,ER_alpha-targeting	ERX-315	benzamide,ER_alpha-targeting	ERX-315-101	A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors	Advanced Solid Tumor; Metastatic Breast Cancer; Metastatic Ovarian Cancer; Metastatic Endometrial Cancer; Metastatic Liver Cancer; Metastatic Pancreatic Cancer	2010 - Sydney - The Kinghorn Cancer Center; 2109 - Ryde - Macquarie University Health; 5000 - Adelaide - Cancer Research SA; 5037 - Adelaide - Icon Cancer Centre Adelaide	https://clinicaltrials.gov/ct2/show/NCT06533332
NCT06537310	BP44956	Phase 1	RECRUITING	NSW, VIC	2024-08-01	2024-09-16	2029-06-19	Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	BP44956	An Open-label, Multicenter, Dose-escalation, Randomized, Phase I Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of RO7567132, as a Single Agent and in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors	Cancer-Neoplasms	2010 - Darlinghurst - Kinghorn Cancer Centre; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06537310
NCT06538610	CTNZ-2022-08	NA	RECRUITING	NZ	2024-08-04	2024-11-01	2026-01	Fluorouracil	Fluorouracil; fluoropyrimidine	Fluorouracil	Fluorouracil; fluoropyrimidine	CTNZ-2022-08	Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy	Gastrointestinal Malignancy	1023 - Auckland - Auckland City Hospital	https://clinicaltrials.gov/ct2/show/NCT06538610
NCT06542250	TITANium	Phase 1 / Phase 2	RECRUITING	VIC, WA	2024-08-02	2024-09-18	2028-02-14	AZD5492	bispecific_T-cell_engager,CD20-targeting	AZD5492	bispecific_T-cell_engager,CD20-targeting	D9960C00001	A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)	B-cell Malignancies	3000 - Melbourne - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06542250
NCT06544655	CA233-0000	Phase 1	RECRUITING	NSW, SA	2024-08-05	2024-10-10	2027-10-14	BMS-986484; BMS-986484 + Capecitabine + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin; BMS-986484 + Nivolumab; Capecitabine; Fluorouracil; Leucovorin; Nivolumab; Oxaliplatin	Fluorouracil; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + unknown_drug_class; folinic_acid; unknown_drug_class; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + unknown_drug_class; anti-PD-1_monoclonal_antibody; fluoropyrimidine	BMS-986484; BMS-986484 + Capecitabine + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin; BMS-986484 + Nivolumab	anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + unknown_drug_class; anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; Fluorouracil	CA233-0000	A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies	Advanced Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT06544655
NCT06551324	MEVPRO-1	Phase 3	RECRUITING	QLD, VIC	2024-08-09	2024-10-21	2028-10-29	Abiraterone; Docetaxel; Docetaxel + Enzalutamide; Enzalutamide; Enzalutamide + PF-06821497; PF-06821497	antiandrogen,nonsteroidal,second_generation; EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation + taxane; EZH2_inhibitor	Docetaxel + Enzalutamide; Enzalutamide + PF-06821497; Abiraterone	EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation + taxane; CYP17A1_inhibitor	C2321014	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Health; 4066 - Auchenflower - Icon Cancer Centre Wesley	https://clinicaltrials.gov/ct2/show/NCT06551324
NCT06554795	DB-1419-O-1001	Phase 1 / Phase 2	RECRUITING	NSW, WA	2024-08-14	2024-09-03	2027-02	DB-1419	bispecific_B7H3/PD-L1_antibody	DB-1419	bispecific_B7H3/PD-L1_antibody	DB-1419-O-1001	A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors	Solid Tumor, Adult	2031 - Randwick - AUS01-0; 2109 - North Ryde - AUS03-0; 6009 - Nedlands - AUS02-0	https://clinicaltrials.gov/ct2/show/NCT06554795
NCT06555744	ZWI-ZW191-101	Phase 1	RECRUITING	NSW, WA	2024-08-13	2024-10-30	2027-01	ZW191	anti-FR-alpha_antibody-drug_conjugate	ZW191	anti-FR-alpha_antibody-drug_conjugate	ZWI-ZW191-101	A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors	Advanced Solid Tumors	NSW 2065 - St Leonards - Royal North Shore Hospital Northern Sydney Cancer Centre; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06555744
NCT06560645	PRT7732-01	Phase 1	RECRUITING	NSW, VIC, WA	2024-08-16	2024-11-04	2027-04	PRT7732	SMARCA2_degrader	PRT7732	SMARCA2_degrader	PRT7732-01	A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4	Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Carcinoma; SMARCA4 Mutation	2031 - Randwick - Scientia Clinical Research Ltd; 2576 - Bowral - Southern Highlands Cancer Centre; 2640 - Albury - Border Medical Oncology Research Unit; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06560645
NCT06561386	RELATIVITY1093	Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC, WA	2024-08-16	2024-10-07	2032-08-04	Carboplatin; Carboplatin + Cisplatin + Nivolumab + Pemetrexed + Relatlimab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Nivolumab; Pembrolizumab; Pemetrexed; Relatlimab	anti-LAG3_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; antimetabolite	Carboplatin + Cisplatin + Nivolumab + Pemetrexed + Relatlimab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	CA224-1093	A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%	Non-small Cell Lung Cancer	1023 - Auckland - Local Institution - 0405; 2065 - St Leonards - GenesisCare North Shore; 2250 - Gosford - Gosford Hospital; 3112 - Tauranga - Local Institution - 0407; 3112 - Tauranga - Local Institution - 0447; 3128 - Box Hill - Box Hill Hospital; 4032 - Brisbane - The Prince Charles Hospital; 4120 - Brisbane - Gallipoli Medical Research Ltd; 5112 - Elizabeth Vale - Local Institution - 0057; 6021 - Wellington - Local Institution - 0406; 6150 - Murdoch - Fiona Stanley Hospital; 6150 - Murdoch - St. John of God Murdoch Hospital; 9016 - Dunedin - Local Institution - 0425	https://clinicaltrials.gov/ct2/show/NCT06561386
NCT06581432	1479-0009	Phase 2	RECRUITING	NSW, QLD, WA	2024-08-30	2024-10-11	2028-12-29	Zongertinib	ERBB2_inhibitor,second_generation	Zongertinib	ERBB2_inhibitor,second_generation	1479-0009	Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours	Solid Tumours	2065 - St Leonards - GenesisCare North Shore; 2109 - Macquarie Park - Macquarie University; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT06581432
NCT06585488	BGB-53038-101	Phase 1	RECRUITING	NSW, NZ, VIC, WA	2024-09-03	2024-11-26	2026-12	BGB-53038; BGB-53038 + Cetuximab + Tislelizumab; Cetuximab; Tislelizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; anti-PD-1_monoclonal_antibody; pan-KRAS_inhibitor; anti-EGFR_monoclonal_antibody	BGB-53038; BGB-53038 + Cetuximab + Tislelizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; pan-KRAS_inhibitor	BGB-53038-101	A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications	Metastatic Solid Tumors; Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Colorectal Cancer; Advanced Pancreatic Ductal Adenocarcinoma; Advanced Gastric Cancer; Advanced Gastroesophageal Junction Cancer; Advanced Esophageal Adenocarcinoma	1023 - Auckland - Auckland City Hospital; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3168 - Clayton - Monash Health; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06585488
NCT06589596	BGB-58067-101	Phase 1	RECRUITING	NSW, VIC, WA	2024-09-06	2024-10-11	2027-06	BG-89894; BG-89894 + BGB-58067; BGB-58067	PRMT5_inhibitor,MTA-co-operative; MAT2A_inhibitor + PRMT5_inhibitor,MTA-co-operative; MAT2A_inhibitor	BG-89894 + BGB-58067; BGB-58067	MAT2A_inhibitor + PRMT5_inhibitor,MTA-co-operative; PRMT5_inhibitor,MTA-co-operative	BGB-58067-101	A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumor	NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; VIC 3084 - Heidelberg - Austin Health; VIC 3168 - Clayton - Monash Health; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06589596
NCT06593522	NCT06593522	Phase 2	RECRUITING	NSW, QLD, SA	2024-09-10	2024-12-26	2029-09-11	AMG 193	PRMT5_inhibitor	AMG 193	PRMT5_inhibitor	20230153	A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)	MTAP-deleted NSCLC	2065 - St Leonards - GenesisCare -North Shore Oncology; 2298 - Waratah - Calvary Mater Newcastle Hospital; 4101 - South Brisbane - Mater Hospital Brisbane; 5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT06593522
NCT06596473	BG-C477-101	Phase 1	RECRUITING	NSW, NZ, SA, VIC, WA	2024-09-11	2024-10-03	2028-10-27	BG-C477	anti-CEACAM5_antibody-drug_conjugate	BG-C477	anti-CEACAM5_antibody-drug_conjugate	BG-C477-101	A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors	Advanced Solid Tumors	1023 - Auckland - Auckland City Hospital; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; SA 5000 - Adelaide - Cancer Research South Australia; VIC 3004 - Melbourne - The Alfred Hospital; WA 6009 - Nedlands - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06596473
NCT06596694	1022-011	Phase 1 / Phase 2	RECRUITING	NSW, NZ, VIC, WA	2024-09-11	2024-11-03	2028-07-24	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	1022-011	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers	Gastrointestinal Cancer	1023 - Auckland - Harbour Cancer & Wellness ( Site 0800); 2145 - Sydney - Westmead Hospital ( Site 0100); 3004 - Melbourne - Alfred Health ( Site 0102); 3084 - Melbourne - Austin Health ( Site 0103); 6009 - Mount Pleasant - One Clinical Research ( Site 0104)	https://clinicaltrials.gov/ct2/show/NCT06596694
NCT06597721	ADCE-T02-01	Phase 1	RECRUITING	NSW, SA, VIC, WA	2024-09-12	2024-11-25	2026-12-31	ADCE-T02	anti-TF_antibody-drug_conjugate	ADCE-T02	anti-TF_antibody-drug_conjugate	ADCE-T02-01	First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research; 3144 - Malvern - Cabrini Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology and Oncology Group (PSEHOG); 5042 - Bedford Park - Southern Oncology Clinical Research Unit; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06597721
NCT06598306	DeLLphi-308	Phase 1	RECRUITING	NSW, VIC	2024-09-13	2024-10-07	2030-03-27	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20230298	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)	Extensive Stage Small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3004 - Melbourne - The Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT06598306
NCT06598800	BG-T187-101	Phase 1	RECRUITING	NSW, VIC, WA	2024-09-12	2024-10-18	2028-01-31	BG-T187	trispecific_EGFR/cMET/cMET_antibody	BG-T187	trispecific_EGFR/cMET/cMET_antibody	BG-T187-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors	Advanced Solid Tumor	NSW 2109 - North Ryde - Macquarie University; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; VIC 3144 - Malvern East - Cabrini Hospital Malvern; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06598800
NCT06599502	ALAFOSS-01	Phase 1 / Phase 2	RECRUITING	VIC	2024-09-13	2024-10-18	2028-01-20	AZD0022; AZD0022 + Cetuximab; Cetuximab	KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody	AZD0022; AZD0022 + Cetuximab	KRAS_G12D_inhibitor; KRAS_G12D_inhibitor + anti-EGFR_monoclonal_antibody	D7080C00001	A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)	Advanced Solid Tumours; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC)	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06599502
NCT06608927	PRISM-1	Phase 3	RECRUITING	NSW, SA, WA	2024-09-20	2024-12-13	2030-11-30	Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Quemliclustat; Nab-paclitaxel; Placebo; Quemliclustat	placebo; antimetabolite + taxane; CD73_inhibitor + antimetabolite + taxane; CD73_inhibitor; gemcitabine; taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Quemliclustat; Placebo	CD73_inhibitor + antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo	PRISM-1	A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma	Metastatic Pancreatic Ductal Adenocarcinoma	Camperdown - Chris O'Brien Lifehouse; Clayton - Monash Health; Murdoch - Oncology West - Murdoch; Wollongong - Wollongong Hospital	https://clinicaltrials.gov/ct2/show/NCT06608927
NCT06613009	CIBI3009A101	Phase 1	RECRUITING	NSW, VIC	2024-09-22	2024-12-30	2027-08-30	IBI3009	anti-DLL3_antibody-drug_conjugate	IBI3009	anti-DLL3_antibody-drug_conjugate	CIBI3009A101	A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital; 2500 - Wollongong - Wollongong Hospital; 3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT06613009
NCT06617169	MNPR101-Lu-1-01	Phase 1	RECRUITING	VIC	2024-09-26	2024-10-08	2027-01	MNPR-101-PCTA-177Lu	177Lu-anti-uPAR_radioconjugate	MNPR-101-PCTA-177Lu	177Lu-anti-uPAR_radioconjugate	MNPR101-Lu-1-01	Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma; Triple-negative Breast Cancer; Lung Cancer; Colorectal Cancer; Gastric Cancer; Ovarian Cancer; Pancreatic Cancer	3051 - North Melbourne - Melbourne Theranostic Innovation Centre (MTIC)	https://clinicaltrials.gov/ct2/show/NCT06617169
NCT06618287	CA244-0001	Phase 1 / Phase 2	RECRUITING	NSW, QLD	2024-09-26	2025-02-04	2028-08-24	Izalontamab Brengitecan; Izalontamab Brengitecan + Nivolumab; Izalontamab Brengitecan + Osimertinib; Izalontamab Brengitecan + Pembrolizumab; Nivolumab; Osimertinib; Pembrolizumab	bispecific_EGFR/ERBB3_antibody; EGFR_inhibitor,third_generation + bispecific_EGFR/ERBB3_antibody; EGFR_inhibitor,third_generation; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/ERBB3_antibody	Izalontamab Brengitecan + Nivolumab; Izalontamab Brengitecan + Osimertinib; Izalontamab Brengitecan + Pembrolizumab	EGFR_inhibitor,third_generation + bispecific_EGFR/ERBB3_antibody; anti-PD-1_monoclonal_antibody + bispecific_EGFR/ERBB3_antibody	CA244-0001	A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors	Lung Cancer; Breast Cancer	2170 - Liverpool - Liverpool Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT06618287
NCT06619587	GO45416	Phase 1	_COHORTS_FULL	NSW, VIC	2024-09-27	2024-11-14	2028-05-31	GDC-7035	KRAS_G12D_inhibitor	GDC-7035	KRAS_G12D_inhibitor	GO45416	A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation	Solid Tumor	2010 - Darlinghurst - St Vincent's Hospital Sydney; 3052 - Parkville - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06619587
NCT06625593	BG-C137-101	Phase 1	RECRUITING	NSW, QLD, VIC	2024-10-01	2024-12-09	2026-12-31	BG-C137	anti-FGFR2b_antibody-drug_conjugate	BG-C137	anti-FGFR2b_antibody-drug_conjugate	BG-C137-101	A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors	Advanced Solid Tumor	NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; NSW 2170 - Liverpool - Liverpool Hospital; QLD 4101 - South Brisbane - Icon Cancer Centre South Brisbane; VIC 3144 - Malvern East - Cabrini Hospital Malvern; VIC 3168 - Clayton - Monash Health	https://clinicaltrials.gov/ct2/show/NCT06625593
NCT06625775	TBBO10203-101	Phase 1	RECRUITING	NSW, VIC	2024-10-01	2024-10-29	2028-11	BBO-10203; BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; BBO-10203 + Fulvestrant + Ribociclib; BBO-10203 + Trastuzumab; Bevacizumab; Fluorouracil; Fulvestrant; Leucovorin; Oxaliplatin; Ribociclib; Trastuzumab	anti-VEGF_monoclonal_antibody; CDK4/6_inhibitor + PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; platinum-based_antineoplastic_agent; PI3K_alpha-RAS_breaker + anti-ERBB2_monoclonal_antibody; Fluorouracil; PI3K_alpha-RAS_breaker + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; PI3K_alpha-RAS_breaker	BBO-10203; BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; BBO-10203 + Fulvestrant + Ribociclib; BBO-10203 + Trastuzumab	CDK4/6_inhibitor + PI3K_alpha-RAS_breaker + selective_estrogen_receptor_degrader; PI3K_alpha-RAS_breaker; PI3K_alpha-RAS_breaker + anti-ERBB2_monoclonal_antibody; PI3K_alpha-RAS_breaker + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	TBBO10203-101	A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)	Solid Tumor, Adult; Metastatic Breast Cancer; Advanced Breast Cancer; HER2 Mutation-Related Tumors; HER2-positive Metastatic Breast Cancer; KRAS Mutant Metastatic Colorectal Cancer; Metastatic Lung Cancer; Metastatic Colorectal Cancer; Advanced Lung Cancer; HR-positive, HER2-negative Advanced Breast Cancer; HER2-positive Advanced Breast Cancer	2031 - Randwick - Scientia Clinical Research; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06625775
NCT06627647	D702FC00001	Phase 3	RECRUITING	NSW, QLD	2024-10-03	2024-11-27	2030-03-25	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed + Rilvegostomig; Cisplatin; Pembrolizumab; Pemetrexed; Rilvegostomig	platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody; antimetabolite	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed + Rilvegostomig	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent	D702FC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)	Non-squamous Non-small Cell Lung Cancer	2010 - Darlinghurst - Research Site; 2500 - Wollongong - Research Site; 4215 - Southport - Research Site; 4812 - Hyde Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT06627647
NCT06629779	C2321003	Phase 3	RECRUITING	NZ, Waikato Region	2024-09-27	2024-10-22	2028-11-30	Enzalutamide; Enzalutamide + PF-06821497; PF-06821497; Placebo	placebo; antiandrogen,nonsteroidal,second_generation; EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; EZH2_inhibitor	Enzalutamide; Enzalutamide + PF-06821497; Placebo	EZH2_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; placebo	C2321003	A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)	Metastatic Castration-Resistant Prostate Cancer	1023 - Auckland - Auckland City Hospital; 3112 - Tauranga - Imed Radiology; 3112 - Tauranga - Tauranga Hospital; 3204 - Hamilton - Waikato Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT06629779
NCT06634589	BGB-16673-104	Phase 1 / Phase 2	RECRUITING	NSW, NZ, QLD, VIC, WA	2024-10-08	2024-11-27	2029-12-02	BGB-16673; BGB-16673 + Glofitamab + Obinutuzumab; BGB-16673 + Mosunetuzumab; BGB-16673 + Sonrotoclax; BGB-16673 + Zanubrutinib; Glofitamab; Mosunetuzumab; Obinutuzumab; Sonrotoclax; Zanubrutinib	BTK_PROTAC_degrader + anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; BTK_PROTAC_degrader + BTK_inhibitor; BTK_inhibitor; bispecific_T-cell_engager,CD20-targeting; BTK_PROTAC_degrader; BTK_PROTAC_degrader + Bcl2_inhibitor; anti-CD20_monoclonal_antibody; Bcl2_inhibitor; BTK_PROTAC_degrader + bispecific_T-cell_engager,CD20-targeting	BGB-16673 + Glofitamab + Obinutuzumab; BGB-16673 + Mosunetuzumab; BGB-16673 + Sonrotoclax; BGB-16673 + Zanubrutinib	BTK_PROTAC_degrader + BTK_inhibitor; BTK_PROTAC_degrader + Bcl2_inhibitor; BTK_PROTAC_degrader + anti-CD20_monoclonal_antibody + bispecific_T-cell_engager,CD20-targeting; BTK_PROTAC_degrader + bispecific_T-cell_engager,CD20-targeting	BGB-16673-104	A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies	B-cell Malignancy; Relapsed Cancer; Refractory Cancer; B-cell Lymphoma	0622 - Auckland - North Shore Hospital; 1023 - Auckland - Auckland City Hospital; NSW 2217 - Kogarah - St George Hospital; QLD 4101 - South Brisbane - Mater Cancer Care Centre; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3004 - Melbourne - The Alfred Hospital; VIC 3168 - Clayton - Monash Health; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06634589
NCT06634849	PTT-4256-01	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC, WA	2024-10-08	2024-11-04	2027-10-30	PTT-4256	GPR65_inhibitor	PTT-4256	GPR65_inhibitor	PTT-4256-01	A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research; 2148 - Blacktown - Blacktown Hospital; 3084 - Heidelberg - Austin Health; 5042 - Adelaide - Southern Oncology Clinical Research Unit (SOCRU); 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06634849
NCT06635824	GCT1046-06	Phase 3	RECRUITING	NSW, QLD, TAS, VIC, WA	2024-10-08	2024-11-25	2029-10-31	Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	GCT1046-06	A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)	PD-L1-positive Metastatic NSCLC	Camperdown - Chris OBrien LifeHouse; Fitzroy - St Vincent's Hospital Melbourne; Perth - Sir Charles Gairdner Hospital; Southport - Gold Coast Hospital; Sydney - Westmead Hospital; Wendouree - Ballarat Oncology & Haematology Service	https://clinicaltrials.gov/ct2/show/NCT06635824
NCT06644300	BM230-01	Phase 1	RECRUITING	QLD	2024-10-14	2024-12-16	2027-12	BM230	unknown_drug_class	BM230	unknown_drug_class	BM230-01	A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors	Solid Tumor	4101 - Brisbane - Icon Cancer Centre - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06644300
NCT06646276	CA245-0001	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2024-10-16	2025-02-25	2031-09-05	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Etoposide; Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; platinum-based_antineoplastic_agent; anti-fucosyl-GM1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Carboplatin + Etoposide; BMS-986012 + Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CA245-0001	A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).	Extensive-Stage Small Cell Lung Cancer	2560 - Campbelltown - GenesisCare - Campbelltown; 2750 - Penrith - Nepean Hospital; 3350 - Ballarat Central - Grampians Health; 4120 - Brisbane - Gallipoli Medical Research Ltd; 6150 - Murdoch - St. John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT06646276
NCT06649708	HX044-I-01	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2024-10-17	2024-12-30	2027-10-31	HX044	unknown_drug_class	HX044	unknown_drug_class	HX044-I-01	A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies	Advanced Solid Tumor Malignancies	2148 - Blacktown - Blacktown Hospital; 3144 - Malvern - Cabrini Health Limited; 4066 - Auchenflower - Icon Cancer Centre Wesley	https://clinicaltrials.gov/ct2/show/NCT06649708
NCT06650566	LM299-01-102	Phase 1 / Phase 2	RECRUITING	WA	2024-10-17	2024-10-09	2027-07	LM-299	bispecific_PD-1/VEGF_antibody	LM-299	bispecific_PD-1/VEGF_antibody	LM299-01-102	A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors	Malignant Tumors	Perth - One Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06650566
NCT06651229	90189892AML1001	Phase 1	RECRUITING	VIC, WA	2024-10-18	2025-03-21	2028-12-01	JNJ-90189892	unknown_drug_class	JNJ-90189892	unknown_drug_class	90189892AML1001	A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms	Leukemia, Myeloid, Acute; Myelodysplastic Neoplasms	2139 - Concord - Concord Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06651229
NCT06656390	ALK201-01	Phase 1 / Phase 2	RECRUITING	NSW	2024-10-22	2024-10-24	2028-04-22	ALK-201	anti-FGFR2b_antibody-drug_conjugate	ALK-201	anti-FGFR2b_antibody-drug_conjugate	ALK201-01	A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors	Advanced Cancer; Advanced Solid Tumors	2500 - Wollongong - Cancer Care Wollongong	https://clinicaltrials.gov/ct2/show/NCT06656390
NCT06659341	NCT06659341	Phase 1	_COHORTS_FULL	NSW, VIC	2024-10-24	2024-11-08	2028-03-07	BAY3498264; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; SOS1-KRAS_inhibitor; KRAS_G12C_inhibitor	BAY3498264; Sotorasib	SOS1-KRAS_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C_inhibitor	22676	Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	Advanced Solid Tumors Harboring KRAS G12C Mutation	2109 - Macquarie Park - Macquarie University Hospital - Oncology Department; 2640 - Albury - Border Medical oncology - Albury Wodonga Regional Cancer Centre; 3199 - Frankston - Peninsula and Southeast Oncology	https://clinicaltrials.gov/ct2/show/NCT06659341
NCT06669975	AP402-101	Phase 1 / Phase 2	RECRUITING	NSW, SA, WA	2024-10-31	2025-04-22	2027-12-01	AP402	bispecific_p95ERBB2/CD137_antibody; bispecific_p95ERBB2/4-1BB_antibody	AP402	bispecific_p95ERBB2/4-1BB_antibody; bispecific_p95ERBB2/CD137_antibody	AP402-101	A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors	Advanced Solid Tumor	2109 - Macquarie - Macquarie University Clinical Trials Unit; 5043 - Bedford Park - Flinders Medical Centre; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06669975
NCT06672185	ARC101-P1-101	Phase 1	RECRUITING	QLD, SA, VIC	2024-10-31	2025-02-05	2028-08-01	ARC101	bispecific_T-cell_engager,CLDN6-targeting	ARC101	bispecific_T-cell_engager,CLDN6-targeting	ARC101-P1-101	A Phase 1 Study of ARC101 in Advanced Solid Tumors	Advanced Solid Tumor	3144 - Malvern - Cabrini Health Research; 4575 - Birtinya - Sunshine Coast University Private Hospital; 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT06672185
NCT06679985	CHS-388-202	Phase 2	RECRUITING	Brisbane, NSW, QLD	2024-11-06	2024-12-20	2027-09	Bevacizumab; Bevacizumab + Casdozokitug + Toripalimab; Bevacizumab + Toripalimab; Casdozokitug; Toripalimab	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-IL27_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-IL27_monoclonal_antibody	Bevacizumab + Casdozokitug + Toripalimab; Bevacizumab + Toripalimab	anti-IL27_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	CHS-388-202	A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma	Hepatocellular Carcinoma	4006 - Herston - Royal Brisbane and Women's Hospital; NSW 2010 - Darlinghurst - St Vincent's Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT06679985
NCT06682988	IMGN853-0425	Phase 2	RECRUITING	QLD, VIC	2024-11-08	2025-05-28	2028-03	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	IMGN853-0425	A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment	Advanced High-Grade Epithelial Ovarian; Primary Peritoneal; Fallopian Tube Cancers; High Folate Receptor-Alpha Expression; Platinum Resistant	3168 - Clayton - Monash Health - Monash Medical Centre /ID# 272234; 4032 - Chermside - Icon Cancer Centre Chermside /ID# 272220	https://clinicaltrials.gov/ct2/show/NCT06682988
NCT06685718	BG-60366-101	Phase 1	RECRUITING	NSW, NZ, QLD, SA, VIC	2024-11-11	2024-11-26	2028-04	BG-60366; Cladribine	EGFR_CDAC_degrader; antimetabolite	BG-60366; Cladribine	EGFR_CDAC_degrader; antimetabolite	BG-60366-101	Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer; Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); EGFR Activating Mutation; EGFR Mutation-Related Tumors	1023 - Auckland - Harbour Cancer and Wellness; NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; NSW 2170 - Liverpool - Liverpool Hospital; QLD 4102 - Woolloongabba - Princess Alexandra Hospital; SA 5000 - Adelaide - Cancer Research South Australia; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06685718
NCT06690775	TORL123-002	Phase 2	RECRUITING	Melbourne, NSW, QLD, SA, VIC, WA	2024-11-13	2024-11-20	2027-12	Dexamethasone; Pegfilgrastim	granulocyte_colony_stimulating_factor; glucocorticoid	Pegfilgrastim; Dexamethasone	granulocyte_colony_stimulating_factor; glucocorticoid	TORL123-002	Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6	Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Endometrioid Ovarian Cancer	2148 - Blacktown - Blacktown Hospital; 5042 - Bedford Park - Flinders Medical Centre; QLD 4032 - Chermside - Icon Cancer Centre Chermside; VIC 3168 - Clayton - Monash Medical Centre; WA 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06690775
NCT06691984	NCT06691984	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2024-11-14	2024-12-09	2029-07-30	Abiraterone; Abiraterone + Cabazitaxel + Enzalutamide; Cabazitaxel; Enzalutamide; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; bispecific_T-cell_engager,STEAP1-targeting; taxane	Abiraterone + Cabazitaxel + Enzalutamide; Xaluritamig	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + taxane; bispecific_T-cell_engager,STEAP1-targeting	20230005	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	Metastatic Castration-resistant Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 2109 - North Ryde - Macquarie University; 3004 - Melbourne - The Alfred Hospital; 3168 - Clayton - Monash Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT06691984
NCT06692738	D702BC00001	Phase 3	RECRUITING	NSW, QLD	2024-11-14	2024-11-18	2029-10-08	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel + Rilvegostomig; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Rilvegostomig	taxane; bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel + Rilvegostomig	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; bispecific_PD-1/TIGIT_antibody + platinum-based_antineoplastic_agent + taxane	D702BC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)	Non-small Cell Lung Cancer	2010 - Darlinghurst - Research Site; 2500 - Wollongong - Research Site; 4215 - Southport - Research Site; 4812 - Hyde Park - Research Site	https://clinicaltrials.gov/ct2/show/NCT06692738
NCT06697301	EIK1001-006	Phase 2 / Phase 3	RECRUITING	NSW, NZ, QLD, SA, VIC	2024-11-18	2025-05-22	2040-12	EIK1001; EIK1001 + Pembrolizumab; Pembrolizumab; Placebo	placebo; TLR7/TLR8_agonist; anti-PD-1_monoclonal_antibody; TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody	EIK1001 + Pembrolizumab; Pembrolizumab; Placebo	TLR7/TLR8_agonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	EIK1001-006	A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)	Advanced Melanoma	1023 - Auckland - Auckland City Hospital; 2500 - Wollongong - Cancer Care Wollongong; 3128 - Box Hill - Eastern Health; 4032 - Chermside - Icon Cancer Centre Chermside; 5042 - Bedford Park - Southern Adelaide Local Health Network Incorporated Flinders Medical Centre; 8011 - Christchurch - Christchurch Public Hospital	https://clinicaltrials.gov/ct2/show/NCT06697301
NCT06706076	SOLARA	Phase 1 / Phase 2	RECRUITING	VIC	2024-11-22	2025-01-09	2029-07-31					BH-30643-01	A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)	NSCLC (Advanced Non-small Cell Lung Cancer)	3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT06706076
NCT06707610	ALK202-01	Phase 1	RECRUITING	NSW	2024-11-25	2025-02-10	2028-12	ALK-202	anti_EGFR/cMET_antibody-drug_conjugate	ALK-202	anti_EGFR/cMET_antibody-drug_conjugate	ALK202-01	A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors	Advanced Cancer; Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research Ltd; 2109 - Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT06707610
NCT06710132	MS202329-0010	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA	2024-11-25	2025-01-29	2028-01-26	M9140	anti-CEACAM5_antibody-drug_conjugate	M9140	anti-CEACAM5_antibody-drug_conjugate	MS202329_0010	PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)	Solid Tumors; Gastric Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)	Bedford Park - Flinders Medical Centre; South Brisbane - Mater Misericordiae Ltd - PARENT; Sydney - Macquarie University Hospital - PARENT	https://clinicaltrials.gov/ct2/show/NCT06710132
NCT06710847	SYLVER	Phase 1 / Phase 2	RECRUITING	VIC	2024-11-26	2024-12-13	2028-06-16	GSK4418959	WRN_inhibitor	GSK4418959	WRN_inhibitor	221971	A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)	Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06710847
NCT06712316	BNT327-06	Phase 2 / Phase 3	RECRUITING	NSW, QLD, SA, VIC	2024-11-26	2025-01-07	2030-12	BNT327; BNT327 + Carboplatin + Paclitaxel; BNT327 + Carboplatin + Pemetrexed; Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; bispecific_PD-L1/VEGFA_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + taxane	BNT327 + Carboplatin + Paclitaxel; BNT327 + Carboplatin + Pemetrexed; Carboplatin + Paclitaxel + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; antimetabolite + bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + taxane	BNT327-06	A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	2500 - Wollongong - Cancer Care Wollongong Pty Limited; 2830 - Dubbo - Dubbo Hospital; 3021 - St Albans - Western Health Sunshine Hospital; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4812 - Townsville - ICON Cancer Care - Townsville; 4870 - Cairns - Cairns Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06712316
NCT06712355	BNT327-03	Phase 3	ACTIVE_NOT_RECRUITING	NSW, SA, VIC	2024-11-26	2025-02-03	2028-09	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; BNT327; BNT327 + Carboplatin + Etoposide; Carboplatin; Etoposide	platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody; anti-PD-L1_monoclonal_antibody; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Atezolizumab + Carboplatin + Etoposide; BNT327 + Carboplatin + Etoposide	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; bispecific_PD-L1/VEGFA_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	BNT327-03	A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer	Extensive-stage Small-cell Lung Cancer	2298 - Waratah - Calvary Mater Newcastle; 2500 - Wollongong - Cancer Care Wollongong Pty Limited; 3021 - St Albans - Western Health Sunshine Hospital; 3084 - Heidelberg - Olivia Newton-John Cancer Wellness & Research centre; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 5011 - Woodville - The Queen Elizabeth Hospital; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06712355
NCT06726148	CECI830A12101	Phase 1 / Phase 2	RECRUITING	VIC	2024-12-05	2025-04-03	2028-09-25	ECI830; ECI830 + Fulvestrant; ECI830 + Fulvestrant + Ribociclib; Fulvestrant; Fulvestrant + Ribociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor; CDK4/6_inhibitor; selective_estrogen_receptor_degrader	ECI830; ECI830 + Fulvestrant; ECI830 + Fulvestrant + Ribociclib; Fulvestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	CECI830A12101	An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors	Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors	3004 - Melbourne - Novartis Investigative Site; 3168 - Clayton - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT06726148
NCT06726265	TACTI-004	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC	2024-12-05	2025-03-21	2029-09	Carboplatin; Carboplatin + Cisplatin + Eftilagimod Alpha + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Cisplatin; Eftilagimod Alpha; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	taxane; platinum-based_antineoplastic_agent; placebo; T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody; antimetabolite; T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cisplatin + Eftilagimod Alpha + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Placebo	T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; placebo	TACTI-004	TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Elizabeth Vale - Lyell McEwin Hospital; Greenslopes - Greenslopes Private Hospital; Melbourne - The Alfred Hospital; Southport - Tasman Oncology Research Ltd; Waratah - Calvary Mater Newcastle; Wollongong - Cancer Care Wollongong Pty Limited	https://clinicaltrials.gov/ct2/show/NCT06726265
NCT06727565	VELOCITY-HNSCC	Phase 2	RECRUITING	NSW, SA, VIC	2024-12-09	2025-02-18	2026-08	Carboplatin; Carboplatin + Domvanalimab + Paclitaxel + Zimberelimab; Carboplatin + Paclitaxel + Zimberelimab; Domvanalimab; Paclitaxel; Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-TIGIT_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Domvanalimab + Paclitaxel + Zimberelimab; Carboplatin + Paclitaxel + Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	GS-US-699-7184	A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2145 - Sydney - Westmead Hospital; 3004 - Melbourne - Alfred Health; 3168 - Clayton - Monash Health; 5037 - Kurralta Park - ICON Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06727565
NCT06730386	AK138D1-101	Phase 1	RECRUITING	NSW, QLD, VIC	2024-12-09	2025-02-24	2028-08-30	AK138D1	anti-ERBB3_antibody-drug_conjugate	AK138D1	anti-ERBB3_antibody-drug_conjugate	AK138D1-101	A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	Solid Cancer	2109 - North Ryde - Macquarie University; 2148 - Blacktown - Blacktown Hospital-Blacktwon Cancer and Haematology Centre; 3199 - Frankston - Peninsula & South Eastern Haematology and Oncology Group; 4101 - South Brisbane - ICON Cancer Centre South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06730386
NCT06730750	CA238-0001	Phase 1 / Phase 2	RECRUITING	QLD	2024-12-09	2025-02-12	2029-12-09	BMS-986490; BMS-986490 + Bevacizumab; Bevacizumab	unknown_drug_class; anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + unknown_drug_class	BMS-986490; BMS-986490 + Bevacizumab	anti-VEGF_monoclonal_antibody + unknown_drug_class; unknown_drug_class	CA238-0001	A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	Advanced Solid Tumors	4215 - Southport - Tasman Oncology Research	https://clinicaltrials.gov/ct2/show/NCT06730750
NCT06731478	DS8201-724	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2024-12-09	2025-02-27	2030-02-01	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab Deruxtecan; Capecitabine + Fluorouracil + Trastuzumab Deruxtecan; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; Fluorouracil; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + fluoropyrimidine; platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab Deruxtecan; Capecitabine + Fluorouracil + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	DS8201-724	A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)	Gastric Cancer; Gastroesophageal Junction Cancer	Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre Clayton; Douglas - Townsville University Hospital; North Melbourne - Peter MacCallum Cancer Centre; St Leonards - GenesisCare North Shore (Oncology); Subiaco - St John of God Subiaco Hospital; Wollongong - Wollongong Hospital	https://clinicaltrials.gov/ct2/show/NCT06731478
NCT06736704	SNV4818-101	Phase 1	RECRUITING	NSW, VIC, WA	2024-12-12	2025-02-20	2026-12	Fulvestrant; Fulvestrant + SNV4818; SNV4818	PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor,allosteric,mutant-selective; selective_estrogen_receptor_degrader	Fulvestrant + SNV4818; SNV4818	PI3K_alpha_inhibitor,allosteric,mutant-selective; PI3K_alpha_inhibitor,allosteric,mutant-selective + selective_estrogen_receptor_degrader	SNV4818-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research; 2050 - Camperdown - Chris O'Brien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06736704
NCT06738966	BL0175-102	Phase 1	RECRUITING	NSW	2024-12-18			BL0175	unknown_drug_class	BL0175	unknown_drug_class	BL0175-102	An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer	Ovarian Cancer; Breast Cancer; Endometrial Cancer	- Sydney	https://clinicaltrials.gov/ct2/show/NCT06738966
NCT06741644	CS2009-101	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2024-12-15	2025-02-24	2028-01	CS2009; CS2009 + Capecitabine + Carboplatin + Etoposide + Nab-paclitaxel + Oxaliplatin + Paclitaxel + Pemetrexed; Capecitabine; Carboplatin; Etoposide; Nab-paclitaxel; Oxaliplatin; Paclitaxel; Pemetrexed	trispecific_PD-1/VEGFA/CTLA4_antibody; topoisomerase_inhibitor; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane + topoisomerase_inhibitor + trispecific_PD-1/VEGFA/CTLA4_antibody; taxane; platinum-based_antineoplastic_agent; fluoropyrimidine; antimetabolite	CS2009; CS2009 + Capecitabine + Carboplatin + Etoposide + Nab-paclitaxel + Oxaliplatin + Paclitaxel + Pemetrexed	antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane + topoisomerase_inhibitor + trispecific_PD-1/VEGFA/CTLA4_antibody; trispecific_PD-1/VEGFA/CTLA4_antibody	CS2009-101	A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors	Advanced Solid Tumors	Melbourne - Alfred Hospital (Alfred Health); Melbourne - Austin Hospital (Austin Health); Melbourne - Monash Medical Centre (Monash Health); South Brisbane - Icon Cancer Centre South Brisbane; Sydney - Blacktown Hospital; Sydney - Macquarie University Hospital; Sydney - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06741644
NCT06745323	DeLLphi-309	Phase 2	RECRUITING	VIC	2024-12-17	2025-02-26	2028-12-31	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20240092	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)	Small Cell Lung Cancer (SCLC)	3084 - Heidelberg - Austin Health, Austin Hospital; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT06745323
NCT06750094	OrigAMI-3	Phase 3	RECRUITING	SA, VIC	2024-12-20	2024-12-12	2029-04-13	Amivantamab; Amivantamab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab; Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab; Fluorouracil; Irinotecan; Leucovorin	anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; topoisomerase_inhibitor; folinic_acid; bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; bispecific_cMET/EGFR_antibody	Amivantamab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin	anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; bispecific_cMET/EGFR_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	61186372COR3002	A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy	Colorectal Neoplasms	2139 - Concord - Concord Hospital; 3021 - St Albans - Western Health Sunshine Hospital; 3084 - Heidelberg - Warringal Private Hospital; 5011 - South Woodville - Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT06750094
NCT06750185	BNT317-01	Phase 1	RECRUITING	NSW, QLD, VIC	2024-12-19	2025-01-13	2028-06	BNT317	cancer_therapy,undisclosed_mechanism	BNT317	cancer_therapy,undisclosed_mechanism	BNT317-01	A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick - Scientia Clinical Research; 3168 - Clayton - Monash Medical Centre Clayton; 4215 - Southport - Tasman Oncology Research Ltd	https://clinicaltrials.gov/ct2/show/NCT06750185
NCT06751329	DM002001	Phase 1	RECRUITING	NSW	2024-12-26	2025-02-17	2028-04-18	DM002	bispecific-ERBB3/MUC1_antibody-drug_conjugate	DM002	bispecific-ERBB3/MUC1_antibody-drug_conjugate	DM002001	A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors	Ovarian Neoplasms; Prostatic Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Solid Carcinoma	2500 - Wollongong - Cancer Care Wollongong	https://clinicaltrials.gov/ct2/show/NCT06751329
NCT06756932	BGB-21447-102	Phase 1	RECRUITING	NSW, QLD, VIC, WA	2024-12-24	2025-02-04	2027-06-30	BGB-21447; BGB-21447 + BGB-43395 + Fulvestrant; BGB-21447 + Fulvestrant; BGB-43395; Fulvestrant	CDK4_selective_inhibitor; Bcl2_inhibitor + selective_estrogen_receptor_degrader; Bcl2_inhibitor; selective_estrogen_receptor_degrader; Bcl2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader	BGB-21447; BGB-21447 + BGB-43395 + Fulvestrant; BGB-21447 + Fulvestrant	Bcl2_inhibitor; Bcl2_inhibitor + CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader	BGB-21447-102	A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer	Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer	NSW 2010 - Darlinghurst - Saint Vincents Hospital Sydney; NSW 2298 - Waratah - Calvary Mater Newcastle; QLD 4575 - Birtinya - Sunshine Coast University Private Hospital; VIC 3000 - Melbourne - Peter Maccallum Cancer Centre; VIC 3021 - St Albans - Western Health Sunshine Hospital; WA 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06756932
NCT06757634	CELC-G-302	Phase 3	RECRUITING	NSW, QLD, SA, WA	2025-01-02	2025-06-30	2028-12-30	Fulvestrant; Fulvestrant + Gedatolisib + Palbociclib + Ribociclib; Gedatolisib; Palbociclib; Ribociclib	pan-PI3K/mTORC1/mTORC2_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Fulvestrant + Gedatolisib + Palbociclib + Ribociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader	CELC-G-302	VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer	Breast Cancer	2076 - Wahroonga - Sydney Adventist Hospital; 2145 - Westmead - Westmead Hospital; 4215 - Southport - Icon Cancer Centre Southport; 5000 - Adelaide - GenesisCare - St Andrews; 6009 - Nedlands - Breast Cancer Research Centre	https://clinicaltrials.gov/ct2/show/NCT06757634
NCT06758401	Be6A-Lung-02	Phase 3	RECRUITING	QLD	Help: Date registered 2025-01-03	2025-07-23		Pembrolizumab; Pembrolizumab + Sigvotatug vedotin; Sigvotatug vedotin	anti-PD-1_monoclonal_antibody; anti-ITGB6_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ITGB6_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sigvotatug vedotin	anti-ITGB6_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2024-517968-36-00  C5751003	AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (=50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)	Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung (NSCLC); Carcinoma, Non-Small-Cell Lung	4575 - Birtinya; 4560 - Nambour; 4570 - Gympie	https://clinicaltrials.gov/ct2/show/NCT06758401
NCT06760637	FourLight-3	Phase 3	RECRUITING	QLD, VIC	2025-01-03	2025-01-06	2037-12-29	Abemaciclib; Abemaciclib + Letrozole + Palbociclib + Ribociclib; Letrozole; Letrozole + PF-07220060; PF-07220060; Palbociclib; Ribociclib	CDK4_selective_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor	Abemaciclib + Letrozole + Palbociclib + Ribociclib; Letrozole + PF-07220060	CDK4/6_inhibitor + aromatase_inhibitor; CDK4_selective_inhibitor + aromatase_inhibitor	C4391024	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)	Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Parkville - Royal Melbourne Hospital; 3199 - Frankston - Frankston Hospital; 3940 - Capel Sound - Rosebud Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 4814 - Douglas - Townsville University Hospital	https://clinicaltrials.gov/ct2/show/NCT06760637
NCT06760819	panSOHO	Phase 2	NOT_RECRUITING	NSW, QLD	2024-12-30	2025-02-13	2027-10-25	Sevabertinib	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent	Sevabertinib	EGFR/ERBB2_inhibitor,mutant-selective,non-covalent	22752	A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations	Advanced Solid Tumors; HER2 Mutation	2109 - Sydney - Macquarie University Hospital - Oncology Department; 2148 - Blacktown - Blacktown Cancer & Haematology Centre; 4215 - Southport - ICON Cancer Centre - Southport	https://clinicaltrials.gov/ct2/show/NCT06760819
NCT06764485	rechARge	Phase 3	RECRUITING	NSW, QLD, SA, TAS, VIC, WA	2025-01-02	2025-03-13	2029-01-19	Abiraterone; Abiraterone + Enzalutamide + Prednisolone + Prednisone; BMS-986365; Docetaxel; Docetaxel + Prednisolone; Enzalutamide; Prednisolone; Prednisone	glucocorticoid + taxane; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; taxane; CYP17A1_inhibitor; dual_AR_degrader_antagonist	Abiraterone + Enzalutamide + Prednisolone + Prednisone; BMS-986365; Docetaxel + Prednisolone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; dual_AR_degrader_antagonist; glucocorticoid + taxane	CA071-1000	A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge	Metastatic Castration-resistant Prostate Cancer	2010 - Darlinghurst - St Vincent's Hospital; 2076 - Wahroonga - Sydney Adventist Hospital; 2109 - Macquarie University - Macquarie University; 2444 - Port Macquarie - Port Macquarie - Mid North Coast Cancer Institute; 2560 - Campbelltown - GenesisCare - Campbelltown; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health; 3144 - Malvern - Cabrini Hospital - Malvern; 4120 - Greenslopes - Greenslopes Private Hospital - Gallipoli Medical Research Foundation; 4215 - Southport - Tasman Oncology Research; 5000 - Adelaide - Royal Adelaide Hospital; 5037 - Kurralta Park - ICON Cancer Centre - Kurralta Park; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6150 - Murdoch - St. John of God Murdoch Hospital; 7000 - Hobart - Icon Cancer Centre Hobart	https://clinicaltrials.gov/ct2/show/NCT06764485
NCT06764771	CA234-0001	Phase 1	RECRUITING	QLD	2025-01-03	2025-03-25	2027-10-15	Adagrasib; Adagrasib + BMS-986488; Adagrasib + BMS-986488 + Cetuximab; BMS-986488; BMS-986488 + Nivolumab; Cetuximab; Nivolumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib + BMS-986488; Adagrasib + BMS-986488 + Cetuximab; BMS-986488; BMS-986488 + Nivolumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CA234-0001	A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors	Advanced Malignant Tumors	4029 - Brisbane - Local Institution - 0031	https://clinicaltrials.gov/ct2/show/NCT06764771
NCT06764875	D702AC00001	Phase 3	RECRUITING	NSW, VIC, WA	2025-01-07	2025-03-01	2030-12-09	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Rilvegostomig + Trastuzumab; Capecitabine + Fluorouracil + Rilvegostomig + Trastuzumab Deruxtecan; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Rilvegostomig; Trastuzumab; Trastuzumab Deruxtecan	platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; Fluorouracil; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody; anti-ERBB2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Rilvegostomig + Trastuzumab; Capecitabine + Fluorouracil + Rilvegostomig + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	D702AC00001	A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)	HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	2010 - Darlinghurst - Research Site; 2145 - Westmead - Research Site; 3084 - Heidelberg - Research Site; 6150 - Murdoch - Research Site	https://clinicaltrials.gov/ct2/show/NCT06764875
NCT06770569	HRS-3802-101	Phase 1	RECRUITING	NSW, QLD, SA, VIC	2025-01-07	2025-01-21	2028-12	HRS-3802	unknown_drug_class	HRS-3802	unknown_drug_class	HRS-3802-101	Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors: a Single-arm, Open, Multicenter Phase I Study	Advanced Solid Tumors	2065 - Saint Leonards - GenesisCare North Shore (Oncology); 2109 - Sydney - Macquarie University Hospital; 3199 - Frankston - Peninsula and South Eastern Haematology & Oncology Group; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - GenesisCare St Andrews	https://clinicaltrials.gov/ct2/show/NCT06770569
NCT06780137	6070-002	Phase 1 / Phase 2	RECRUITING	QLD	2025-01-13	2025-02-27	2029-08-31	Durvalumab; Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	Durvalumab; Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	6070-002	A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	4102 - Wooloongabba - Princess Alexandra Hospital ( Site 5300)	https://clinicaltrials.gov/ct2/show/NCT06780137
NCT06780670	PSMAcTION	Phase 2 / Phase 3	RECRUITING	NSW, QLD	2025-01-16	2025-02-27	2033-04-11	225Ac-PSMA-617	radioligand,PSMA-targeting	225Ac-PSMA-617	radioligand,PSMA-targeting	CAAA817A12201	PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy	Prostate Cancer	2010 - Darlinghurst - Novartis Investigative Site; 4029 - Herston - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT06780670
NCT06784193	OP-3136-101	Phase 1	RECRUITING	SA	2025-01-14	2024-12-16	2027-08-30	Fulvestrant; Fulvestrant + OP-3136; OP-3136	KAT6_inhibitor + selective_estrogen_receptor_degrader; KAT6_inhibitor; selective_estrogen_receptor_degrader	Fulvestrant + OP-3136; OP-3136	KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader	OP-3136-101	A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Breast Cancer; Fulvestrant	5000 - Adelaide - Cancer Research South Australia	https://clinicaltrials.gov/ct2/show/NCT06784193
NCT06788990	FORTIFI-HN01	Phase 2 / Phase 3	RECRUITING	NSW, NZ, QLD, VIC, WA	2025-01-17	2025-01-28	2029-07	BCA101; Pembrolizumab; Placebo	placebo; anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein	Pembrolizumab; BCA101; Placebo	anti-PD-1_monoclonal_antibody; bifunctional_EGFR/TGF-beta_fusion_protein; placebo	BCA101X301	A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma	2050 - Camperdown - Site#0302; 2298 - Waratah - Site#0304; 2747 - Kingswood - Site #0306; 3010 - Rotorua - Site#0402; 3051 - North Melbourne - Site#0301; 3084 - Heidelberg - Site #0303; 4215 - Southport - Site #0305; 4224 - Tugun - Site#0307; 6150 - Murdoch - Site#0308	https://clinicaltrials.gov/ct2/show/NCT06788990
NCT06789172	INVOKE	Phase 1	RECRUITING	NSW, WA	2025-01-17	2025-01-23	2028-09	OKN4395; OKN4395 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; prostaglandin_EP2/EP4/DP1_receptor_inhibitor; anti-PD-1_monoclonal_antibody + prostaglandin_EP2/EP4/DP1_receptor_inhibitor	OKN4395; OKN4395 + Pembrolizumab	anti-PD-1_monoclonal_antibody + prostaglandin_EP2/EP4/DP1_receptor_inhibitor; prostaglandin_EP2/EP4/DP1_receptor_inhibitor	OKN-4395-121	A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors	Solid Tumours; Sarcoma; HNSCC; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; NSCLC; Pancreatic Adenocarcinoma; Colorectal Cancer (CRC); Myxofibrosarcoma (MFS); Solitary Fibrous Tumors; Dedifferentiated Liposarcoma; Undifferentiated Pleomorphic Sarcoma (UPS)	6009 - Perth - Linear Clinical Research; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT06789172
NCT06790693	INAVO123	Phase 3	RECRUITING	NSW, SA	2025-01-22	2025-04-09	2032-05-30	Inavolisib; Inavolisib + Letrozole; Letrozole; Placebo	placebo; aromatase_inhibitor; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	Inavolisib + Letrozole; Letrozole; Placebo	PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; placebo	WO45654	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer	Breast Cancer	2065 - St Leonards - Royal North Shore Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital	https://clinicaltrials.gov/ct2/show/NCT06790693
NCT06792695	CANTOR	Phase 2	RECRUITING	NSW, SA, VIC	2025-01-20	2025-03-12	2028-01-11	Bevacizumab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Volrustomig; Fluorouracil; Irinotecan; Leucovorin; Volrustomig	anti-VEGF_monoclonal_antibody; Fluorouracil; topoisomerase_inhibitor; bispecific_PD-L1/CTLA4_antibody; folinic_acid; anti-VEGF_monoclonal_antibody + bispecific_PD-L1/CTLA4_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Volrustomig	anti-VEGF_monoclonal_antibody + bispecific_PD-L1/CTLA4_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil	D798VC00001	A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)	Metastatic Colorectal Cancer	2500 - Wollongong - Research Site; 3002 - East Melbourne - Research Site; 5011 - Woodville South - Research Site	https://clinicaltrials.gov/ct2/show/NCT06792695
NCT06796907	BEHOLD-2	Phase 1 / Phase 2	RECRUITING	NSW	2025-01-22	2025-03-04	2028-04-05	GSK5733584	anti-B7H4_antibody-drug_conjugate	GSK5733584	anti-B7H4_antibody-drug_conjugate	223559	A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors	Tumours, Gynecological	2170 - Liverpool - GSK Investigational Site; 2500 - Wollongong - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06796907
NCT06797362	NVL-520-EAP		AVAILABLE	NSW, VIC	2025-01-22			Zidesamtinib	ROS1_inhibitor	Zidesamtinib	ROS1_inhibitor	NVL-520-EAP	Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors	Non Small Cell Lung Cancer; ROS1-positive Non-Small Cell Lung Cancer (NSCLC)	2050 - Camperdown - Chris O'Brien Lifehouse - (AVAILABLE); 3000 - Melbourne - Peter MacCallum Cancer Centre - (AVAILABLE)	https://clinicaltrials.gov/ct2/show/NCT06797362
NCT06801834	EVOKE-SCLC-04	Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2025-01-24	2025-04-04	2029-10	Amrubicin; Amrubicin + Topotecan; Sacituzumab Govitecan; Topotecan	anthracycline + topoisomerase_inhibitor; anti-Trop2_antibody-drug_conjugate; topoisomerase_inhibitor; anthracycline	Amrubicin + Topotecan; Sacituzumab Govitecan	anthracycline + topoisomerase_inhibitor; anti-Trop2_antibody-drug_conjugate	GS-US-600-6165	A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	2500 - New South Wales - Cancer Care Wollongong; 3065 - Fitzroy - St Vincent's Hospital Melbourne; 4006 - Queensland - Metro North HHS (The Prince Charles Hospital); 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT06801834
NCT06803680	BGB-B455-101	Phase 1	RECRUITING	NSW, QLD	2025-01-27	2025-03-18	2027-10-30	BGB-B455	bispecific_T-cell_engager,CLDN6-targeting	BGB-B455	bispecific_T-cell_engager,CLDN6-targeting	BGB-B455-101	A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor	NSW 2148 - Blacktown - Blacktown Cancer and Haematology Centre; NSW 2170 - Liverpool - Liverpool Hospital; QLD 4101 - South Brisbane - Mater Cancer Care Centre	https://clinicaltrials.gov/ct2/show/NCT06803680
NCT06804824	VVD-159642-01	Phase 1	RECRUITING	SA, WA	2025-01-27	2025-02-25	2027-08-01	Sotorasib; Sotorasib + VVD-159642; Trametinib; Trametinib + VVD-159642; VVD-159642	MEK_inhibitor; KRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; RAS-PI3Kalpha_inhibitor; MEK_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor	Sotorasib + VVD-159642; Trametinib + VVD-159642; VVD-159642	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; KRAS_G12C_inhibitor + RAS-PI3Kalpha_inhibitor; MEK_inhibitor + RAS-PI3Kalpha_inhibitor; RAS-PI3Kalpha_inhibitor	VVD-159642-01	A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors	Advanced Solid Tumors	5000 - Adelaide - Clinical Research South Australia (CRSA); 6009 - Nedlands - Linear Clinical	https://clinicaltrials.gov/ct2/show/NCT06804824
NCT06806852	1501-0002	Phase 1	RECRUITING	NSW, VIC	2025-01-28	2025-05-14	2028-03-30	BI 770371; BI 770371 + Cetuximab + Pembrolizumab; BI 770371 + Pembrolizumab; Cetuximab; Pembrolizumab	anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody	BI 770371 + Cetuximab + Pembrolizumab; BI 770371 + Pembrolizumab; Pembrolizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	1501-0002	A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)	Head and Neck Squamous Cell Carcinoma	2250 - Gosford - Gosford Hospital; 3220 - Geelong - Andrew Love Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06806852
NCT06806982	VRN101099-01	Phase 1	RECRUITING	NSW	2025-01-30	2025-02-17	2027-07-31	VRN101099	ERBB2_inhibitor,second_generation	VRN101099	ERBB2_inhibitor,second_generation	VRN101099_01	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors	HER2-positive Solid Tumors	2010 - Darlinghurst - St Vincent's Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT06806982
NCT06815575	RAC-010	Phase 1	RECRUITING	NSW	2025-02-03	2025-04-02	2029-01-31	Bisantrene; Bisantrene + Doxorubicin; Doxorubicin	doxorubicin; anthracycline; antimetabolite; anthracycline + antimetabolite	Bisantrene + Doxorubicin	anthracycline; anthracycline + antimetabolite; doxorubicin	RAC-010	A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.	Solid Tumours; Advanced Solid Tumours	2228 - Miranda - Cancer Care Foundation; 2250 - Gosford - Gosford Hospital; 2259 - Wyong - Wyong Hospital	https://clinicaltrials.gov/ct2/show/NCT06815575
NCT06816992	ORIC-114-05	Phase 1	RECRUITING	VIC	2025-02-06	2025-02-27	2027-05	Amivantamab; Amivantamab + ORIC-114; ORIC-114	EGFR_inhibitor,exon_20_selective; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; ERBB2_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; ERBB2_inhibitor,exon_20_selective	Amivantamab + ORIC-114	EGFR_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody; ERBB2_inhibitor,exon_20_selective + bispecific_cMET/EGFR_antibody	ORIC-114-05	Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC	Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC; EGFR-mutated NSCLC	03000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06816992
NCT06819735	DOMISOL	Phase 1 / Phase 2	RECRUITING	NSW, SA, VIC, WA	2025-02-06	2025-06-25	2028-01	DT-7012	anti-CCR8_monoclonal_antibody	DT-7012	anti-CCR8_monoclonal_antibody	DT-7012-CLI-001	A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)	Advanced Solid Tumors	2109 - North Ryde - Macquarie University Clinical Trial Unit; 3144 - Malvern - Cabrini Health Limited; 3199 - Frankston - Peninsula & South Eastern Haematology & Oncology Group; 5000 - Adelaide - Cancer Research SA; 6009 - Nedlands - One Clinical Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT06819735
NCT06820463	AndroMETa-CRC	Phase 2	RECRUITING	NSW, QLD, SA, VIC, WA	2025-02-06	2025-04-24	2028-04	Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Telisotuzumab adizutecan; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab; Fluorouracil + Leucovorin + Panitumumab + Telisotuzumab adizutecan; Leucovorin; Oxaliplatin; Panitumumab; Telisotuzumab adizutecan	anti-VEGF_monoclonal_antibody; Fluorouracil; folinic_acid; anti-EGFR_monoclonal_antibody + anti-cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; anti-EGFR_monoclonal_antibody; anti-cMET_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Telisotuzumab adizutecan; Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab; Fluorouracil + Leucovorin + Panitumumab + Telisotuzumab adizutecan	anti-EGFR_monoclonal_antibody + anti-cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	M24-533	A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2109 - Sydney - Macquarie University /ID# 271514; 3084 - Heidelberg - Austin Health /ID# 270692; 4101 - South Brisbane - Mater Hospital Brisbane /ID# 270694; 5011 - Woodville - The Queen Elizabeth Hospital /ID# 270693; 6009 - Nedlands - One Clinical Research /ID# 270695	https://clinicaltrials.gov/ct2/show/NCT06820463
NCT06824155	RAD202	Phase 1	RECRUITING	NSW, WA	2025-02-07	2025-02-12	2027-09	177Lu-RAD202	radioconjugate,ERBB2-targeting	177Lu-RAD202	radioconjugate,ERBB2-targeting	RAD202.2022.0002	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients With Advanced Solid Tumours	HER2 Gene Mutation; Advanced Solid Tumors	2747 - Kingswood - Nepean Hospital; 6150 - Murdoch - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT06824155
NCT06824467	2870-022	Phase 3	RECRUITING	NSW, QLD, VIC	2025-02-07	2025-04-09	2032-10-15	Bevacizumab; Bevacizumab + Dexamethasone + Sacituzumab tirumotecan; Dexamethasone; Sacituzumab tirumotecan	anti-VEGF_monoclonal_antibody; glucocorticoid; anti-Trop2_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + glucocorticoid; anti-Trop2_antibody-drug_conjugate	Bevacizumab; Bevacizumab + Dexamethasone + Sacituzumab tirumotecan	anti-Trop2_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody + glucocorticoid; anti-VEGF_monoclonal_antibody	2870-022	A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	2148 - Sydney - Blacktown Hospital ( Site 0211); 3002 - East Melbourne - Epworth Freemasons ( Site 0217); 3199 - Frankston - Frankston Hospital ( Site 0216); 4120 - Brisbane - Gallipoli Medical Research Ltd ( Site 0214)	https://clinicaltrials.gov/ct2/show/NCT06824467
NCT06830850	HRS-5041-103	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2025-02-12	2025-06-15	2027-03-15	HRS-5041	AR_PROTAC_degrader	HRS-5041	AR_PROTAC_degrader	HRS-5041-103	A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer	Adelaide - Cancer Research SA; Adelaide - Southern Oncology Clinical Research Unit; Brisbane - Icon Cancer Centre South Brisbane; Brisbane - John Flynn Private Hospital; Melbourne - Eastern Health (Box Hill Hospital); Perth - Linear Clinical Research Ltd; Sydney - GenesisCare North Shore (Oncology); Sydney - MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy; Sydney - Macquarie University; Sydney - Sydney Adventist Hospital; Wollongong - Illawarra Shoalhaven Local Health District (Wollongong Hospital)	https://clinicaltrials.gov/ct2/show/NCT06830850
NCT06834074	NVL-655-EAP		AVAILABLE	NSW, VIC	2025-02-11			NVL-655; NVL-655 + Neladalkib; Neladalkib	ALK_inhibitor,fourth_generation	NVL-655; NVL-655 + Neladalkib	ALK_inhibitor,fourth_generation	NVL-655-EAP	Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors	Non Small Cell Lung Cancer; ALK-positive Non-small Cell Lung Cancer (NSCLC)	2065 - St Leonards - Royal North Shore Hospital - (AVAILABLE); 3000 - Melbourne - Peter MacCallum Cancer Centre - (AVAILABLE)	https://clinicaltrials.gov/ct2/show/NCT06834074
NCT06840119	IMC-R117C-1004	Phase 1 / Phase 2	RECRUITING	VIC	2025-02-17	2024-01-10	2027-11-30	IMC-R117C	bispecific_T-cell_engager,PIWIL1-targeting	IMC-R117C	bispecific_T-cell_engager,PIWIL1-targeting	IMC-R117C-1004	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers	Cancer; HLA-A*02:01-positive	Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06840119
NCT06840483	Duravelo-3	Phase 2	RECRUITING	VIC	2025-02-18	2025-03-03	2028-12-30	BT8009	bicycle_toxin_conjugate,NECTIN4-targeting	BT8009	bicycle_toxin_conjugate,NECTIN4-targeting	BT8009-201 (Duravelo-3)	Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer	Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT06840483
NCT06841055	BNT327-07	Phase 2	RECRUITING	SA, South Austraila	2025-02-20	2025-03-03	2028-10	BNT327; BNT327 + Docetaxel; Docetaxel	bispecific_PD-L1/VEGFA_antibody + taxane; bispecific_PD-L1/VEGFA_antibody; taxane	BNT327 + Docetaxel	bispecific_PD-L1/VEGFA_antibody + taxane	BNT327-07	A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell Lung Cancer (NSCLC) Following Chemoimmunotherapy	Non-small Cell Lung Cancer	5000 - Adelaide - Cancer Research SA (CRSA)	https://clinicaltrials.gov/ct2/show/NCT06841055
NCT06841354	2870-011	Phase 3	RECRUITING	NZ	2025-02-18	2025-03-16	2030-05-18	Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	gemcitabine; taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Pembrolizumab + Sacituzumab tirumotecan; Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine	2870-011	A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)	Triple Negative Breast Neoplasms	1023 - Newmarket - Harbour Cancer & Wellness ( Site 5600)	https://clinicaltrials.gov/ct2/show/NCT06841354
NCT06855277	AcTFirst	Phase 3	RECRUITING	NSW, SA	2025-02-26	2025-07-01	2032-11-04	225Ac-PSMA-617; Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; radioligand,PSMA-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; 225Ac-PSMA-617	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; radioligand,PSMA-targeting	CAAA817B12301	A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer	Prostate Cancer	2010 - Darlinghurst - Novartis Investigative Site; 5000 - Adelaide - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT06855277
NCT06855771	CA240-0009	Phase 2	RECRUITING	NSW, QLD, SA	2025-02-27	2025-09-15	2031-12-30	BMS-986504	PRMT5_inhibitor,MTA-co-operative	BMS-986504	PRMT5_inhibitor,MTA-co-operative	CA240-0009	A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown - Local Institution - 0059; 2560 - Campbelltown - GenesisCare - Campbelltown; 4102 - Woolloongabba - Princess Alexandra Hospital; 5000 - Adelaide - GenesisCare - St Andrew's	https://clinicaltrials.gov/ct2/show/NCT06855771
NCT06863272	2400-01A	Phase 1 / Phase 2	RECRUITING	NSW, NZ	2025-03-03	2025-07-03	2030-02-24	Abiraterone; Abiraterone + Enzalutamide + Ifinatamab Deruxtecan; Docetaxel; Enzalutamide; Ifinatamab Deruxtecan; Ifinatamab Deruxtecan + Opevesostat; Opevesostat	antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor + anti-B7H3_antibody-drug_conjugate + antiandrogen,nonsteroidal,second_generation; CYP11A1_inhibitor + anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate; CYP17A1_inhibitor; CYP11A1_inhibitor	Abiraterone + Enzalutamide + Ifinatamab Deruxtecan; Docetaxel; Ifinatamab Deruxtecan; Ifinatamab Deruxtecan + Opevesostat	CYP11A1_inhibitor + anti-B7H3_antibody-drug_conjugate; CYP17A1_inhibitor + anti-B7H3_antibody-drug_conjugate + antiandrogen,nonsteroidal,second_generation; anti-B7H3_antibody-drug_conjugate; taxane	2400-01A	MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)	Castration-Resistant Prostatic Cancer; Metastasis	1023 - Auckland - Auckland City Hospital ( Site 0831); 2109 - Macquarie University - Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)	https://clinicaltrials.gov/ct2/show/NCT06863272
NCT06868199	LM168-01-101	Phase 1 / Phase 2	RECRUITING	NSW, WA	2025-03-04	2025-05-06	2028-02-01	LM-168; LM-168 + Toripalimab; Toripalimab	unknown_drug_class; anti-PD-1_monoclonal_antibody + unknown_drug_class; anti-PD-1_monoclonal_antibody	LM-168; LM-168 + Toripalimab	anti-PD-1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	LM168-01-101	A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours	Advanced Solid Tumours	2109 - Ryde - MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy; 2109 - Ryde - Macquarie University; 6009 - Perth - Bayview Health-Investigational Drug Services; 6009 - Perth - One Clinical Reasearch; Wollongong - Cancer Care Wollongong Pty Limited	https://clinicaltrials.gov/ct2/show/NCT06868199
NCT06868277	ARTEMIDELung04	Phase 3	RECRUITING	QLD, TAS	2025-03-07	2025-04-10	2030-12-02	Pembrolizumab; Rilvegostomig	bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody	D702GC00001	A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)	Carcinoma, Non-Small Cell Lung	4102 - Woolloongabba - Research Site; 7000 - Hobart - Research Site	https://clinicaltrials.gov/ct2/show/NCT06868277
NCT06875310	CA239-0004	Phase 3	RECRUITING	ACT, NSW, QLD, SA, VIC, WA	2025-03-07	2025-04-24	2032-04-30	Adagrasib; Adagrasib + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Placebo	platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; antimetabolite	Adagrasib + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	CA239-0004	A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)	Carcinoma, Non-Small-Cell Lung	2340 - North Tamworth - Tamworth Hospital; 2605 - Canberra - Canberra Hospital; 2800 - Orange - Orange Hospital; 3076 - Melbourne - Northern Hospital; 3199 - Frankston - Frankston Hospital; 3844 - Traralgon - Latrobe Regional Health; 4102 - Brisbane - Princess Alexandra Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6027 - Joondalup - Joondalup Health Campus	https://clinicaltrials.gov/ct2/show/NCT06875310
NCT06879041	D7580C00001	Phase 1	RECRUITING	VIC	2025-03-11	2025-03-10	2029-04-16	225Ac-AZD2284	radioligand,PSMA-targeting	225Ac-AZD2284	radioligand,PSMA-targeting	D7580C00001	A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT06879041
NCT06884618	YO45758	Phase 1	RECRUITING	NZ, VIC	2025-03-18	2025-04-30	2029-05-25	RO7673396	pan-KRAS_inhibitor	RO7673396	pan-KRAS_inhibitor	YO45758	A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)	Neoplasms	1010 - Auckland - New Zealand Clinical Research - Auckland; 3052 - Parkville - Peter MacCallum Cancer Center; 8011 - Christchurch - New Zealand Clinical Research - Christchurch	https://clinicaltrials.gov/ct2/show/NCT06884618
NCT06885034	NCT06885034	Phase 1 / Phase 2	RECRUITING	VIC	2025-03-13	2025-06-11	2028-06-23	GSK5764227	anti-B7H3_antibody-drug_conjugate	GSK5764227	anti-B7H3_antibody-drug_conjugate	223675	A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors	Gastrointestinal Neoplasms	3000 - Melbourne - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT06885034
NCT06892548	2024-520238-31-00--BNT324-01	Phase 1	RECRUITING	VIC	Help: Date registered 2025-03-24	2025-05-02		BNT327; BNT327 + DB-1311; DB-1311	anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody; anti-B7H3_antibody-drug_conjugate; bispecific_PD-L1/VEGFA_antibody	BNT327 + DB-1311	anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody	2024-520238-31-00  BNT324-01	A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer	Advanced Lung Cancer	3021 - Saint Albans	https://clinicaltrials.gov/ct2/show/NCT06892548
NCT06897735	EDDIS-a1	Phase 1	NOT_YET_RECRUITING	NZ	2025-03-26	2025-08-25	2026-03-25	Afatinib	ERBB2_inhibitor,second_generation; EGFR_inhibitor,second_generation	Afatinib	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	233-1-10AfD	A Phase I Pilot Study to Evaluate the Bioequivalence, Pharmacokinetics, and Safety of Inhaled Afatinib Dimaleate Compared to the Reference Oral Afatinib Dimaleate in Healthy Smoking Volunteers (EDDIS-a1)	Lung Cancer; Oral Cancer; Melanoma	Auckland - Central Contact	https://clinicaltrials.gov/ct2/show/NCT06897735
NCT06898450	9216-101	Phase 1 / Phase 2	RECRUITING	NSW, SA	2025-03-25	2025-03-31	2031-12	NDI-219216	WRN_inhibitor	NDI-219216	WRN_inhibitor	9216-101	A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair	Advanced Solid Tumors Cancer; MSI-H Cancer	2170 - Liverpool - Liverpool Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT06898450
NCT06905197	DZ2023C0001	Phase 1	RECRUITING	NSW	2025-03-25	2025-05-13	2028-12	DZD6008	EGFR_inhibitor,fourth_generation	DZD6008	EGFR_inhibitor,fourth_generation	DZ2023C0001	A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)	Non Small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2148 - Blacktown - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT06905197
NCT06907043	EIK1004-001	Phase 1 / Phase 2	RECRUITING	VIC	2025-03-31	2025-04-30	2028-12	EIK1004	PARP1-selective_inhibitor	EIK1004	PARP1-selective_inhibitor	EIK1004-001(IMP1707-101)	A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors	Advanced Solid Tumors	3199 - Frankston - PASO Medical	https://clinicaltrials.gov/ct2/show/NCT06907043
NCT06909825	FPI-2265-203	Phase 2	ACTIVE_NOT_RECRUITING	NSW, QLD, SA, VIC	2025-03-27	2025-02-26	2030-08-12	225Ac-PSMA-I&T; 225Ac-PSMA-I&T + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + radioligand,PSMA-targeting; radioligand,PSMA-targeting	225Ac-PSMA-I&T + Olaparib	PARP_inhibitor + radioligand,PSMA-targeting	FPI-2265-203	A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	2113 - Macquarie Park - Macquarie University Hospital; 3000 - Melbourne - Peter MacCallum Cancer Center; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - Icon Cancer Centre Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT06909825
NCT06910657	VM-002-101	Phase 1	RECRUITING	NSW, VIC	2025-03-27	2025-08-25	2027-05-31	IDOV-Immune	oncolytic_virus,undisclosed_mechanism	IDOV-Immune	oncolytic_virus,undisclosed_mechanism	VM-002-101	A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors	Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors	2065 - Saint Leonards - Royal North Shore Hospital; 2145 - Westmead - Westmead Hospital; 3004 - Melbourne - The Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT06910657
NCT06914128	NCT06914128	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2025-03-31	2025-03-21	2029-06-17	BAY3713372	PRMT5_inhibitor	BAY3713372	PRMT5_inhibitor	22931	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.	MTAP-deleted Solid Tumors	2050 - Camperdown - Chris O'Brien Lifehouse; 2139 - Concord - Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre; 3076 - Epping - Northern Hospital	https://clinicaltrials.gov/ct2/show/NCT06914128
NCT06921785	ARTEMIDE-HCC01	Phase 3	RECRUITING	NSW, QLD, VIC	2025-04-03	2025-05-06	2030-03-14	Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Bevacizumab + Rilvegostomig; Bevacizumab + Rilvegostomig + Tremelimumab; Rilvegostomig; Tremelimumab	anti-VEGF_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-VEGF_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody; bispecific_PD-1/TIGIT_antibody; anti-CTLA4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody	Atezolizumab + Bevacizumab; Bevacizumab + Rilvegostomig; Bevacizumab + Rilvegostomig + Tremelimumab	anti-CTLA4_monoclonal_antibody + anti-VEGF_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody	D7029C00001	A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	2050 - Camperdown - Research Site; 3084 - Heidelberg - Research Site; 4066 - Auchenflower - Research Site	https://clinicaltrials.gov/ct2/show/NCT06921785
NCT06921837	BBI-4182-101	Phase 1 / Phase 2	RECRUITING	NSW, QLD, VIC	2025-04-04	2025-05-26	2029-05	BDC-4182	anti-CLDN18.2_immune-stimulating_antibody_conjugate,TLR7/8_agonist	BDC-4182	anti-CLDN18.2_immune-stimulating_antibody_conjugate,TLR7/8_agonist	BBI-4182-101	A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer	Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma	Birtinya - AUS Site 1; Darlinghurst - AUS Site 2; Heidelberg - AUS Site 3	https://clinicaltrials.gov/ct2/show/NCT06921837
NCT06923761	EMITT-1	Phase 1 / Phase 2	RECRUITING	NSW, QLD, SA, VIC	2025-04-04	2023-05-21	2028-04-30	Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies	Advanced Solid Malignancy	Adelaide - GenesisCare Research; Bedford Park - Southern Oncology Clinical Research Unit (SOCRU); Blacktown - Blacktown Hospital; Darlinghurst - Kinghorn Cancer Centre (KCC); Heidelberg - Austin Health; Melbourne - Alfred Health; South Brisbane - Mater Research; Wollongong - Cancer Care Wollongong	https://clinicaltrials.gov/ct2/show/NCT06923761
NCT06925737	2400-001	Phase 3	RECRUITING	NSW, QLD, VIC	2025-04-07	2025-05-13	2031-01-06	Docetaxel; Docetaxel + Prednisone; Ifinatamab Deruxtecan; Prednisone	anti-B7H3_antibody-drug_conjugate; glucocorticoid + taxane; glucocorticoid; taxane	Docetaxel + Prednisone; Ifinatamab Deruxtecan	anti-B7H3_antibody-drug_conjugate; glucocorticoid + taxane	2400-001	A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)	Prostate Cancer; Prostatic Neoplasms	2148 - Blacktown - Blacktown Hospital ( Site 0154); 3000 - Melbourne - Peter MacCallum Cancer Centre ( Site 0152); 4120 - Greenslopes - Gallipoli Medical Research Ltd ( Site 0153)	https://clinicaltrials.gov/ct2/show/NCT06925737
NCT06926075	ADVICE	Phase 1	NOT_YET_RECRUITING		Help: Date registered 2025-04-13			Kesonotide	hGIIA-vimentin_inhibitor	Kesonotide	hGIIA-vimentin_inhibitor	FLM-CT002	An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours	Lung Cancers; Breast Cancer; Pancreas Cancer; Glioblastoma Multiforme (GBM); Skin Cancer; Prostate Cancers; Ovarian Cancer		https://clinicaltrials.gov/ct2/show/NCT06926075
NCT06926868	CA244-0008	Phase 2 / Phase 3	RECRUITING	QLD, VIC, WA	2025-04-08	2025-07-15	2030-05-15	Capecitabine; Capecitabine + Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Carboplatin; Gemcitabine; Izalontamab Brengitecan; Nab-paclitaxel; Paclitaxel	bispecific_EGFR/ERBB3_antibody; gemcitabine; taxane; platinum-based_antineoplastic_agent; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; fluoropyrimidine	Capecitabine + Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel; Izalontamab Brengitecan	antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; bispecific_EGFR/ERBB3_antibody; gemcitabine	CA244-0008	A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment	Breast Neoplasms	3000 - Melbourne - Local Institution - 0274; 3084 - Heidelberg - Local Institution - 0031; 3350 - Ballarat Central - Local Institution - 0197; 4029 - Brisbane - Local Institution - 0035; 6008 - Subiaco - Local Institution - 0028	https://clinicaltrials.gov/ct2/show/NCT06926868
NCT06926920	GS-US-576-7321	Phase 1 / Phase 2	RECRUITING	NSW	2025-04-08	2025-04-30	2028-06	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	GS-US-576-7321	A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst - St. Vincent's Hospital - Kinghorn Cancer Center	https://clinicaltrials.gov/ct2/show/NCT06926920
NCT06929663	AK146D1-102	Phase 1	RECRUITING	NSW	2025-04-08	2025-07-02	2027-05-05	AK146D1	bispecific_Trop2/Nectin4_antibody-drug_conjugate	AK146D1	bispecific_Trop2/Nectin4_antibody-drug_conjugate	AK146D1-102	A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 for Injection, an Anti-Trop2/Nectin4 Bispecific Antibody-drug Conjugate, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Sydney - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT06929663
NCT06952504	TroFuse-033	Phase 3	RECRUITING	NSW, VIC	2025-04-23	2025-05-22	2032-05-24	Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Sacituzumab tirumotecan; Docetaxel; Paclitaxel; Pembrolizumab; Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent + taxane; taxane; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2870-033	A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)	Endometrial Cancer	2148 - Blacktown - Blacktown Hospital ( Site 0201); 3002 - Melbourne - Epworth Freemasons ( Site 0207)	https://clinicaltrials.gov/ct2/show/NCT06952504
NCT06953089	DB-1311-201	Phase 2	RECRUITING	NSW, QLD, SA	2025-04-23	2025-07-18	2030-06-30	BNT325; BNT325 + DB-1311; BNT327; BNT327 + DB-1311; DB-1311	anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody; anti-B7H3_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + anti-Trop2_antibody-drug_conjugate; bispecific_PD-L1/VEGFA_antibody	BNT325 + DB-1311; BNT327 + DB-1311	anti-B7H3_antibody-drug_conjugate + anti-Trop2_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + bispecific_PD-L1/VEGFA_antibody	DB-1311-201	A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors	Solid Tumors	2060 - North Sydney - AUS07-0; 4217 - Benowa - AUS06-0; 4575 - Birtinya - AUS04-0; 5000 - Adelaide - AUS05-0	https://clinicaltrials.gov/ct2/show/NCT06953089
NCT06956690	ENV-ONC-501	Phase 1 / Phase 2	RECRUITING	NSW	2025-05-01	2025-09	2027-07	ENV-501	anti-ERBB3_antibody-drug_conjugate	ENV-501	anti-ERBB3_antibody-drug_conjugate	ENV-ONC-501	A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors	Melanoma (Skin); Non Small Cell Lung Cancer; Breast Cancer	2228 - Miranda - Research Site; 2560 - Campbelltown - Research Site	https://clinicaltrials.gov/ct2/show/NCT06956690
NCT06960395	VIR-5525-V101	Phase 1	RECRUITING	NSW, QLD	2025-04-28	2025-07-22	2029-08	Pembrolizumab; Pembrolizumab + VIR-5525; VIR-5525	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting; bispecific_T-cell_engager,EGFR-targeting	Pembrolizumab + VIR-5525; VIR-5525	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting; bispecific_T-cell_engager,EGFR-targeting	VIR-5525-V101	A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Solid Tumor Malignancies; EGFR Positive Solid Tumors; EGFR	2500 - Wollongong - Wollongong Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT06960395
NCT06961006	V940-012	Phase 2	RECRUITING	NSW, NZ, WA	2025-04-29	2025-05-29	2031-09-05	Pembrolizumab; Pembrolizumab + mRNA-4157; Placebo; mRNA-4157	placebo; mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine	Pembrolizumab; Pembrolizumab + mRNA-4157; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; placebo	V940-012	A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)	Malignant Melanoma	1023 - Auckland - Harbour Cancer & Wellness ( Site 3040); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 2000); 2148 - Blacktown - Blacktown Hospital ( Site 2001); 6009 - Nedlands - One Clinical Research ( Site 2002)	https://clinicaltrials.gov/ct2/show/NCT06961006
NCT06973863	PEP08-101	Phase 1	NOT_YET_RECRUITING	NSW	2025-05-07	2025-09-15	2028-03	PEP08	PRMT5_inhibitor	PEP08	PRMT5_inhibitor	PEP08-101	A Phase 1a/1b Study Evaluating the Clinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Efficacy of PEP08 as Monotherapy and Combination Therapy in MTAP-Del Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Solid Tumors; MTAP-deleted Solid Tumors; MTAP Deletion	2145 - Wentworthville - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT06973863
NCT06974110	MOMA-341-001	Phase 1	RECRUITING	NSW, QLD, SA, VIC, WA	2025-05-07	2025-07-16	2028-05	Irinotecan; Irinotecan + MOMA-341; MOMA-341	topoisomerase_inhibitor; WRN_inhibitor; WRN_inhibitor + topoisomerase_inhibitor	Irinotecan + MOMA-341; MOMA-341	WRN_inhibitor; WRN_inhibitor + topoisomerase_inhibitor	MOMA-341-001	A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor; Metastatic Solid Tumor; Endometrial Cancer; MSI-H Cancer; Colorectal Cancer; Gastric Cancer; dMMR Cancer	Adelaide - Investigative Site #125; Clayton - Investigative Site #126; Perth - Investigative Site #119; Sydney - Investigative Site #122; Westmead - Investigative Site #123; Woolloongabba - Investigative Site #124	https://clinicaltrials.gov/ct2/show/NCT06974110
NCT06989112	DE-01	Phase 3	RECRUITING	NSW, QLD, VIC, WA	2025-05-15	2025-03-27	2031-02-19	Carboplatin; Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Docetaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Trastuzumab Deruxtecan; Rilvegostomig; Rilvegostomig + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; taxane; platinum-based_antineoplastic_agent; bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab; Pembrolizumab + Trastuzumab Deruxtecan; Rilvegostomig + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + bispecific_PD-1/TIGIT_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	D781DC00001	DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer	Endometrial Cancer	2148 - Blacktown - Research Site; 3002 - East Melbourne - Research Site; 4101 - South Brisbane - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT06989112
NCT06991556	CJSB462C12201	Phase 2	RECRUITING	SA, VIC	2025-05-23	2025-07-07	2035-09-08	Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone; Abiraterone + Enzalutamide	CYP17A1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	CJSB462C12201	A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Metastatic Hormone-sensitive Prostate Cancer	3168 - Clayton - Novartis Investigative Site; 5000 - Adelaide - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT06991556
NCT06997497	MK-1084-012--1084-012	Phase 3	RECRUITING	QLD	Help: Date registered 2025-05-30	2025-07-16		Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Cetuximab; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin; Fluorouracil; Leucovorin; MK-1084; Oxaliplatin	anti-VEGF_monoclonal_antibody; Fluorouracil; folinic_acid; anti-EGFR_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor; fluoropyrimidine; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin	KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil	MK-1084-012  1084-012	A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)	Rectal Adenocarcinoma; Colon Adenocarcinoma	4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT06997497
NCT07000149	eVOLVE-RCC02	Phase 3	RECRUITING	QLD, SA, VIC, WA	2025-05-23	2025-07-28	2032-07-29	AB-521; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Volrustomig	bispecific_PD-L1/CTLA4_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA4_monoclonal_antibody; anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	Ipilimumab + Nivolumab; Volrustomig; AB-521	anti-CTLA4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; bispecific_PD-L1/CTLA4_antibody; HIF2a_inhibitor	D798NC00001	A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Advanced Clear Cell Renal Cell Carcinoma	3002 - East Melbourne - Research Site; 4032 - Syndey - Research Site; 5000 - North Adelaide - Research Site; 5112 - Elizabeth Vale - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT07000149
NCT07005102	M25-287	Phase 2 / Phase 3	RECRUITING	SA, VIC, WA	2025-05-27	2025-08-03	2031-12	Osimertinib; Osimertinib + Telisotuzumab adizutecan; Telisotuzumab adizutecan	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-cMET_antibody-drug_conjugate; anti-cMET_antibody-drug_conjugate	Osimertinib; Osimertinib + Telisotuzumab adizutecan	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-cMET_antibody-drug_conjugate	M25-287	A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer	Non-Squamous Non-Small Cell Lung Cancer	3084 - Heidelberg - Austin Health /ID# 275505; 5011 - Woodville - The Queen Elizabeth Hospital /ID# 275719; 6150 - Murdoch - St John Of God Murdoch Hospital /ID# 275700	https://clinicaltrials.gov/ct2/show/NCT07005102
NCT07005128	DeLLphi-312	Phase 3	RECRUITING	NSW, VIC	2025-05-27	2025-08-18	2029-07-15	Carboplatin; Carboplatin + Durvalumab + Etoposide; Carboplatin + Durvalumab + Etoposide + Tarlatamab; Durvalumab; Etoposide; Tarlatamab	platinum-based_antineoplastic_agent; bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Carboplatin + Durvalumab + Etoposide; Carboplatin + Durvalumab + Etoposide + Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	20240178	A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)	Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT07005128
NCT07016490	SSGJ-709-101	Phase 1	RECRUITING	VIC	2025-06-04	2025-06-06	2027-12-30	SSGJ-709	bispecific_PD-1/LAG3_antibody	SSGJ-709	bispecific_PD-1/LAG3_antibody	SSGJ-709-101	A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors	Adelaide - Southern Oncology Clinical Research Unit (SOCRU)	https://clinicaltrials.gov/ct2/show/NCT07016490
NCT07023627	INCB123667-203	Phase 2	RECRUITING	NSW, SA, TAS	2025-06-09	2025-09-30	2027-10-24	INCB123667	CDK2_inhibitor	INCB123667	CDK2_inhibitor	INCB123667-203	A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression	Ovarian Cancer	02139 - Concord - Concord General Repatriation Hospital; 02148 - Blacktown - Blacktown Cancer & Haematology Centre-Blacktown Hospital; 05000 - Adelaide - Cancer Research Sa (Crsa); 05042 - South Australia - Southern Oncology Clinical Research Unit; 05065 - Adelaide - Burnside War Memorial Hospital - the Brian Fricker Oncology Centre; 07000 - Hobart - Hobart Hospital-Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT07023627
NCT07026279	AMP945-PC-202	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2025-06-10	2025-08-18	2029-07	Narmafotinib	FAK_inhibitor	Narmafotinib	FAK_inhibitor	AMP945-PC-202	A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients	Pancreatic Cancer Metastatic	2065 - St Leonards - GenesisCare; 3121 - Richmond - Epworth Healthcare	https://clinicaltrials.gov/ct2/show/NCT07026279
NCT07042100	SBO-154-25-01	Phase 1	RECRUITING	QLD	2025-06-19	2025-07-17	2030-08	SBO-154	anti-MUC1_antibody-drug_conjugate	SBO-154	anti-MUC1_antibody-drug_conjugate	SBO-154-25-01	A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4557 - Birtinya - SPARC Investigative Site	https://clinicaltrials.gov/ct2/show/NCT07042100
NCT07044336	D6900C00003	Phase 3	RECRUITING	NSW, VIC	2025-06-23	2025-08-01	2028-04-03	Doxorubicin; Doxorubicin + Paclitaxel; Paclitaxel; Puxitatug samrotecan	doxorubicin; anti-B7H4_antibody-drug_conjugate; anthracycline + taxane; taxane	Doxorubicin + Paclitaxel; Puxitatug samrotecan	anthracycline + taxane; anti-B7H4_antibody-drug_conjugate; doxorubicin	D6900C00003	Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)	Endometrial Cancer; Malignant Solid Tumour	2031 - Randwick - Research Site; 2145 - Westmead - Research Site; 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT07044336
NCT07047118	CJSB462B12201	Phase 2	RECRUITING	NSW, SA, VIC	2025-06-23	2025-07-03	2028-12-11	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	CJSB462B12201	A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)	Prostatic Cancer, Castration-Resistant	2010 - Darlinghurst - Novartis Investigative Site; 3004 - Melbourne - Novartis Investigative Site; 5000 - Adelaide - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT07047118
NCT07063745	MountainTAP-29	Phase 2 / Phase 3	RECRUITING	ACT, NSW, QLD, SA, TAS, VIC	2025-07-03	2025-10-06	2031-08-12	BMS-986504; BMS-986504 + Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin; Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	PRMT5_inhibitor,MTA-co-operative; taxane; platinum-based_antineoplastic_agent; placebo; PRMT5_inhibitor,MTA-co-operative + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	BMS-986504 + Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab + Pemetrexed; Placebo	PRMT5_inhibitor,MTA-co-operative + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; placebo	CA240-0029	A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion	Metastatic Non-small Cell Lung Cancer With MTAP Deletion	2170 - Liverpool - Local Institution - 0432; 3350 - Ballarat Central - Local Institution - 0367; 4575 - Birtinya - Local Institution - 0382; 5112 - Elizabeth Vale - Local Institution - 0381; 7000 - Hobart - Local Institution - 0431; ACT 2605 - Garran - Local Institution - 0368; QLD 4102 - Woolloongabba - Local Institution - 0373	https://clinicaltrials.gov/ct2/show/NCT07063745
NCT07063875	SILVER	Phase 1 / Phase 2	RECRUITING	NSW, VIC	2025-07-02	2025-06-01	2027-09	Aldesleukin; Tebentafusp	IL-2_variant; bispecfic_T-cell_engager,gp100-targeting	Aldesleukin; Tebentafusp	IL-2_variant; bispecfic_T-cell_engager,gp100-targeting	SILVER Trial	Supplementing With IL-2 to Verifiably eRadicate Radiological Progression	Uveal Melanoma; Metastatic Uveal Melanoma; Metastatic Uveal Melanoma in the Liver	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital; 3004 - Melbourne - Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT07063875
NCT07076121	CA240-0030	Phase 2 / Phase 3	RECRUITING	NSW, QLD, SA, VIC, WA	2025-07-14	2025-11-03	2029-05-03	BMS-986504; BMS-986504 + Gemcitabine + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Placebo	PRMT5_inhibitor,MTA-co-operative; gemcitabine; taxane; placebo; antimetabolite + taxane; PRMT5_inhibitor,MTA-co-operative + antimetabolite + taxane; antimetabolite	BMS-986504 + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	PRMT5_inhibitor,MTA-co-operative + antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo	CA240-0030	A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Pancreatic Ductal Adenocarcinoma	2065 - St Leonards - Local Institution - 0227; 3076 - Melbourne - Local Institution - 0231; 3144 - Malvern - Local Institution - 0232; 4029 - Brisbane - Local Institution - 0228; 4102 - Brisbane - Local Institution - 0226; 5011 - Woodville - Local Institution - 0229; 6150 - Murdoch - Local Institution - 0230	https://clinicaltrials.gov/ct2/show/NCT07076121
NCT07076550	A9-3408-01	Phase 1	NOT_YET_RECRUITING	VIC, WA	2025-07-11	2025-08	2028-01	225Ac-A9-3408	radioligand,unknown-target	225Ac-A9-3408	radioligand,unknown-target	A9-3408-01	A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of [225Ac]Ac-A9-3408 in Subjects With Unresectable or Metastatic Melanoma	Melanoma Metastatic; Uveal Melanoma, Metastatic; Mucosal Melanoma	3004 - Melbourne - Alfred Health; 6150 - Murdoch - Fiona Stanley Hospital; 6150 - Murdoch - GenesisCare Murdoch	https://clinicaltrials.gov/ct2/show/NCT07076550
NCT07085767	OPERA-02	Phase 3	NOT_YET_RECRUITING	SA, VIC, WA	Help: Date registered 2025-07-25			Letrozole; Letrozole + Palazestrant + Ribociclib; Palazestrant; Placebo; Ribociclib	placebo; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor; complete_estrogen_receptor_antagonist	Letrozole + Palazestrant + Ribociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + complete_estrogen_receptor_antagonist; placebo	OPERA-02  OP-1250-302	A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)	HER2 Negative Breast Carcinoma; Metastatic Breast Cancer; ER Positive Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer	6009 - Nedlands; 5000 - Adelaide; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT07085767
NCT07086105	ADZE1.C-001	Phase 1	NOT_YET_RECRUITING	QLD, SA	2025-07-18	2025-09-01	2027-07-01	Adze1.C	oncolytic_virus,CD40L-payload	Adze1.C	oncolytic_virus,CD40L-payload	ADZE1.C-001	A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Preliminary Efficacy of Intratumoural Adze1.C in Participants With Metastatic Melanoma	Metastatic Melanoma	4215 - Southport - Tasman Oncology Research; 5011 - Adelaide - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT07086105
NCT07090369	LumOnate	Phase 1	NOT_YET_RECRUITING	VIC	2025-07-24	2025-11-01	2028-12-01	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Olaparib + Pembrolizumab; Olaparib; Pembrolizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; radioconjugate,PSMA-targeting; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan + Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radioconjugate,PSMA-targeting	24/186	Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT07090369
NCT07094113	NCT07094113	Phase 1	RECRUITING	VIC	2025-07-23	2025-07-31	2030-09-09	AMG 410; AMG 410 + Panitumumab; AMG 410 + Pembrolizumab; Panitumumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + pan-KRAS_inhibitor; pan-KRAS_inhibitor; anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; anti-EGFR_monoclonal_antibody	AMG 410; AMG 410 + Panitumumab; AMG 410 + Pembrolizumab	anti-EGFR_monoclonal_antibody + pan-KRAS_inhibitor; anti-PD-1_monoclonal_antibody + pan-KRAS_inhibitor; pan-KRAS_inhibitor	20240031	A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors	KRAS Altered Advanced or Metastatic Solid Tumors	3050 - Parkville - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT07094113
NCT07098338	LIBRA	Phase 2	NOT_YET_RECRUITING	SA, WA	2025-07-25	2025-08-08	2029-04-09	Datopotamab deruxtecan; Datopotamab deruxtecan + Ramucirumab + Rilvegostomig; Ramucirumab; Ramucirumab + Rilvegostomig; Rilvegostomig	anti-Trop2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody; anti-VEGFR2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody; anti-VEGFR2_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate + anti-VEGFR2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody	Datopotamab deruxtecan + Ramucirumab + Rilvegostomig; Ramucirumab + Rilvegostomig	anti-Trop2_antibody-drug_conjugate + anti-VEGFR2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody; anti-VEGFR2_monoclonal_antibody + bispecific_PD-1/TIGIT_antibody	D6187C00001	An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)	Non-Small Cell Lung Cancer	5011 - Woodville - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT07098338
NCT07099898	NCT07099898	Phase 3	RECRUITING	NSW	2025-07-30	2025-08-11	2028-09-11	GSK5764227; Topotecan	anti-B7H3_antibody-drug_conjugate; topoisomerase_inhibitor	GSK5764227; Topotecan	anti-B7H3_antibody-drug_conjugate; topoisomerase_inhibitor	223674	Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)	Neoplasms, Lung	2065 - St Leonards - GSK Investigational Site; 2148 - Blacktown - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT07099898
NCT07100730	IPAX-BrIGHT	Phase 3	NOT_YET_RECRUITING	QLD	2025-07-27	2025-09-01	2027-11	131I-IPA; Lomustine	radioiodine_conjugate; alkylating_agent	Lomustine; 131I-IPA	alkylating_agent; radioiodine_conjugate	131I-TLX-101-003	A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])	Neoplastic Disease; Glioblastoma; Glioblastoma (GBM); Glioblastoma Multiform; Glioblastoma Multiforme, Adult; Glioblastoma Multiforme (GBM) WHO Grade IV	Gold Coast - Gold Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT07100730
NCT07106762	CA244-0012	Phase 2 / Phase 3	NOT_YET_RECRUITING	NSW, VIC	2025-08-05	2025-10-22	2033-11-18	Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Gemcitabine; Izalontamab Brengitecan	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; bispecific_EGFR/ERBB3_antibody; gemcitabine	Carboplatin + Cisplatin + Gemcitabine; Izalontamab Brengitecan	antimetabolite + platinum-based_antineoplastic_agent; bispecific_EGFR/ERBB3_antibody; gemcitabine	CA244-0012	IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment	Urothelial Cancer	2065 - St Leonards - Local Institution - 0151; 2109 - Macquarie University - Local Institution - 0149; 3084 - Heidelberg - Local Institution - 0150	https://clinicaltrials.gov/ct2/show/NCT07106762
NCT07110584	MDX-2004-101	Phase 1 / Phase 2	RECRUITING	NSW	2025-07-30	2025-09-30	2031-06-30	MDX-2004	trispecific-CD28/4-1BB/CD3_fusion_protein	MDX-2004	trispecific-CD28/4-1BB/CD3_fusion_protein	MDX-2004-101	A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors	Advanced Tumors	2298 - Waratah - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT07110584
NCT07112222	LM350-01-101	Phase 1 / Phase 2	NOT_YET_RECRUITING	VIC	2025-08-01	2025-09-30	2030-06-30	LM-350	anti-CDH17_antibody-drug_conjugate	LM-350	anti-CDH17_antibody-drug_conjugate	LM350-01-101	A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors	Malignant Tumors	Frankston - Peninsula and South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT07112222
NCT07115043	D7350C00001	Phase 1 / Phase 2	RECRUITING	VIC	2025-08-04	2025-07-29	2029-04-09	Rilvegostomig	bispecific_PD-1/TIGIT_antibody	Rilvegostomig	bispecific_PD-1/TIGIT_antibody	D7350C00001	A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors	Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma (Skin); Renal Cell Carcinoma; Merkel Cell Carcinoma; Triple Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastric Cancer/Gastroesophageal Junction Cancer; High Grade Serous Ovarian Carcinoma	3002 - East Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT07115043
NCT07121244	R11228-101	Phase 1	NOT_YET_RECRUITING	VIC	Help: Date registered 2025-08-13	2025-10-01						R11228-101	Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Patients With Advanced Breast Cancer	Locoregionally Recurrent Hormone-receptor Positive Breast Cancer; Metastatic Hormone Receptor Positive Breast Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT07121244
NCT07140900	NCT07140900	Phase 1	NOT_YET_RECRUITING	NSW	Help: Date registered 2025-08-26	2025-10-07		Abiraterone; Abiraterone + Xaluritamig; Darolutamide; Darolutamide + Xaluritamig; Xaluritamig	antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; bispecific_T-cell_engager,STEAP1-targeting; CYP17A1_inhibitor + bispecific_T-cell_engager,STEAP1-targeting	Abiraterone + Xaluritamig; Darolutamide + Xaluritamig	CYP17A1_inhibitor + bispecific_T-cell_engager,STEAP1-targeting; antiandrogen,nonsteroidal,second_generation + bispecific_T-cell_engager,STEAP1-targeting	20240361	A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer	Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	2298 - Waratah; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT07140900
NCT07141706	DB-1317-101	Phase 1	NOT_YET_RECRUITING	NSW	2025-08-25	2025-09	2028-06	DB-1317	unknown_drug_class	DB-1317	unknown_drug_class	DB-1317-101	A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	2031 - Randwick - AUS01-0	https://clinicaltrials.gov/ct2/show/NCT07141706
NCT07147348	BNT3212-01	Phase 1	NOT_YET_RECRUITING	NSW	Help: Date registered 2025-08-29	2025-08-27		BNT327	bispecific_PD-L1/VEGFA_antibody	BNT327	bispecific_PD-L1/VEGFA_antibody	BNT3212-01	A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT07147348
NCT07156136	IMC-P115C-1005	Phase 1	RECRUITING	NSW, SA, WA	2025-09-03	2024-11-07	2029-08-30	IMC-P115C	bispecific_T-cell_engager,PRAME-targeting	IMC-P115C	bispecific_T-cell_engager,PRAME-targeting	IMC-P115C-1005	A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers	PRAME Positive; Cancer; HLA-A*02:01-positive	06009 - Nedlands - Linear Clinical Research ltd.; 2065 - Wollstonecraft - Melanoma Institute Australia; 5000 - Adelaide - Cancer Research South Australia (CRSA)	https://clinicaltrials.gov/ct2/show/NCT07156136
NCT07158918	ABL103-1002	Phase 1 / Phase 2	RECRUITING	VIC	2025-08-28	2025-08-06	2027-12-02	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	ABL103-1002	A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors	Solid Tumors	3199 - Frankston - PASO Medical	https://clinicaltrials.gov/ct2/show/NCT07158918
NCT07164443	KLK2-comPAS	Phase 3	RECRUITING	QLD, SA, VIC	2025-09-04	2025-09-02	2028-05-30	JNJ-78278343; Placebo	placebo; bispecific_T-cell_engager,KLK2-targeting	JNJ-78278343; Placebo	bispecific_T-cell_engager,KLK2-targeting; placebo	78278343PCR3001	A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms	3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Warringal Private Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - ICON Cancer Care	https://clinicaltrials.gov/ct2/show/NCT07164443
NCT07165067	AP601-101	Phase 1	NOT_YET_RECRUITING	QLD, VIC	2025-09-02	2025-09-20	2028-01-30	AP601	bispecific_CD73/4-1BB_antibody	AP601	bispecific_CD73/4-1BB_antibody	AP601-101	A Phase 1, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients With Solid Tumors.	Solid Tumours	3121 - Melbourne - Epworth HealthCare; 4217 - Brisbane - Pindara Private Hospital	https://clinicaltrials.gov/ct2/show/NCT07165067
NCT07174336	J6M-MC-JSGD--27726	Phase 3	NOT_YET_RECRUITING	NSW, VIC, WA	Help: Date registered 2025-09-15			Abemaciclib; Anastrozole; Exemestane; Fulvestrant; Letrozole; Palbociclib; Placebo; Ribociclib	selective_estrogen_receptor_degrader; placebo; aromatase_inhibitor; CDK4/6_inhibitor	Abemaciclib; Anastrozole; Exemestane; Fulvestrant; Letrozole; Palbociclib; Placebo; Ribociclib	CDK4/6_inhibitor; aromatase_inhibitor; placebo; selective_estrogen_receptor_degrader	J6M-MC-JSGD  27726	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)	Neoplasm Metastasis; Breast Neoplasms	6008 - Subiaco; 2290 - Newcastle; 3630 - Shepparton	https://clinicaltrials.gov/ct2/show/NCT07174336
NCT07197580	LUTEON	Phase 3	NOT_YET_RECRUITING	VIC, WA, Washington	2025-09-22	2025-11-15	2029-02-28	177Lu-TLX250	177Lu-anti-CA9-radioconjugate	177Lu-TLX250	177Lu-anti-CA9-radioconjugate	177Lu-TLX250-302	A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)	ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Renal Cell Cancer Metastatic; Renal Cell Cancer, Recurrent; Clear Cell Renal Cell Cancer (ccRCC)	3051 - Melbourne N. - Melbourne Theranostic Innovation Centre (MTIC); 3084 - Heidelberg - Austin Health; 6150 - Murdoch - GenesisCare, Fiona Stanley Hospital (Murdoch)	https://clinicaltrials.gov/ct2/show/NCT07197580
NCT07197827	YL242-INT-101-01	Phase 1 / Phase 2	RECRUITING	NSW, VIC, WA	2025-09-26	2025-09-22	2028-11	Fluorouracil; Fluorouracil + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + fluoropyrimidine; Fluorouracil; anti-PD-1_monoclonal_antibody; fluoropyrimidine	Fluorouracil; Fluorouracil + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; Fluorouracil	YL242-INT-101-01	A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.	Advanced Solid Tumor	2010 - Darlinghurst - AUS-102; 2170 - Liverpool - AUS-101; 3065 - Fitzroy - AUS-104; 3084 - Heidelberg - AUS-103; 6009 - Nedlands - AUS-105	https://clinicaltrials.gov/ct2/show/NCT07197827
NCT07203391	TRIUMPH	Phase 1	RECRUITING	NSW, VIC	2025-09-29	2025-12-01	2029-12-01	Tebentafusp	bispecfic_T-cell_engager,gp100-targeting	Tebentafusp	bispecfic_T-cell_engager,gp100-targeting	TRIUMPH	TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis	Uveal Melanoma, Metastatic	2010 - Sydney - St Vincents Hospital; Melbourne - Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT07203391
NCT07204340	TLN-372-2501	Phase 1	RECRUITING	VIC, WA	2025-09-24	2025-10-09	2032-04-01	Cetuximab; Cetuximab + Pembrolizumab; Pembrolizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Cetuximab + Pembrolizumab	anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	TLN-372-2501	An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors	KRAS Mutant Solid Tumors	6009 - Perth - Linear Clinical Research; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT07204340
NCT07206056	TulmiSTAR-01	Phase 1 / Phase 2	RECRUITING	NSW	2025-09-26	2025-11-28	2030-12-17	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioconjugate,PSMA-targeting	CDZR123A12107	TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer	Progressive Metastatic Castrate Resistant Prostate Cancer	2065 - St Leonards - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT07206056
NCT07218380	FORAGER-2	Phase 3	NOT_YET_RECRUITING	NSW, QLD, VIC, WA	2025-10-16	2025-11	2033-05	Enfortumab Vedotin; Enfortumab Vedotin + Pembrolizumab; Pembrolizumab; Placebo	placebo; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	Enfortumab Vedotin + Pembrolizumab; Pembrolizumab; Placebo	anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo	27333	FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration	Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis	2031 - Randwick - Prince of Wales Hospital; 2109 - Macquarie University - Macquarie University; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 4101 - Brisbane - Mater Misericordiae Limited; 6009 - Perth - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT07218380
